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Abstract
An increasing prevalence of metabolic syndrome and obesity has been linked to the rise
in transplant indication for cryptogenic cirrhosis and nonalcoholic fatty liver disease
(NAFLD), creating a growing challenge to public health. NAFLD liver transplant (LT)
candidates are listed with low priority, and their waiting mortality is high. The impact of
community/geographic factors on donor risk models is unknown. The purpose of this
study was to develop a parsimonious donor risk-adjusted model tailored to NAFLD
recipients by assessing the impact of donor, recipient, transplant, and external factors on
graft survival. The theoretical framework was the social ecological model. Secondary
data were collected from 3,165 consecutive recipients from the Scientific Registry of
Transplant Recipients and Community Health Scores, a proxy of community health
disparities derived from the Robert Wood Johnson Foundation’s community health
rankings. Data were examined using univariate and multivariate analyses. The donor riskadjusted model was developed using donor-only factors and supplemented with recipient
and transplant factors, classifying donors as low, medium, and high risk. NAFLD
residents in high-risk counties had increased likelihood of liver graft failure. Findings
may be used to allocate high-risk donors to a subset of NAFLD with excellent outcomes,
increasing the donor pool and decreasing mortality on the wait list.
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Chapter 1: Introduction to the Study
An increasing prevalence of metabolic syndrome and obesity has been linked to
the rise in transplant indication for cryptogenic cirrhosis (CC) and nonalcoholic fatty liver
disease (NAFLD) creating a growing challenge to public health (Fazel, Koenig, Sayiner,
Goodman, & Younossi, 2016; Pais et al., 2016). Many NAFLD patients who develop
cirrhosis or hepatocellular carcinoma (HCC) and CC patients are in need of a liver
transplant (LT). Therefore, NAFLD-related end-stage liver disease including
nonalcoholic steatohepatitis (NASH) cirrhosis will soon become a leading indication for
LT (Mikolasevic et al., 2018).
CC is a chronic liver disease of unknown etiology, and most CC cases are
attributed to advanced NASH cirrhosis (Caldwell & Marchesini, 2018). The current liver
allocation system based on the model for end-stage liver disease (MELD) does not
accurately capture the risk of wait-list mortality of NAFLD/CC patients (Bambha &
Biggins, 2008; Patel, Berg, & Moylan, 2016). Patients with NAFLD/CC and low MELD
scores have slower disease progression and low priority on the LT wait list than patients
listed for other end-stage liver diseases (Kwong, Lai, Dodge, & Roberts, 2015). Although
patients with NAFLD/CC cirrhosis have short-term morbidity and mortality, their midand long-term posttransplant outcomes are favorable, similar to other etiologies,
suggesting that an LT can be an excellent treatment option for NAFLD/CC (Patel et al.,
2016).
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Organ shortage is a major problem that accounts for remarkable wait-list
mortality (Elwir & Lake, 2016). As a result, many NAFLD/CC patients, who often have
many comorbidities, are likely to drop out from the wait list or die while waiting for an
LT at a higher rate compared to other etiologies (O’Leary, Landaverde, Jennings,
Goldstein, & Davis, 2011; Pais et al., 2016).
Transplant centers are increasing the utilization of marginal deceased donors
including older donors, extended criteria donors, and donors after cardiac death to expand
the donor pool (Akkina et al., 2012; Diwan, Paterno, & Shah, 2015). The main purpose of
this study was to create and validate a novel model for donor quality score tailored to
NAFLD/CC recipients of LT, or the donor quality-nonalcoholic fatty liver disease (DQNAFLD) model, using data from the Scientific Research Transplant Registry (SRTR) as
well as county-level data to incorporate the community health indicators (County Health
Rankings & Roadmaps, 2018). The DQ-NAFLD model could lead to positive social
change if used as a tool to quantify donor quality and assist the decision-making during
an organ offer. The use of DQ-NAFLD score could be clinically relevant if used in
donor-recipient matching to identify the highest DQ-NAFLD scores associated with
acceptable outcomes for subsets of NAFLD/CC patients. The donor pool would increase,
and more suboptimal donors would be allocated to NAFLD/CC patients on the wait list
for LTs who have lower priority. Otherwise, there is a good possibility that NAFLD/CC
patients could die while on the wait list because no liver will be offered to them.
In Chapter 1, I provide a brief review of the study background, the statement of
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the problem, the purpose of the study, and the research questions. This chapter also
provides a brief introduction to the socioecological theoretical framework, the definition
of the study variables, the scope of the study, and the assumptions and limitations.
Finally, I describe the significance of this study and its potential contributions in
matching the right donors, including marginal donors, to NAFLD/CC recipients, and in
reducing the percentage of organs wasted that could be allocated to the appropriate
NAFLD/CC recipients with excellent outcomes.
Background
Liver transplant surgery has become a widely accepted, curative, and life-saving
treatment for people with end-stage liver disease. Currently in the United States, about
14,000 patients are waiting for a liver donation, but only about 7,500 LTs are performed
annually (United Network for Organ Sharing [UNOS], 2018). Between 2015 and 2016,
LTs increased by 10.0%. Nevertheless, the proportion of liver recovered but not
transplanted has reached 9.4% in 2014 (Kim et al., 2016). The disparity between liverorgan supply and demand has resulted in a remarkable organ shortage and a large number
of potentially preventable deaths, which is a public health crisis (UNOS, 2018).
Strategies to improve organ-recipient matching are needed (Flores & Asrani, 2017).
The U.S. Department of Health and Human Services Organ Procurement and
Transplantation Network (OPTN) Final Rule contains the regulatory requirements and
ethical principles for organ allocation. The organ allocation system must be fair and just
and should not put any member of society in a disadvantageous position for having
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access to available organs (UNOS, 2018). Liver allocation requires an appropriate
balance between medical urgency and efficiency (UNOS, 2018).
Liver allocation policies have shifted from a wait-time designation to addressing
more urgent cases based on the calculated MELD score (Merion et al., 2005).
Nevertheless, the MELD score designed to predict short-term wait-list mortality is a
weak predictor of posttransplant survival, and it is insufficient to optimize the value of
each donor’s liver (Asrani & Kim, 2011). In recent years, grounded in the principle of
utilitarianism, investigators have developed organ allocation models seeking to maximize
survival benefit of the whole population or aiming at saving more years of life, rather
than more lives (Briceño, Ciria, & de la Mata, 2013). Steps taken in this direction include
the development of the first donor risk index (Feng et al., 2006) and subsequent donor
risk models, which seek to predict the survival of the donated liver after transplantation,
enabling matching between the expected posttransplant life span of the liver with that of
the recipient (Porrett, ter Horst, & Shaked, 2012; Weiss et al., 2012).
Several models have been proposed using donor factors, recipient factors, and
intraoperative factors to predict posttransplant survival and facilitate transplant decisionmaking (Flores & Asrani, 2017). However, almost all proposed models are not widely
used in clinical practice because they require inputs not readily available at the time of
the evaluation of an organ offer or because they are not reliable metrics of donor
characteristics that fail to consider essential predictors or include irrelevant factors (Blok
et al., 2012; Braat et al., 2012; Campos-Varela, Dodge, Stock, & Terrault, 2016;
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Dutkowski et al., 2011; Halldorson, Bakthavatsalam, Fix, Reyes, & Perkins, 2009; Hoyer
et al., 2015; Mataya, Aronsohn, Thistlethwaite, & Friedman Ross, 2014; Northup et al.,
2015; Rana et al., 2008). Additionally, some of the risk models do not reflect current
clinical practice as they were developed using data before the implementation of the
MELD score allocation system.
Clinical studies often focus on clinical and biological factors ignoring the
importance of community conditions in risk-adjusted models. Epidemiologic factors such
as socioeconomic status; access to quality health care; ecological, behavioral, and
psychosocial factors; and geographic variations create disparities in posttransplant
outcomes and prevent the current allocation systems from making organs available to the
highest number of people (Northup et al., 2015). Understanding the epidemiologic factors
that lead to inequalities in the liver allocation and posttransplant outcomes are of
paramount public health importance. None of the donor risk models proposed are tailored
to the NAFLD/CC population, and none of them considered unmeasured characteristics
that can impact posttransplant liver allograft survival, including environmental,
behavioral, and psychosocial aspects of the communities where transplant recipients
reside (Nandi, Glymour, & Subramanian, 2014). Chapter 2 provides a more extensive
review of the literature related to the NAFLD/CC patients, the current allocation system,
and how a quantified donor quality metric can help in decision-making. This study
complemented existing work and may assist researchers with donor risk models tailored
to NAFLD/CC patients useful in organ allocation decision-making.
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Statement of the Problem
Due to the rise in obesity and diabetes mellitus type 2, NAFLD patients listed for
LT are expected to increase steadily. Nevertheless, the MELD allocation score fails to
capture the actual risk of death of NAFLD candidates. As a result, many of them receive
low priority and continue to die while waiting for an LT (Asrani & O’Leary, 2015).
Organ shortage leads to the utilization of nonoptimal donors, and donor risk models
provide a metric to quantify donor quality and help allocate nonoptimal donors to
appropriate recipients. On the other hand, many organs are discarded while some of them
can be utilized with excellent results if adequately selected and matched to the
appropriate LT candidates. Donor risk models provide the first step to match marginal
donors to the appropriate recipients. The creation and validation of a novel model for
donor quality score, the DQ- NAFLD, tailored to NAFLD/CC recipients of LT can fill a
gap in the current knowledge base and be a step forward in the optimal utilization of a
scarce resource to achieve the ultimate goal of improving liver graft survival. None of the
previously proposed liver donor risk models has considered the impact of community risk
factors on the performance of donor risk models (Nandi et al., 2014).
Purpose of Study
The primary goals of this quantitative study were to develop a parsimonious riskadjusted model, use this model to derive a donor quality score for NAFLD/CC LT
recipients that will predict graft failure at 1-year post LT, and explore its relationship
with transplant and recipient characteristics and with geographic and county health risk
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factors. I used a quantitative method and secondary data. To be useful in clinical practice,
the DQ-NAFLD will only include donor and recipient variables known at the time of the
organ offer and will be built with data in the post-MELD era (see Flores & Asrani, 2017).
An extended version of the model that includes transplant factors not available at the time
of offer but estimable, such as cold ischemia time, will be useful for donor-recipient
matching.
Recipient characteristics included age, gender, biological MELD score, and body
mass index (BMI). Donor characteristics consisted of donor age, gender, height, weight,
BMI, cause of death, hypertension, diabetes, donor after circulatory death (DCD),
hepatitis C virus (HCV) status, Hepatitis B surface antibody (HBsAb) status, Hepatitis B
surface antigen (HBsAg) status, modification of diet in renal disease (MDRD) clearance,
and donor hypernatremia. Transplant variables included ABO compatibility, size
compatibility, and cold ischemia time. Most importantly, the study addressed distance
from the transplant center, used to identify recipients in remote communities and in
geographic isolation from transplant centers, and underlying community health factors
from the location of LT recipients that are significantly associated with posttransplant
outcomes and can bias the performance of the novel DQ- NAFLD (see Galea, Tracy,
Hoggatt, DiMaggio, & Karpati, 2011).
By finding a donor quality metric for NAFLD/CC recipients, this model will
contribute to identifying NAFLD/CC LT candidates who may die while on the wait list or
may be removed because they are too sick to be transplanted. Both groups would benefit
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from an LT when matched appropriately. By optimizing survival benefit of NAFLD/CC
LT candidates on the wait list, this model will attempt to increase the organ pool for
NAFLD/CC patients, reduce wait-list mortality, improve survival outcomes, and meet the
dual goal of fair allocation and optimum efficiency (Kamath et al., 2001). This study had
four objectives:
1. to develop a donor risk model tailored to NASH/CC LT recipients with
intrinsic donor factors to improve risk stratification for liver organs;
2. to develop an extended donor risk model tailored to NASH/CC LT recipients
with donor, recipient, and transplant factors;
3. to examine the modifying effect of distance from center and its interaction
with donor risk score on liver graft failure; and
4. to explore the modifying effect of community risk factors and their interaction
with donor risk on liver graft failure.
Research Questions and Hypotheses
The variables used to formulate the research questions and hypotheses are defined
and operationalized in the section Study Variables and Operational Definitions of
Chapter 3 and in Appendix A. This retrospective cohort study was conducted to answer
the following research questions through testing of corresponding hypotheses:
Research Question 1
What are the relationships between posttransplant graft survival among
NAFLD/CC recipients and a number of donor characteristics (age, gender, height,
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weight, BMI, the cause of death, hypertension, diabetes, donor after circulatory death,
HCV status, HBsAb status, HBsAg status, MDRD, and hypernatremia)?
𝐻01 : There is no association between posttransplant graft survival among
NAFLD/CC recipients and a number of donor characteristics (age, gender, height,
weight, BMI, the cause of death, hypertension, diabetes, donor after circulatory death,
HCV status, HBsAb status, HBsAg status, MDRD, and hypernatremia).
𝐻𝑎1 : There is an association between posttransplant graft survival among
NAFLD/CC recipients and a number of donor characteristics (age, gender, height,
weight, BMI, the cause of death, hypertension, diabetes, donor after circulatory death,
HCV status, HBsAb status, HBsAg status, MDRD, and hypernatremia).
Research Question 2
What are the relationships between posttransplant graft survival among
NAFLD/CC recipients and transplant factors (cold ischemia time, ABO matching, and
size matching)?
𝐻02 : There is no association between posttransplant graft survival among
NAFLD/CC recipients and a number of transplant factors (cold ischemia time, ABO
matching, and size matching).
𝐻𝑎2 : There is an association between posttransplant graft survival among
NAFLD/CC recipients and transplant factors (cold ischemia time, ABO matching, and
size matching).
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Research Question 3
What are the relationships between posttransplant graft survival among
NAFLD/CC recipients and a number of donor factors (age, gender, height, weight, BMI,
the cause of death, hypertension, diabetes, donor after circulatory death, HCV status,
HBsAb status, HBsAg status, MDRD, hypernatremia) and transplant factors (cold
ischemia time, ABO matching, size matching) after adjusting for characteristics of
recipients of LT (age, gender, BMI, biological MELD)?
𝐻03 : There is no association between posttransplant graft survival among
NAFLD/CC recipients and a number of donor factors (age, gender, height, weight, BMI,
the cause of death, hypertension, diabetes, donor after circulatory death, HCV status,
HBsAb status, HBsAg status, MDRD, hypernatremia) and transplant factors (cold
ischemia time, ABO matching, size matching) after adjusting for characteristics of
recipients of LT (age, gender, BMI, biological MELD).
𝐻𝑎3 : There is an association between posttransplant graft survival among
NAFLD/CC recipients and a number of donor factors (age, gender, height, weight, BMI,
the cause of death, hypertension, diabetes, donor after circulatory death, HCV status,
HBsAb status, HBsAg status, MDRD, hypernatremia) and transplant factors (cold
ischemia time, ABO matching, size matching) after adjusting for characteristics of
recipients of LT (age, gender, BMI, biological MELD).
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Research Question 4
What are the relationships between posttransplant graft survival among
NAFLD/CC recipients and the health risk status of the county where recipients reside, as
measured by the community health score (CHS)?
𝐻04 : There is no association between posttransplant graft survival among
NAFLD/CC recipients and the health risk status of the county where recipient resides, as
measured by the CHS.
𝐻𝑎4 : There is an association between posttransplant graft survival among
NAFLD/CC recipients and the health risk status of the county where recipient resides, as
measured by the CHS.
Research Question 5
What are the relationships between posttransplant graft survival among
NAFLD/CC recipients and the distance from transplant center?
𝐻05 : There is no association between posttransplant graft survival among
NAFLD/CC recipients and distance from center.
𝐻𝑎5 : There is an association between posttransplant graft survival among
NAFLD/CC recipients and distance from transplant center.
Research Question 6
What are the relationships between posttransplant graft survival among
NAFLD/CC recipients, DQ-NAFLD risk score, and external community factors (CHS
and distance from the transplant center)?
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𝐻06 : There is no association between posttransplant graft survival among
NASH/CC recipients, DQ-NAFLD risk score, and external community factors (CHS and
distance from the transplant center).
𝐻𝑎6 : There is an association between posttransplant graft survival among
NAFLD/CC recipients, DQ-NAFLD risk score, and external community factors (CHS
and distance from the transplant center).
Theoretical Framework for the Study
Social-ecological theory recognizes that individuals are embedded in their social
structure that interacts with individual and environmental factors. Based on
Bronfenbrenner’s (1977) seminal work, McLeroy, Bibeau, Steckler, and Glanz (1988)
proposed a five-level social-ecological system and examined the complex interplay
between public policy and intrapersonal, interpersonal, institutional, and community
factors. From this theory, it follows that there are complicated social determinants that
increase or decrease the risk of poor posttransplant outcomes (Braveman & Gottlieb,
2014). It is necessary to act on multiple levels to improve patient and graft survival after
LT.
The social-ecological model was the most appropriate framework for this study.
The individual domain includes patient-level and biological factors. The family and
social network levels include family members who are involved in supporting patients
throughout their transplant journey. Health care system level comprises the clinical
pathway to an LT, such as donor match, the transplant surgery, and quality of health care
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provided. The community domain includes the contextual environment or the nature of
the community where patients reside, the wait list, and organ donation policies. The
social-ecological model provided the guiding framework for the literature review
presented in Chapter 2.
Nature of the Study
The nature of the study was quantitative with secondary data. A retrospective
cohort of consecutive NAFLD/CC adult recipients of LT who met the inclusion criteria
was analyzed. To identify quantitative donor characteristics predictive of liver-graft
survival after LT; the risk model associated; and the relationships with recipient,
transplant, geographic, and community health indicators, Cox’s proportional hazard (PH)
models as well as random survival forests, a machine learning approach appropriate to
analyze time-to-event outcomes, were considered. This quantitative study led to the
development of a DQ- NAFLD model that quantified the donor quality associated with
an LT for NAFLD/CC patients.
Definitions
The conceptual definitions of specific terms used in this study are included in this
section. Some of these concepts have been further defined in Chapter 2.
Cold ischemic time (CIT): Cold ischemic time is the amount of time, usually
about 12–18 hours, after a donor’s liver is harvested for transplantation. CIT is defined as
the time from cross clamping of the donor liver to removal from cold storage solution.
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Reducing CIT improves the quality of the liver allograft. CIT can be lowered by lowering
the logistical and transportation time (Pan et al., 2018).
Community Health Score (CHS): Community Health Score is a composite health
index that incorporates county-level environmental and behavioral conditions, the
prevalence of comorbidities, and quality of health care (a surrogate of sociodemographic
characteristics). The Study Variables and Operational Definition section in Chapter 3 and
Appendix A provide more details about the county health indicators used in the CHS.
Cryptogenic cirrhosis: Chronic liver disease of unknown etiology, often attributed
to NASH cirrhosis (Caldwell & Marchesini, 2018).
Death drain donor (DBD): Donation after brain death (DBD) represents the
majority of deceased donors and is associated with excellent liver transplant outcomes.
Neurological brain death is the standard criteria for organ donation that takes place after
the irreversible loss of clinical function occurs.
Donation after cardiac death (DCD): Non–heart-beating organ donation takes
place after circulatory death of the donor. DCD livers are usually procured after
withdrawal of life support and have a period of absence of blood flow before cold
preservation, as opposed to heart beating donors who maintain organ perfusion until
initiation of cold preservation (OPTN, 2018). Therefore, DCD donors are more
susceptible to further ischemic injury and increased risk of graft failure than DBD donors
(Halldorson et al., 2015).
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Donor risk index (DRI): Donor risk index is a measurement of the donor liver
quality developed from a predictive model of donor factors including donor age, race,
donation after cardiac death, donor high, and use of split/partial grafts (Feng et al., 2006).
Distance from transplant center: The distance between recipient primary
residence zip code and transplant center zip code.
Expanded criteria donor (ECD): Any deceased donor age 70 years or above, or
age 60 years with significant medical history, or a donor with a history of hepatitis B or
hepatitis C. The patient must give informed consent to accept the liver of an ECD donor
(Rodrigue, Hanto, & Curry, 2011).
Modification of diet in renal disease (MDRD): Equation that utilizes four
variables, including age, gender, ethnicity, and serum creatinine, to estimate glomerular
filtration rate (Levey et al., 1999).
Model for end-stage liver disease (MELD) score: Model for end-stage liver
disease score is used to quantify the severity of end-stage liver disease for LT and to
prioritize liver allocation. The MELD score is a predictor of short-term wait-list mortality
(Bernardi, Gitto, & Biselli, 2011).
Nonalcoholic fatty liver disease (NAFLD): NAFLD is a multisystem disease
characterized by excess fat stored in the liver, primarily associated with other comorbid
conditions such as obesity, diabetes mellitus, cardiovascular disease, hyperlipidemia,
metabolic syndrome, and chronic kidney disease (Mikolasevic et al., 2018). In this study,
patients with progressive NAFLD in need of a liver transplant were considered.
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Nonalcoholic steatohepatitis (NASH): NASH is an advanced status of NAFLD to
steatohepatitis, a progressive fibrotic liver disease indicating liver transplant is necessary
(Argo & Caldwell, 2009).
Organ procurement organization (OPO): Organ procurement organization is an
organization authorized by the Centers for Medicare and Medicaid Services (CMS) to
procure organs for transplantation. For each OPO, CMS defines a geographic
procurement territory within which the OPO concentrates its procurement efforts. No
OPO is limited to or granted exclusive right to procure organs in its territory (OPTN,
2018).
Organ procurement and transplantation network (OPTN): Organ procurement
and transplantation network is an organization governed by the U.S. Department of
Health and Human Services and is formed by multiple committees to develop organ
transplantation policies (OPTN, 2018).
Public health service (PHS) increased risk donor: The Centers for Disease
Control and Prevention (CDC) developed guidelines in 1994 to designate high-risk
donors based on a category of high-risk behaviors likely to increase chance of human
immunodeﬁciency virus (HIV) transmission (Rogers, Simonds, Lawton, Moseley, &
Jones, 1994). On July 2013 the PHS increased-risk criteria were introduced as an
extension of the CDC high-risk criteria by adding the risk of recent hepatitis B and
hepatitis C, in addition to the risk of HIV (Seem, Lee, Umscheid, & Kuehnert, 2013).
More details about the two criteria are provided in Appendix B.
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Scientific Registry of Transplant Recipients (SRTR): Scientific Registry of
Transplant Recipients is a national database that receives transplant data from many
organizations and stores data on transplant candidates, donors, transplant recipients, and
posttransplant follow-up data (SRTR, 2018).
Standard criteria donor (SCD): Standard criteria donor liver comes from a
deceased donor who is brain dead but still has a beating heart that may be supported by a
respirator (Rodrigue et al., 2011).
Split liver donation: Split or partial liver donation refers to the split of the liver
organ into two segments, the left lateral segment often transplanted to child and the right
segment transplanted to an adult, although splitting the donor between two adults is also
performed (Vagefi, Parekh, Ascher, Roberts, & Freise, 2011).
Transplant center: A hospital in which transplants are performed. The transplant
surgeon of the transplant center receiving the organ offer for a surgeon’s candidate is
responsible for ensuring the medical suitability according to the candidate’s blood type
and subtype (OPTN, 2018).
United Network for Organ Sharing (UNOS): United Network for Organ Sharing
is a private, nonprofit organization that manages the nation’s organ transplant system
under contract with the federal government (UNOS, 2018).
Wait list: This is a computerized list of candidates who are waiting to be matched
with specific donor organs in hopes of receiving transplants. Wait list candidates are
registered on the list by member transplant centers (OPTN, 2018).
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Assumptions
Several basic assumptions were made during this investigation. During patient
selection, environmental factors were assumed to be constant across all patients who
resided in the same county. I assumed that all patients received clinical services of
equivalent quality as the transplant center and center effect were not analyzed.
Moreover, I assumed that data were accurately collected and correctly measured by
clinical, administrative, and research staff and that lab values were not flawed. Late graft
failures, which happen after 1-year posttransplant, were ignored. I assumed that an ideal
donor was a standard criteria liver donor (i.e., with brain death, age less than 45 years, a
whole non-split graft) and that the risk model could quantify donor risks for a
heterogeneous group of nonideal donors.
Scope and Delimitation
In this study, only adult recipients (18 years or older) of cadaveric single-organ
LTs were considered. Recipients of multiorgan transplants were excluded. The study
population was limited to patients transplanted for NAFLD/CC; all other etiologies for
LT were excluded. A cohort of patients transplanted in the most recent 5 years with at
least 1-year follow-up in the post-MELD era was considered to develop models to predict
graft survival within 1-year posttransplant. To develop a valid risk adjustment model, an
adequate number of events (in this case graft failures or deaths) must have occurred in the
development cohort to allow selection of variables for risk adjustment. A proposed
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convention in multivariate prognostic modeling was to require at least 10-15 events per
risk adjuster in the final model (see Harrell, Lee, & Mark, 1996).
The SRTR technical advisory committee recommends a more conservative
minimum of 25 events in the development data set to attempt to build a risk adjustment
model (Snyder et al., 2016). Final decisions on which variables to include for donor risk
adjustment were based on published data, knowledge of subject matter, and available
data. A list of potentially appropriate variables for risk adjustment was compiled based on
literature review, availability in SRTR, and expert opinion about the importance and
clinical relevance of proposed data elements. All transplant centers contribute to the
SRTR database. The large sample size ensured that the study was powered to conduct
multivariate analyses. Therefore, inferences from SRTR studies are likely to generalize
across the United States. However, the model is expected to present some threats to
external validity and may not generalize with data from non-U.S. transplant centers with
different policies and procedures (see Massie, Kucirka, & Segev, 2014).
Limitations
SRTR database has a significant amount of data that are missing or inaccurate.
The aggregate nature of the community health factors can lead to model estimates that
may be subject to ecological bias. Lost to follow-up can be a threat to internal validity.
The retrospective nature of SRTR data can lead to confounding attributable to
unobserved variables. Transplant centers prospectively submit their data at transplant
milestones, reducing recall bias. Medical and social history interviews conducted with the
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deceased donor’s close family members can be inaccurate if the persons interviewed have
limited or inaccurate information.
A study suffers from selection bias if individuals in the study population are not
representative of the target population. However, the SRTR database is a comprehensive
registry of transplant recipients, which includes consecutive organ transplants that
occurred in the United States since October 1, 1987. Therefore, the accurate pathologybased diagnosis paired with the inclusion of consecutive patients was likely to reduce
selection bias. The designed inclusion criterion, which limited to NAFLD/CC adult
recipients of LTs, optimized the external and internal validity of the study, reduced
confounding, ensured the homogeneity of the sample population, and increased the
likelihood of finding a true association between independent predictors, covariates, and
outcomes.
Significance and Social Change
The changing patterns in patient demographics and indication for LT pointed to
the development of a post-MELD era donor quality score tailored to NAFLD recipients.
This study can shed some light on understanding how organ quality plays a role in
posttransplant outcomes. Transplant physicians are inaccurate at predicting donor specific
risks and tend to overestimate graft failure for marginal donors (Volk, Roney, & Merion,
2013). Moreover, patients prefer an active involvement in decisions about organ
acceptance, and although they tend not to accept marginal donors, a closer evaluation of
the competing risk of wait-list mortality can lead patients to accept higher-risk donors
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(Dries, Annema, Berg, Ranchor, & Porte, 2014; Volk, 2015; Volk, Tocco, Pelletier,
Zikmund-Fisher, & Lok, 2011). The results of this research have the potential to advance
knowledge in clinical decision-making at the point of care during an organ offer and may
provide an objective tool for physicians and patients.
The DQ-NAFLD objective donor quality metrics could lead to positive social
change if used as a tool to quantify donor quality and may assist physicians and patients
in the decision-making during an organ offer. The DQ-NAFLD score could be clinically
relevant if used to identify high-risk donors associated with acceptable outcomes when
matched to subsets of NAFLD/CC recipients. The donor pool could increase, and more
suboptimal donors could be allocated to NAFLD/CC patients on the wait list who have
lower priority to receive an LT. Otherwise, there is a good possibility that these patients
could die while on the wait list because no liver will be offered to them.
Summary
NAFLD is becoming the leading indication for LT. Nevertheless, the wait-list
mortality rate for NAFLD recipients is high compared to other indications for an LT. In
this chapter, I introduced the subject matter and showed that the population of
NAFLD/CC recipients could benefit from an optimized allocation of liver organs. I
explained the lack of donor risk models that address NAFLD/CC patients and the need to
consider community risk factors and their impact on post LT graft survival. Furthermore,
the purpose of this study along with a justification of the need for this research and its
theoretical framework was presented. Research questions and hypotheses were included,
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and the delimitations, assumptions, and limitations of this study were given. Chapter 2
provides a comprehensive literature review of the study background and research
problem.
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Chapter 2: Literature Review
Mirroring obesity and type 2 diabetes prevalence, NAFLD with end-stage liver
disease and NASH are projected to replace HCV as the leading indications for LT in the
United States and the world (Pais et al., 2016). The number of patients with NASH listed
for liver transplant in the United States has increased by 168% from 2003 to 2014,
becoming the second leading etiology for liver transplantation after 2008, and still
trending upward (Cholankeril et al., 2017). With the introduction of highly effective
direct antiviral agents, the incidence of HCV-related decompensated cirrhosis is steadily
decreasing. NASH patients on the transplant wait list have low priority, are often old with
comorbidities, and have a high likelihood to die on the wait list. To fill the gap between
the demand for LT and the supply of deceased donor organs, transplant centers are forced
to consider using high-risk donors for transplant candidates with the longest waiting time.
Factors such as donor age, donor cause of death, and donation after cardiac death can
contribute to increasing the risk for graft failure that can lead to the death of the
transplant recipient (SRTR, 2018).
To quantify the impact of donor factors, researchers have developed organspecific donor risk indices to identify predictors of graft and patient survival post LT
using various combinations of donor, transplant, and recipient characteristics and are
actively searching to fit useful statistical risk models using objective variables that
quantify the risk associated with donor organs. The concept of donor risk index (DRI)
introduced by Feng et al. (2006), and the subsequent models following the development
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of the DRI are important advances. However, they need to be updated to be considered in
liver allocation policies and to be useful in clinical practice to guide transplant clinicians
in the use of nonoptimal donors by accounting for the impact of geography and
unmeasured donor characteristics. DRI could be tailored for NAFLD/CC recipients to
reflect features unique to this population (Flores & Asrani, 2017). I performed a thorough
literature review to gain an understanding of the current knowledge about the relationship
between donor quality and patient characteristics in the NAFLD/CC population, and to
identify a gap in the knowledge base about the impact of community risk factors on
donor risk models. This review led to the development and validation of a novel donor
quality model tailored to NAFLD/CC recipients of LT: the DQ-NAFLD. This chapter
includes the following items:


the literature review strategies;



the theoretical framework that shaped this study and framed the research
questions;



review of literature related to the source, concept, and constructs of the
theoretical framework and how the theory has been applied in similar studies;



review of literature to describe the spectrum of NAFLD and NASH, including
the donor allocation system based on the MELD score and its impact on the
wait-list mortality of NAFLD patients;
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review of donor risk models previously developed, including machine
learning approaches to donor-recipient matching models, the variables
utilized, the similarities, the differences and the limitations of each model;



review of the utilization of marginal donors, including older donors and
donation after cardiac death; and



review of literature that addressed the impact of community health indicators
on post liver transplant outcomes.
Literature Review Strategy

A comprehensive literature review including the most recent literature and
seminal studies on the study topic was conducted. This included the period 2002 through
2018 by querying the following databases: MEDLINE, Science Direct, ProQuest Central,
and PubMed. Also queried were major peer-review liver transplant journals, including
the American Journal of Transplantation, Liver Transplantation, Journal of Hepatology,
Journal of Gastroenterology and Hepatology, and BMC Gastroenterology. Key words (in
combination with liver transplantation) included donor quality, donor risk index, donor
allocation, liver transplantation, NASH, NAFLD, cryptogenic cirrhosis, wait list
mortality, liver wait list mortality, donor allocation, MELD, marginal donors, suboptimal
donors, DCD, donation after cardiac death, non-heart beating donors, Socio Ecological
Model, SES, and community health indicators. The criteria for selection of peer-reviewed
articles were (a) U.S. system of allocation (although some international studies were also
considered for comparison purposes), (b) English language, (c) adult subjects, (d) related
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to study concept of donor quality and variables, and (e) related to the study population.
Titles, abstracts, and articles were reviewed, and articles that met the inclusion criteria
were selected for review.
Theoretical Foundation
The theoretical framework is the backbone of planning research. Theories shape
the way research is conducted and add structure and consistency from topic selection to
the literature review, development of research questions, study design, and analysis plan
(Alderson, 1998). The theoretical framework that shaped this study and framed the
research questions was based on the social-ecological model (SEM) (McLeroy et al.,
1988). SEM is a theory-based framework that can be used to examine the complex
interplay between individual, community, and social factors that increase or decrease the
risk of poor posttransplant outcomes (Stilley et al., 2010). The SEM can help to
understand the multifaceted and multilevel interactions between personal and
environmental factors that determine behaviors and guide in identifying the social
determinants of health, or those unfair conditions in the social environment that can
impact access to liver donors and can increase the risk of poor post liver transplant
outcomes.
Figure 1 illustrates the five nested hierarchical levels of influence of the SEM.
The individual levels include biological factors and patient behaviors. The interpersonal
level consists of the family and social networks. The community level includes the
distance from the transplant centers, environmental health risks, and insurance. The

27
organization level in the current study context includes the United Network for Organ
Sharing (UNOS), the Organ Procurement and Transplant Network (OPTN) and the Organ
Procurement Organization (OPOs). The policy level includes the donor allocation
policies.

Figure 1. The social ecological model (SEM) in the context of liver transplantation.
In Figure 1, the first level identifies the patient level, including individual and
biological factors, some of them modifiable through educational interventions. The
family and social network level factors include family members who are involved in
supporting patients throughout their transplant journey or the next of kin who provide
medical and behavioral information about a donor. Health care system level comprises
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the clinical pathway to a liver transplant, such as donor match, the transplant surgery,
quality of health care provided, and the nature of the community where patients reside.
Social level factors including listing and organ donation policies.
Researchers have studied the impact of social factors on health. Braveman and
Gottlieb (2014) suggested that healthcare is responsible for only 10-15% of preventable
mortality. However, individual behaviors have an impact on people’s health by 40%,
genetics by 30%, and social and environmental factors by 20%. Therefore, there is
substantial evidence in the United States, and globally, that social determinants of health
have a substantial impact on morbidity and mortality in the general population. In
addition to individual factors, such as socioeconomic status, education, individual
behavior, and social support, environmental factors, such as access to healthcare and
healthy food options vary by region and county.
One of the implications of heterogeneity in these risks is its potential impact on
risk models that predict patient outcomes. Ignoring these underlying risk factors of
transplant recipients not available from medical charts can result in biased performance
of transplant risk models, because social determinants of health impact the outcomes
(Schold, Phelan, & Buccini, 2017). Given a socioecological conceptual framework, a
donor risk model that evaluates recipient and donor match and their impact on posttransplant outcomes can be refined by adjusting for community characteristics.
The SEM framework was used in transplant studies to identify social determinant
of referral for kidney transplant evaluations to plan educational intervention aimed at

29
improving equity in access to kidney transplant or to analyze the sociocultural pathways
to organ donation among American Indian adults (Fahrenwald & Stabnow, 2005). The
social-ecological theory implies that there are complex social determinants of post-liver
transplant outcomes (Braveman & Gottlieb, 2014). It is necessary to act on multiple
levels to improve survival after liver transplant.
Nonalcoholic Fatty Liver Disease
During the past century, the world has experienced a significant decline in
mortality and a substantial increase in life expectancy. Chronic diseases have replaced
acute infectious diseases becoming the predominant cause of morbidity and mortality
worldwide. NAFLD is becoming the new epidemic in chronic liver disease, which
mimics the worldwide epidemics of obesity and type 2 diabetes. It is projected to become
the most frequent indication for LT by 2030 (Byrne & Targher, 2015).
NAFLD Spectrum
NAFLD. NAFLD is a multisystem disease in which excess fat is stored in the
liver, primarily associated with other comorbid conditions such as obesity, diabetes
mellitus, cardiovascular disease, hyperlipidemia, metabolic syndrome, and chronic
kidney disease (Argo & Caldwell, 2009). Patients with NAFLD are often older age, with
obesity and other metabolic comorbidities, and at a high risk to develop cardiovascular
complications. NAFLD affects the hepatic structure and function and can lead to
cirrhosis, liver failure, and hepatocellular carcinoma (HCC). Consequently, NAFLD is a
leading cause of cirrhosis, HCC, and the need for liver transplantation. However,
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cardiovascular disease is the primary cause of deaths among NAFLD patients (Byrne &
Targher, 2015).
NASH. The spectrum of NAFLD includes simple steatosis and steatohepatitis
(NASH) which is a progressive, and fibrotic liver disease. Fatty liver accumulation or
steatosis alone is classified as Type 1 NAFLD, steatosis and lobar inflammation as Type
2 NAFLD, steatosis and ballooning degeneration as Type 3 NAFLD, steatosis ballooning
degeneration and fibrosis is Type 4 NAFLD. Types 3 and 4 are defined as NASH.
Described for the first time by Ludwig, Viggiano, Mcgill, and Oh (1980) as “a poorly
understood and hitherto unnamed liver disease” (p. 434), NASH is a progressive fibrotic
liver disease that can lead to HCC and end-stage liver disease. One consequence of
NASH is the appearance of liver fibrosis, measured by a score that ranges from F0
(absence of fibrosis) to F4 (liver cirrhosis) (Chalasani et al., 2018). NASH is diagnosed
with a liver biopsy.
Cryptogenic cirrhosis. Cryptogenic cirrhosis (CC) is the end stage of chronic
liver disease in which the underlying etiology is unknown and undentified after extensive
clinical, serological, and pathological evaluations. Powell et al. (1990) observed a gradual
loss of steatosis in cases that progressed from NASH to cirrhosis, and Caldwell and
Marchesini (2018) noted that metabolic risk factors were common among individuals
with CC. This suggests that some cases of CC can be attributed to advanced NASH,
although other causes of CC do exist. Thuluvath, Kantsevoy, Thuluvath, and Savva
(2018) revealed that CC should not be considered the same as NASH cirrhosis. It remains
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debatable if the two entities are essentially the same. Further investigations are required
to identify unknown causes of cirrhosis (Caldwell & Marchesini, 2018; Thuluvath et al.,
2018). Figure 2 illustrates the NAFLD disease spectrum as revealed by biopsy results.

Figure 2. NAFLD spectrum.
Note. Source: NASH Biotech. Retrieved from
http://www.nashbiotechs.com/newsletter.html. NAFL=Non-alcoholic fatty liver;
NASH=Nonalcoholic steatohepatitis.
Epidemiology of NAFLD and NASH
The epidemiology and demographic characteristics of NAFLD usually constellate
obesity and type 2 diabetes; however, a portion of NAFLD patients are lean (Younossi et
al., 2016). NAFLD is increasingly prevalent in the U.S. and globally and is a major cause
of advanced liver disease. Consequently, the number of liver transplants for NASH
nationwide has increased over time. Many NAFLD patients are likely to progress to more
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advanced liver disease. However, it is challenging to screen for NASH because invasive
liver biopsy is needed.
The global prevalence of NAFLD is currently estimated to be 24% (Younossi et
al., 2016). In the United States among patients with NAFLD and in the general
population, the prevalence of NASH is estimated to be 21%, and 3-4%, respectively
(Younossi et al., 2016). The prevalence of NAFLD in the United States varies by
ethnicity: highest among American Hispanics followed by Americans of European origin
and African Americans. The ethnic disparity in the prevalence of NAFLD is not fully
understood. The high prevalence of obesity and hypertension and the low prevalence of
NAFLD among African Americans suggest that ethnicity may influence the association
of metabolic syndrome with NAFLD (Smits, Ioannou, Boyko, & Utzschneider, 2013).
Moreover, even within a specific ethnic group in the United States, there may be
differences in the prevalence of NAFLD associated with the country of origin, which
remain unknown (Fleischman, Budoff, Ifran Zeb, & Foster, 2014). Genetic and
environmental factors may explain some of these differences.
Risk Factors of NAFLD
The progression of NAFLD from steatosis to NASH fibrosis is estimated to be 14
years, and progression to each subsequent fibrosis stage is estimated to be seven years.
As the stage of fibrosis increases, so does the risk of liver-related mortality. Authors of
population-based and familial-aggregation studies, as well as twin-studies, have given
evidence of a heritable component of NAFLD that ranges from 20 to 70 %. NAFLD
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heritability differs among ethnicities, greater among Hispanics (33%), as compared to
African Americans (14%) (Loomba et al., 2015; Speliotes et al., 2011).
Epigenetic factors. Various factors contribute to the development of NAFLD,
including genetic predisposition, environmental exposures, and lifestyle (Gerhard &
DiStefano, 2015). Major advances have uncovered the genetic basis for the heritability of
NAFLD. In NAFLD, genome-wide HCV association studies have identified novel loci
associated with disease severity phenotypes and approximately seven categories of genes
associated with NAFLD (Anstee & Day, 2015).
Role of environmental factors. A combination of genetic predisposition and
environmental factors contribute to the development of NAFLD. Dietary habits, activity,
and socioeconomic factors predispose individuals to NAFLD. Patients with NAFLD tend
to have easy access to fast food places and restaurants, and, therefore, more likely to have
unhealthy eating habits and low physical activity levels as compared to healthy
individuals. The role of socioeconomic factors is not well defined. Kallwitz et al. (2015)
explored the role of environmental factors in different ethnic groups with NAFLD to
investigate the effect of environmental factors on genetic predisposition. They studied the
impact of dietary and lifestyle factors together with the impact of acculturation, education
level, income and access to health care, and found that they were not independently
associated with the risk of developing NAFLD, suggesting a joint effect between
environmental and genetic factors (Younossi et al., 2016).
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Historical and Logistical Aspects of Liver Allocation
The National Transplant Act of 1984 established an organ matching and
procurement network which prohibits the buying and selling of organs and mandates the
maintenance of an equitable system for the allocation and distribution (Coombes &
Trotter, 2005). The Organ Procurement and Transplantation Network (OPTN) is a system
for donor matching and allocation, and its membership includes every transplant hospital
program, organ procurement organization (OPO), and histocompatibility laboratory in the
United States, certified by the United Network for Organ Sharing (UNOS). Each UNOS
entity plays an active role in forming the policies that govern the transplant community.
The Transplant Act also required that the OPTN, under federal contract, is managed by
UNOS via a Board of Directors and committee members to operate the OPTN (UNOS,
2018).
UNOS Regions
The system of allocation employed by UNOS divides the United States into 11
geographical areas called UNOS regions as depicted in Figure 3.
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Figure 3. UNOS regions.
Note. Source: OPTN (n.d.) Retrieved from
https://optn.transplant.hrsa.gov/members/regions.
The states in each region are shown in Table 1. Each of these regions, initially
established by the OPTN for administrative and representative purposes, are represented
on the Board of Directors and each of the standing OPTN committees. The geographic
subdivisions were never established with the purpose to provide an equal distribution of
organs among populations of transplant centers. The division of these 11 geographic
regions was designed to recognize existing relationships within the transplant community
as well as the local interests of each transplant center (OPTN, 2018).
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Table 1
States in UNOS Regions
Region States
1

Connecticut, Maine, Massachusetts, New Hampshire, Rhode Island, Eastern
Vermont

2

Delaware, District of Columbia, Maryland, New Jersey, Pennsylvania, West
Virginia, Northern Virginia

3

Alabama, Arkansas, Florida, Georgia, Louisiana, Mississippi, Puerto Rico

4

Oklahoma, Texas

5

Arizona, California, Nevada, New Mexico, Utah

6

Alaska, Hawaii, Idaho, Montana, Oregon, Washington

7

Illinois, Minnesota, North Dakota, South Dakota, Wisconsin

8

Colorado, Iowa, Kansas, Missouri, Nebraska, Wyoming

9

New York, Western Vermont

10

Indiana, Michigan, Ohio

11

Kentucky, North Carolina, South Carolina, Tennessee, Virginia

Note. Source: OPTN (n.d.) Retrieved from
https://optn.transplant.hrsa.gov/members/regions
Donation Service Areas
Within each UNOS region, there are variable numbers of donation service areas
(DSAs). Each DSA is served by one of the 58 OPOs that are responsible for identifying
potential donors and coordinating all the activity leading up to and including the organ
procurement. Each OPO is considered the first point of contact when a potential organ
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donor is identified in a specific DSA. The Center for Medicare Services designates these
DSAs (Figure 4), but they vary regarding the number of transplant centers served, square
mileage of the area, state boundaries, candidate/donor ratios, and procurement rates and
characteristics.

Figure 4. OPO donation service area map.
Note. Source: Wedd, Harper, and Biggins (2013)
This current allocation scheme was adopted over 20 years ago. Livers are offered
to sicker patients within the donor area before being offered to other parts of the country.
The variation in DSAs has raised concerns that access to deceased donors is unequal
across DSAs leading to a regional variation in posttransplant outcomes. Yeh, Smoot,
Schoenfeld, and Markmann (2011) analyzed organ availability in terms of transplant rate
and MELD with exceptions using national data from 2002 to 2009. They found
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remarkable differences across DSAs. Transplant rates varied by 20.1-fold and average
MELD score ranged from 23.8 to 31.2, indicating that patients in low average MELD
DSA could reach the top of the wait list faster compared to other DSAs. As a result, high
average MELD DSAs, which have low organ availability, were associated with high
mortality rates. Therefore, geographic inequity in access to deceased donor livers
suggests that the organ distribution areas need to be restructured to guarantee equity (Yeh
et al., 2011).
The National Transplant Act established a system of regulation and oversight for
the field, a data management system to track outcomes and is a mandate to review and
continuously provide an equitable distribution of organs in the United States. UNOS is a
regulatory entity where professional input, patient advocacy and public opinion regarding
the field of transplantation are all considered. Although this contracting entity provides
regulations regarding the allocation and distribution of organs, rules regarding allocation
are adopted after exhaustive dialog and consensus among participating members. Given
the competing interests of each member, may be difficulty to reach consensus within the
group (UNOS, 2018).
The disparity in supply and demand of cadaveric organs has driven much of the
policy discussion within the life-saving liver transplantation field. The method by which
donor organs are allocated to individuals on the wait list for transplants is a relevant topic
for research and debate, needed to meet the dual goals of fair allocation and optimum
efficiency.
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The Final Rule
Despite clinical and scientific advances within the field, perceived inequities exist
regarding geographical disparity as well as increased mortality on the wait list for those
awaiting a liver transplant. When liver transplants first initiated, the allocation policy was
based on little more than total time spent on the transplant wait list. This gave
decompensated patients with recent diagnoses of end-stage liver disease little hope for
transplantation. Under this system, wait-list mortality and drop-out rates were high
(OPTN, 2018).
In 1998, these perceived inequities were addressed by the Department of Health
and Human Services in the form of a “Final Rule” to ensure that the allocation of scarce
organs was based on medical need and not on wait time. The Institute of Medicine
addressed this issue of disparity and recommended a restructuring of the liver allocation
process to deemphasize wait time and provide a more equitable distribution based on
predictive prognosis (Coombes & Trotter, 2005). Moreover, the “Final Rule” was
intended to place greater emphasis on acuity and less focus on keeping organs within
local procurement areas. To achieve the goal of equitable distribution of a scarce
resource, the Final Rule provided two recommendations to the transplant community:
1. an expansion of the geographical area served by each OPO to equalize access;
and
2. The development of an allocation system that prioritizes based on acuity and
deemphasizes waiting time.
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Liver Allocation Based on Acuity
To address the recommendation regarding redirecting allocation based on acuity,
Kamath et al. (2001) developed the MELD score in February 2002, a metric for liver
allocation. The MELD score predicts short-term mortality and is calculated using three
laboratory values: the total serum bilirubin, serum creatinine and the international
normalized ratio (INR) according to Equation 1:
MELD=3.78 ln [serum total bilirubin (mg/dL)] +11.2 ln (INR)

(1)

+ 9.57 ln [serum creatinine (mg /dL)] +6.43
The MELD score is used to determine priority for LT candidates, who are placed
on a national transplant list. Donor organs are allocated first regionally, then locally and
regionally. The utilization of the MELD score had several advantages. Easly calculated
from widely available laboratory tests, the MELD score allocation system resulted in a
reduction of wait-list mortality and median waiting times (Asrani & Kim, 2011). The
MELD score is intended to reflect the severity of the candidate’s disease. However, for
certain liver diseases, such as acutely decompensated cirrhosis, HCC,
cholangiocarcinoma, hepatopulmonary syndrome, pulmonary hypertension, and familial
amyloidosis, where the progressions are not weighted into the MELD scores, the
calculated MELD score is inadequate to reflect the candidate’s medical urgency
(Bernardi et al., 2011; Martin & O’Brien, 2015). To balance their risks of tumor
progression or other medical conditions, the MELD score is adjusted by adding exception
points. The MELD score, with or without exception points, determines prioritization on
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the transplant wait list ranked by an increased risk of death. It is applicable to a majority
of chronic liver diseases (Asrani & Kim, 2011). The MELD score allocation rule is not
applicable to Status 1 patients, who have acute fulminant hepatic failure at high risk of
death within a week if a liver transplant is not performed.
Over the years, investigators have proposed numerous modifications to the
MELD scoring system (Kalra, Wedd, & Biggins, 2016). Sharma, Schaubel, Sima,
Merion, and Lok (2008) found that serum creatinine may have a high weight in the
existing MELD formula and proposed a re-weighted MELD score that assigns higher
weight to bilirubin and lower weight to creatinine and IRN. In liver transplant candidates,
serum sodium is an independent predictor of post-transplant mortality, associated with
mortality independent of MELD score, particularly for those with low serum sodium
levels (Kim & Lee, 2013). Huo et al. (2007) developed the MELD to serum sodium
(SNa) ratio (MESO) to combine both the predictive power of MELD and SNa. Several
investigators have shown that incorporating sodium into the MELD score increases its
predictive accuracy (Biggins et al., 2006; Biselli et al., 2010; Heuman et al., 2007).
Kim et al. (2008) showed that using the MELD-Na score over standard MELD
score can reduce wait-list deaths by 7%. Supported by these findings, a modified MELD
score with added serum sodium was implemented on January 11, 2016 (Biggins et al.,
2006). The MELD-Na score is calculated through Equation 2:
MELD-Na = MELD+1.32 x (137-Na) - [0.033 x MELD x (137-Na)]

(2)
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Expansion of the Geographical Areas
The first recommendation to expand all service areas for organ procurement to
serve a population base of nine million people was met with strong opposition from much
of the transplant community and was never adopted (Ahmad, Bryce, Cacciarelli, &
Roberts, 2007). Several states, including Louisiana, Wisconsin, Texas, Arizona,
Oklahoma, Tennessee, and South Carolina, passed legislation prohibiting such expansion
based on established limitations to interstate commerce (Meckler, 1998). Investigators are
exploring new strategies to change the distribution system and reduce geographic
disparities.
Regional sharing for candidates with MELD scores of 15 or greater. Until
January 2005, the allocation of livers by acuity remained almost an exclusive locally
driven system, whereby organs were allocated to the most acutely ill patients (Status 1
patients). This was done locally and then regionally, and before allocation to the highest
MELD score patients locally and regionally. Merion et al. (2005) found that survival
benefits from the liver transplant procedure occurred for patients with MELD score above
18, while undergoing a transplant with a MELD score below 5 yielded a probability of
mortality that was higher than those continuing to wait for a liver transplant. They
suggested reconsidering the liver allocation policy for low MELD candidates and adding
survival benefit component in the liver allocation policy. As a result, a change in the liver
allocation policy occurred when the OPTN implemented the minimum-15 rule on
January 12, 2005 (Regional Share 15 Rule). This rule requires that organs be offered first
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to Status 1 patients locally and then regionally, and then to patients with a minimum
MELD score of 15 locally and then regionally. If no such recipients are identified, offers
to patients with MELD scores less than 15 are allowed. The minimum-15 rules were
intended to address inequities in organ distribution based on the geographical difference
in acuity of liver disease. This organ allocation policy change resulted in a 36% decrease
in the proportion of liver recipients with a MELD score less than 15 undergoing
transplant but did not change the sharing outside DSAs (Bittermann, Makar, & Goldberg,
2012; Elwir & Lake, 2016).
Regional sharing for Status 1 candidates. On December 15, 2010, the OPTN
implemented full regional sharing of adult donor’s livers for all Status 1 candidates.
Previously, livers in most regions were offered to Status 1 candidates first locally, and
then regionally. Implementation of full regional sharing has promoted timely access to
donor livers to Status 1 candidates and decreased wait list death rate.
Regional Share 35/National Share 15. In 2012, the Health and Human Services
Advisory Committee on Transplantation recommended an evidence-based organ
allocation, rather than a system based on arbitrary boundaries of OPOs or their DSAs.
OPTN/UNOS acknowledged that there were unacceptable geographic disparities in
access to transplantation and charged organ-specific committees to develop a policy to
minimize geographic effects. In 2013 the liver allocation policy was modified with the
implementation of Share 15 National and Share 35 Regional to increase regional, national
access for highly urgent liver candidates with MELD score of 35 or higher (Washburn,
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Pomfret, & Roberts, 2011). Regional Share 35 policy resulted in an increase in the
number of transplants and a decrease in the number of discarded liver organs (Halazun et
al., 2016). Additionally, the Regional Share 35 policy resulted in 30% decrease in waitlist mortality for high MELD recipients and an increase in LT patients in the intensive
care unit or on life-support devices (Massie et al., 2015).
Revised Policy Exception Scores for Hepatocellular Carcinoma (HCC)
One unintended consequence of the MELD allocation system has been an
increase in transplanting patients with HCC. To account for their risk of tumor
progression, they were provided with MELD exception points. Subsequent studies
showed that HCC priority points favored HCC candidates. Therefore, the MELD
exception policy was modified several times by decreasing such exception points in 2003
and 2005 (Parikh & Singal, 2016). A recent revision of the OPTN liver allocation policy
implemented in 2015 modified the maximum value and the timing of exception scores for
HCC candidates. This created a better balance in transplant opportunities between
candidates with HCC exceptions and those with allocation priority based on their
calculated MELD score. The maximum HCC exception score was capped at 34 (Pais et
al., 2016).
Currently, a national system that provides equitable access to LT for candidates
whose disease severity is not accurately reflected by the calculated MELD score is not
available. There are regional agreements. Each region has a review board that adopts
independent criteria to evaluate requests for exceptions submitted by the liver transplant
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programs. To create greater consistency in assigning exception scores for medical
conditions not assessed reliably by the MELD score, the Liver Committee in January
2016 distributed a proposal to establish a national liver review board (NLRB) to replace
the regional boards in each of the OPTN regions (OPTN, 2018). This step is still under
evaluation.
Weaknesses of the MELD Allocation Model
In addition to favoring patients with HCC, the MELD allocation system has
resulted in a disproportionate number of patients within larger OPOs who are
transplanted at higher acuity levels than those patients in smaller OPO. Moreover, the
MELD score is not an accurate predictor of post-transplant mortality and does not include
donor characteristics (Habib et al., 2006). The MELD variables are subject to laboratory
variations (Cholongitas et al., 2007; Trotter et al., 2007). Serum creatinine is inaccurate
for cirrhotic patients and is influenced by gender, muscle mass, age, and ethnicity (Martin
& O’Brien, 2015). The MELD score may penalize female candidates because serum
creatinine, a function of muscle mass may underestimate the severity of liver disease in
women who have a lower muscle mass compared to men. As a result, the MELD
allocation system has resulted in a 12% decrease of the probability to receive a liver
allograft, and a 15% increased mortality on the wait list (Lai et al., 2010; Myers,
Shaheen, Aspinall, Quinn, & Burak, 2011). Though the MELD score has improved
equity in the liver allocation process, there is still a significant mortality rate on the LT
wait list. The MELD score may not be a reliable predictor of liver-related mortality for all
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patients (Bambha & Biggins, 2008; Huo et al., 2007). Some candidates may have
clinically significant complications not captured by the MELD, such as the NAFLD/CC
patients, who may experience disproportionate rates of wait-list dropout and are thus at
risk of death while on wait list (Kwong et al., 2015).
The impact of MELD allocation model on NAFLD/NASH. Patients with
NASH, cryptogenic cirrhosis and low MELD score have slower disease progression and
are less likely to receive an LT than patients listed for other end-stage liver diseases.
Cardiovascular comorbidities, renal complications, and older age are likely to increase
the risk of wait-list dropouts and unfavorable short-term outcomes. For this reason,
patients with NAFLD cirrhosis have a low priority, and they often die on transplant wait
list. Although patients with NAFLD cirrhosis have operative difficulties and a high rate
of postoperative complications, their long-term post-transplant outcomes are not inferior
to patients transplanted for other etiologies (Pais et al., 2016). Patients transplanted for
NAFLD cirrhosis have short term morbidity and mortality, but high middle- and longterm post-transplant graft and patient survival rates (O’Leary et al., 2011). Proper
management of NAFLD patients on the wait list can increase access to LT and decrease
the risk of posttransplant complications.
High Risk Donors
Patients waiting for a liver transplant are steadily increasing. Parikh et al. (2015)
conducted a study to project donor growth. They used a Monte Carlo simulation to
measure the impact of several factors on population growth and liver donor utilization,
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and they estimated population growth of 7.1% in 2025 but a lower 6.1% donor utilization
growth. The aging of the U.S. population and the obesity epidemic indicate that potential
LT candidates are growing at a faster rate than potential donors, widening the gap
between donors used and waiting patients.
Organ shortage has extended the standard criteria and led to exploring innovative
approaches to increase organ supply, including live donor transplants, the use of split
livers, non-optimal donors, i.e., donors after circulatory death (DCD), high-risk death
brain donors (DBD), and extended-risk donors (Saracino, 2018).
Donors After Circulatory Death (DCD)
Donation after cardiac death describes the retrieval of no–heart-beating organs for
transplantation following confirmation of death using circulatory criteria. DCD typically
have irreversible brain injuries with no chance for recovery, but they do not meet the
criteria for brain death. They progress to cardiac arrest after withdrawal of life support.
DCD livers are more susceptible to damage than DBD livers and can lead to
posttransplant complications including ischemic-type biliary lesions complications and
higher rates of primary nonfunctioning and graft failure (Blok et al., 2016; Saracino
2018).
Orman, Barritt, Wheeler, and Hayashi (2013) conducted an exploration of the
association between donor characteristics and donor use. They observed a decreasing
trend in donor utilization from 1988 to 2004, and then a gradual increase. The proportion
of nonuse DCD livers increased from 9% in 2004 to 28% in 2010. With an aging
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population, increased body mass index, and the prevalence of diabetes, the donor quality
has worsened, leading to a significant decline in LT availability. The increasing
proportion of discarded DCD livers indicates a reluctance to use these suboptimal
allografts due to the recognition that outcomes will be worse. There is a critical need for
strategies for the optimal utilization of marginal donors in subsets of LT recipients that
would benefit a DCD donor without worsening post-transplant outcomes.
Public Health Service Increased Risk Donors
In 1994 CDC established criteria to define high-risk donors based on social
behaviors that increase their risk for blood-borne diseases, including human
immunodeficiency virus (HIV), even if these donors tested negative by serologic
screening for infectious disease (Rogers et al., 1994). In July 2013 U.S. Public Health
Service (PHS) published the “increased risk” guidelines that expanded the CDC “high
risk” guidelines including the likelihood of recent hepatitis B virus (HBV) and HCV, in
addition to HIV infection (Seem et al., 2013). The increased-risk designation refers to
donor’s risk behaviors including men who have had sex with other men, history of drug
abuse, prostitutes, inmates, persons with hemophilia, persons who have had sex with
persons who engaged in high-risk behaviors, and children born from mothers with highrisk behaviors. CDC high-risk donors before 2013 and increased-risk donors are often
discarded as they are considered at risk of transmitting specific infection pathogen, and
some recipients are unwilling to consider them. I have provided more details about CDC
high-risk and PHS increased-risk criteria in Appendix B.
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Transplant candidates should be informed if they are being offered organs from
increased-risk donors to evaluate the risk of accepting a donor at risk of transmitting
recent blood-born infection versus the risk of prolonging their time on the wait list
(Kucirka et al., 2015). Therefore, PHS increased-risk donors are potentially underutilized
and contribute to increasing wait-list time (Volk, Wilk, Wolfe, & Kaul, 2017). However,
the absolute risk of transmission is very low, and many patients could utilize these organs
and receive a substantial predicted survival benefit instead of prolonging their stay on the
liver transplant wait list and increase their risk of mortality while waiting for a low-risk
donor (Kucirka et al., 2015).
Expanded Criteria Donors (ECD)
Currently, the OPO defines Expanded Criteria Donor (ECD) as a donor at least
60-year-old or a donor between 50- and 60- year-old with at least two of the following
conditions: hypertension, serum creatinine ≥1.5, or stroke as a cause of death. ECD
donors are not considered ideal, but they can expand the donor pool and increase the
options for some candidates to shorten their time on the wait list (Vodkin & Kuo, 2017).
Based on the ECD criteria donors are either classified as ECD or as non-ECD, which
does not capture all the spectrum of donor risk.
The Concept of the Donor Risk Index
The liver allocation policy based on the MELD score only includes LT candidate
characteristics and estimates the short-term risk of death while waiting for an LT.
However, donor-recipient matching and organ acceptance are complex decisions The
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MELD score-base prioritizes sicker patients rather than prioritizing based on achieving
an optimal donor-recipient match or post-transplant survival. In recent years,
investigators have emphasized the need to apply the concept of utilitarianism to the organ
allocation system (Briceño et al., 2013). Organ allocation models seek to maximize the
survival benefit of the entire patient population rather than of an individual patient, or to
save more years of life, rather than more lives (Briceño et al., 2013). Relevant steps
include the development of a donor risk model, which seek to predict the survival of the
donated liver after transplantation, enabling “matching” between the expected posttransplant lifespan of the liver with that of the recipient. Donor quality and recipient
characteristics have an impact on graft survival after a solid organ transplant (Weiss et
al., 2012).
In their seminal paper, Feng et al. (2006) developed the first donor risk index
(DRI), a metrics for donor quality with emphasis on the importance of donor factors for a
successful LT. The DRI has been used in multiple studies to quantify donor quality and to
help understand the impact of donor factors on selected recipients, including those with a
low MELD score or HCV (Flores & Asrani, 2017). In national surveys, 46% of transplant
specialists felt that the availability of a reliable and practical DRI would improve shared
decision making at the time of donor offer. However, unlike the MELD score, the DRI
has not been translated into liver allocation policy and practice. Several risk models have
been proposed using donor, recipient, and interoperative factors to predict post-transplant
survival to facilitate transplant decision-making (Flores & Asrani, 2017).
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With the utilization of ECD and DCD donors, the DRI may assist in decision
making and in evaluating organ and patient outcomes (Akkina et al., 2012). Volk, Lok,
Pelletier, Ubel, and Hayward (2008) showed that high-risk livers or livers with high DRI
were more likely to be used for low disease severity recipients and less likely to be used
for Status 1 or high MELD score recipients. Less urgent candidates or low MELD
patients were likely to receive high-risk organs leading to unfavorable posttransplant
survival. Schaubel, Sima, Goodrich, Feng, and Merion (2008) found that high DRI
donors had a detrimental effect on recipients in the lowest MELD category ranging from
6 to 8, and proposed transplantation of high DRI organs for high-MELD candidates.
Maluf, Edwards, and Kauffman (2006) analyzed the association between extended
criteria donation and DRI>1.7 and found no interaction between DRI and MELD score,
suggesting that high-DRI livers can be transplanted in high-MELD recipients with no
impact. Rauchfuss et al. (2013) found that waiting time is a critical factor in high-MELD
patients while DRI is less critical, suggesting that high-MELD patients would benefit
from earlier transplantation with a high-DRI donor rather than waiting for an optimal
organ. In decision making, it is preferable to use high-risk donors in patients with
advanced MELD score rather than waiting for a low-risk donor (Amin et al., 2004).
Donor Risk Models to Predict Posttransplant Graft Survival
Following the development of the DRI, several risk models to predict posttransplant survival have been developed using donor, recipient, and operative factors to
predict post-transplant survival. Some studies have attempted to identify the most
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relevant risk factors and to develop several statistical models designed to predict graft
outcomes with improved predictive ability, as compared to the DRI. Other studies have
attempted to validate the DRI or to adapt it to other country populations. I summarized
selected models and their relative advantages and disadvantages in Tables 2 and 3.
Table 2
Donor Risk Models to Predict Post-Liver Transplant Graft Survival
Risk model
DRI

Risk factors
Donor: age, race, height, DCD, split liver, COD.
Transplant: allocation, CIT

ET-DRI

Donor: age, DCD, split liver, latest serum GGT gamma-glutamyl
transpeptidase, allocation, rescue allocation.
Transplant: CIT
Donor: age, creatinine, COD.
Recipient: age, BMI, previous LT, previous abdominal surgery,
albumin, dialysis, UNOS status, MELD score, encephalopathy, PVT,
ascites, portal bleed, life support.
Transplant: allocation, CIT

SOFT

BAR

Donor: age.
Recipient: age, MELD score, previous LT, life support
Transplant: CIT

D-MELD

Donor: age.
Recipient: MELD score

DQI

Donor: age, COD, ICU stay, split liver, lowest MDRD creatinine
clearance

Notes: BAR: Balance of risk; BMI: Body mass index; COD: Cause of death; CIT: Cold ischemia time;
DCD: Donation after cardiac death; D-MELD: Donor age Model for End-stage Liver Disease; DQI: Donor
Quality Index; DRI: Donor Risk Index; ET-DRI: Eurotransplant donor risk index; GGT: latest serum GGT
gamma-glutamyl transpeptidase; ICU: Intensive Care Unit; LT: Liver transplant; PVT: Portal vein
thrombosis; SOFT: Survival outcomes following liver transplantation
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Table 3
Donor Risk Models. Strengths and Weaknesses
Risk model

Strengths

Weaknesses

DRI

Validated in recipient subsets.
Variables available at the time of
transplant.

Developed with data pre-MELD.
Variables not all accountable at the
time of donor offer. Race not a
reliable predictor.

ET-DRI

All variables available at the time
of transplant.

Not all variables available at the
time of offer, poor external
validation.

SOFT

Can be used to predict wasteful
transplants and survival benefit.

Complex model with many
variables not available at the time
of offer. Predicts only short-term
mortality. Similar predictions with
and without donor factors.

BAR

Variables available at the time of
transplant.

Predicts only short-term mortality.
Lacks granularity define futility
but only 3% of transplants would
meet the definition.

DRI

Validated in recipient subsets.
Variables available at the time of
transplant.

Developed with data pre-MELD.
Variables not all accountable at the
time of donor offer. Race not a
reliable predictor.

ET-DRI

All variables available at the time
of transplant.

Not all variables available at the
time of offer, poor external
validation.

SOFT

Can be used to predict wasteful
transplants and survival benefit.

Complex model with many
variables not available at the time
of offer. Predicts only short-term
mortality. Similar predictions with
and without donor factors.
(table continues)
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Risk model

Strengths

Weaknesses

BAR

Variables available at the time of
transplant.

Predicts only short-term mortality.
Lacks granularity define futility
but only 3% of transplants would
meet the definition.

D-MELD

Very simple model to use.

Penalizes older donor livers with
high-MELD recipients.

DQI

Use few variables available at the
time of offer

Use data from French transplant
registry. Not externally validated.

Notes: BAR: Balance of risk; D-MELD: Donor age Model for End-stage Liver Disease; DQI: Donor
Quality Index; DRI: Donor Risk Index; ET-DRI: Eurotransplant donor risk index; SOFT: Survival
outcomes following liver transplantation.

The Donor Risk Index
Feng et al. (2006) developed the first DRI using a population of adult recipients of
cadaveric liver transplant in the United States from 1998 to 2002 and data from SRTR.
They identiﬁed seven donor characteristics significantly associated with liver failure,
three of them related to donor demographics (age, race, and height), then donor cause of
death (trauma, cerebrovascular accident, anoxia, and others), the type of death (DCD or
non-DCD) and whole or partial/split transplant. The model also included cold ischemia
time and sharing donor service area (local, regional and national). From the Cox
proportional hazard model, the derived equation to estimate the DRI is presented in
Equation 3:
DRI = exp [(0.154 if 40≤ age <50) + (0.274 if 50≤ age <60)
+ (0.424 if 60≤ age <70)

(3)
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+ (0.501 if 70 ≤ age) + (0.079 if cause of death = anoxia)
+ (0.145 if cause of death = cerebrovascular accident)
+ (0.184 if cause of death = other)
+ (0.176 if race = African American) + (0.126 if race = other)
+ (0.411 if donation after cardiac death) + (0.422 if partial/split)
+ (0.105 if regional share) + (0.24 if national share)
+ (0.010 x cold ischemia time)]
Notes: The term exp implies e raised to a value, i.e., 𝑒𝑥𝑝(𝑣𝑎𝑙𝑢𝑒) = 𝑒 (𝑣𝑎𝑙𝑢𝑒)
The reference donor, or the lowest risk donor, would be a white donor with age
under 40-year, who died of trauma, with height of 170 cm, with a whole local non-DCD
organ with cold ischemia time of eight hours. Lowest risk donors accounted for 19% of
LT recipients in the study population; their estimated one-year graft survival ranged
between 87% and 89% and their estimated three-year graft survival between 80% and
83%.
Recipients with the highest-risk livers, i.e., with African-American donors of age
greater than 40, who died for a cause other than trauma, with height lower than 170 cm,
and a split or partial national DCD liver with cold ischemia time greater than eight hours,
had an estimated 1-year graft survival between 69% and 74% and a 3-year graft survival
between 57% and 63% (Feng et al., 2006).
Validation of the Donor Risk Index. Subsequent studies have validated the DRI
as an independent predictor of liver graft failure in the U.S. populations as well as in
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populations of other countries in the post-MELD era (Hung et al., 2015; Northup et al.,
2015; Rosenberger et al., 2014). Donors with DRI of more than 1.7 have been associated
with a significant increase in the risk of liver failure in each MELD category.
Additionally, the DRI has also been associated with the development of post-transplant
complications, such as hepatic artery thrombosis, biliary complications, end-stage renal
disease (Israni et al., 2013; Stine, Argo, Pelletier, Maluf, & Northup, 2016). Some
researchers have also looked at the economic impact of using high-risk livers on the cost
of LT, including the cost of increasing readmissions (Axelrod, Schnitzler, Salvalaggio,
Swindle, & Abecassis, 2007; Salvalaggio et al., 2011).
Donor quality quantified by the DRI score is associated with progressed fibrosis
among patients with HCV, and with survival in HCC recipients of a LT as well as for
those who undergo re-transplantation (Macdonald, Sewell, Harper, Roberts, & Yao,
2015; Stine et al., 2016).
Strengths and influences on transplant practices. The DRI score has been used
to define organs as high or low risk and enables using this classification of donor risk in
transplant practices (Feng et al., 2006). Moreover, the DRI has been instrumental in
identifying disparities in organ utilization. Mathur, Schaubel, Zhang, Guidinger, and
Merion (2014) showed that Hispanics were 21% more likely to get a lower-risk organ
compared to Caucasians. Since the implementation of Share 35, the DRI has shown the
unintended changes in practice pattern post-Share 35. Although liver acceptance offers
has declined significantly after Share 35, organs discarded pre–Share 35 or post–Share 35
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had no statistically different DRIs, suggesting that changes in organ acceptance could
lead to increasing national discard rates and organ waste (Goldberg, Levine, Karp,
Gilroy, & Abt, 2017).
An objective and effective scoring system that quantifies donor quality could be
beneficial in clinical practice and risk communication. Volk et al. (2013) found that there
is considerable variability among surgeons about their perception of donor risk and in
their estimates of the probability of graft failure for specific clinical scenarios. A useful
metric of donor quality could help physicians evaluate the donor risk and reduce surgeon
bias in organ acceptance practice.
Patients prefer an active role in decision making. Volk et al. (2011) conducted a
study to analyze patient decision making about donor quality in LT, and they found that
patients are biased toward acceptance of high-risk donors and would rather stay on the
wait list then accept a low-quality donor. They found that risk tolerance was associated
with personal beliefs and not with severity of disease, suggesting that understanding how
the patients think about organ quality can be used in risk communication counseling
patients about the risks and benefits of accepting a low-quality organ. They demonstrated
that risk communication needs to be tailored to patient understanding of organ quality.
Although patients may be initially riskaverse, this tendency can be mitigated if they can
understand the competing risk of dying on the wait list. Therefore, donor risk models
have the potentiality to provide a useful tool to transplant clinicians to educate patients on
their risks and benefits so that they can make an informed decision.
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Limitations and weaknesses of the DRI. The DRI is still not accepted in clinical
practice as a tool for donor-recipient matching. Mataya et al. (2014) conducted a survey
among physicians to assess LT decision making and the utilization of DRI. They found
that 73% of physicians perceived that the DRI did not incorporate the risk of liver failure,
while 88% felt that the variables used to develop the DRI were misleading. The DRI was
developed by Feng et al. (2006) using pre-MELD score data and may not reflect the
current LT practice. Moreover, the DRI includes the donor variable race that not only
lacks biological relevance but is also not a reliable predictor of posttransplant graft failure
and should not be included in donor risk models (Asrani et al., 2010; Flores & Asrani,
2017). Unmeasured confounding factors may also have an impact on post LT graft
failure.
Eurotransplant Donor Risk Index (ET-DRI)
Braat et al. (2012) developed a DRI tailored and adapted to the Eurotransplant
region (ET-DRI), using cadaveric LTs from 2003 and 2007. From the Cox proportional
hazard model, the derived six-factors ET-DRI is as shown in Equation 4:
ET-DRI = exp [0.960 ((0.154 if 40≤age<50) + (0.274 if 50≤age<60)

(4)

+(0.424 if 60≤age<70) + (0.501 if 70≤age) + (0.079 if cause of death = anoxia)
+(0.145× if cause of death = cerebrovascular accident)
+ (0.184 if cause of death = other) + (0.411 if donation after cardiac death)
+(0.422 if partial/split) + (0.105 if regional share)
+(0.244 if national share)) + (0.010 × (cold ischemia time−8 h))
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+0.06((latest lab GGT (U/L) - 50)/100) + (0.180 if rescue offer)]
Notes: The term exp implies e raised to a value, i.e. exp(𝑣𝑎𝑙𝑢𝑒) = 𝑒 (𝑣𝑎𝑙𝑢𝑒)
External validations of the DRI and ET-DRI when adapted to the French
transplant registry led to poor calibration and discrimination, suggesting that both models
need further validation and adjustment before being used for donor allocation rules
(Winter et al., 2017). A refinement of the ET-DRI that combined recipient factors, or the
combined donor-recipient model (DRM), showed an improved predictive ability (Blok et
al., 2015)
Survival Outcomes Following Liver Transplantation (SOFT)
The Survival Outcomes Following Liver Transplantation (SOFT) score developed
by Rana et al. (2008) utilized a combination of 18 recipient, donor, and operative factors
to predict 3-month post-transplant survival. The most significant risk factors were
previous transplants, warm ischemia time, and the need for life support. A reduced
version of the SOFT score that utilized only 14 risk factors available at the time of listing,
is the pre-allocation SOFT score (P-SOFT), used to evaluate a candidate prior to liver
allograft allocation. The SOFT score was derived from a multivariable logistic regression
model with the coefficients converted into points. The model includes multiple risk
factors limiting its applicability in clinical practice. Recipient and operative factors
dominate the SOFT score (Rana et al., 2008). Sensitivities analyses have shown that
short-term survival models with and without donor factors have similar performance.
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Therefore, the SOFT score is not an ideal tool to assess donor risk (Flores & Asrani,
2017).
Balance of Risk (BAR)
Dutkowski et al. (2011) developed a score system based on a few strong
predictors of post-transplant mortality. The balance of risk (BAR) score was derived
using UNOS data from 2002 to 2010 and six strong predictors of post-transplant
behavior: recipient MELD score; cold ischemia time; recipient age; donor age; previous
liver transplant; and life support dependence prior to transplant. A BAR score ranges
from 0 to 27 points derived from a logistic regression model. The model reflects an
exponential increase in 3-month mortality, and a BAR score above 18 is a marker of
transplant futility (Dutkowski et al., 2011). However, only 3% of the LT had a BAR
score greater than 18, or equivalently, only 3% met the definition of futile transplant
indicating that the BAR score lacks granularity and has limited applicability in decision
making (Flores & Asrani, 2017).
Donor Age and Recipient Model for End-Stage Liver Disease (D-MELD)
The donor age and recipient model for end-stage liver disease (D-MELD), a
combination of donor age and preoperative MELD, was proposed by (Halldorson et al.,
2009) to optimize donor-recipient matching. In this model, a cutoff of D-MELD score
greater than 1600 predicts unfavorable outcomes. Avoiding matching organs from older
donors with high-MELD recipients results in favorable patient and organ survival.
However, the age of liver donors has increased in the past several years, and a few
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researchers have studied the impact of donor age on LT, reaching contradictory
conclusions (Lué et al., 2016).
Donor Quality Index (DQI)
After showing that the DRI and the ET-DRI were not validated in the French LT
recipients, Winter et al., (2018) developed a donor quality index (DQI) using data from a
French transplant registry. They utilized five donor variables: age; the cause of death;
length of stay in intensive care unit; lowest MDRD creatinine clearance; and liver split.
They adjusted the model for several recipient covariates, used only for adjustment.
Equation 5 shows the derived DQI:
DQI=exp [0.28 (1 if donor age > 69 years, 0 otherwise)

(5)

+0.06 (1 if COD is “other”, 0 otherwise)
+0.30 (1 if COD is “cerebrovascular accident (CVA)”, 0 otherwise)
+0.11 (1 if COD is “trauma”, 0 otherwise)
+0.24 (1 if ICU stay is 4 days, 0 otherwise)
+0.22 (1 if the lowest MDRD creatinine clearance< 60 ml/min/1.73m2 , 0 otherwise)
+0.05 (1 if the lowest MDRD creatinine clearance, 60 ml/min/1.73m2 and 90
ml/min/1.73m2 , 0 otherwise)
+0 39 (1 if split or partial liver, 0 otherwise)]
Notes: The term exp implies e raised to a value, i.e., exp(𝑣𝑎𝑙𝑢𝑒) = 𝑒 (𝑣𝑎𝑙𝑢𝑒)
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The authors identified three risk groups based on the DQI score; a low-risk group with 1.00
< DQI ≤ 1.58; a medium-risk group with 1.58 < DQI ≤ 2.35; and a high-risk group with
DQI > 2.35. The derived DQI is yet to be externally validated in other populations.
Machine Learning Algorithms for Donor-Recipient Matching
Organ shortage has encouraged the development of donor risk models for proper
allocation of donor organs using not only traditional statistical methods but also machine
learning algorithms. Haydon et al. (2005) used for the first time neural network models to
match donors to LT recipients and to identify potential recipients likely to benefit most
from each liver offered. They used pre-MELD data and a self-organizing map, which is a
form of neural network, to predict three and 12-month survival post-LT. Briceño et al.
(2014) conducted a multicenter study of donor-recipient matching using data from 11
transplant centers in Spain to investigate the utilization of artificial neural networks
(ANNs), as a tool to predict three and 12-month graft survival post-LT. They compared
its performance with traditional donor risk models and donor-recipient matching, such as
the DRI, D-MELD, BAR, and SOFT scores. Using the Spanish cohort, they developed an
ANN model, the Model for Allocation of Donor and Recipient in España (MADR-E).
They found that the MADR-E model was able to fit complex non-linear relationships in
donor-recipient matching, better than traditional models.
Furthermore, the MADR-E model is designed to optimize both equity and
efficiency by achieving the lowest rate of death on the wait list and also the optimal
posttransplant outcomes. Using the same approach in a different cohort of LT recipients
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from King’s College Hospital, Ayllón et al. (2018) developed an ANN model (the KCH
model) for donor-recipient matching to predict three and 12-month graft survival.
Compared to traditional models, the KCH model resulted in a remarkable improvement
in 3-month and 1-year graft failure predictions.
Lau et al. (2017) explored the use of machine learning algorithms, such as random
forests and artificial neural networks, to predict graft failure after LT, based on donorrecipient characteristic known before donor allocation. They analyzed LTs from 1998 to
2013 from the Austin health database that includes the population in the states of Victoria
and Tasmania and found that the performance of machine learning methods was
substantially more accurate, as compared to traditional methods of matching recipients to
donors.
Random survival forests (RSF), tree-based ANN methods for survival data, allow
interpreting variable importance (VI) or to calculate some marginal effect of the
independent variable on the dependent variable and provide an excellent tool for data
exploration. RSFs use a robust computer-based algorithm that yields to an unbiased
assessment of variable importance, for accurate prediction, but are still considered not
suited for substantive research due to complexity.
ANN models are very flexible, and they can fit complex data. However, they are “black
boxes,” and it is difficult to elicit the hierarchical contribution of each factor, or to
anticipate how changing a specific variable will affect the model. Moreover, they may
not perform well with new data, limiting their generalization and stability. Additionally,
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ANN models need to be retrained with new data periodically because they can be
susceptible to changes in transplant and allocation policies, and clinical practices. An
optimal dynamic ANN model for organ acceptance and allocation has the potential to
guide decision making. However, before generalizing, their performance across multiple
populations needs to be assessed (Kwong & Asrani, 2018).
There is a debate on weather prediction models should be developed using only
classical statistical methods or if it is appropriate to use ANN methods. When more than
prediction is required, i.e., relevant information about dependent and independent
variables and more insights into the underlying structure of the data, traditional methods
are preferred (see Harrell, 2015).
Social Determinants of Posttransplant Survival
Unmeasured recipient and donor characteristics could potentially confound the
results of donor risk models. Community-level disparities remain poorly understood in
existing risk models. Quillin et al. (2014) have studied the adjusted effect of
socioeconomic status (SES) on access to LT and posttransplant graft and patient survival
in the United States. They have found that LT candidates with lower SES appear to face
barriers to LT, and low SES recipients of LT experience less favorable posttransplant
outcomes. They concluded that SES is an independent predictor of access to transplant
and post-transplant survival.
Schold et al. (2012), for the first time in transplant research, attempted to
investigate community-level disparities. They used county health indicators publicly
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available through the Robert Wood Johnson Foundation project and the University of
Wisconsin Population Health Institute and evaluated the association of community health
indicators with post kidney transplant outcomes. Twelve county-level health indicators
were selected as proxies for community health, environmental and behavioral risks,
social condition, or access to care, and developed a community health score (CHS). They
found that multiple health indicators from the recipients’ residence and CHS risk
categories were independently associated with kidney transplant outcomes.
Ross, Patzer, Goldberg, and Lynch (2017) investigated the impact of sociodemographic considerations on the wait list and posttransplant survival for patients with
end-stage liver disease. They looked at the impact of the county-level socio-demographic
risk as measured by the CHS, and the distance to listing transplant centers. They found
that high risk-CHS candidates and remote candidates who were more than 25 miles away
from a transplant center had greater wait-list mortality but similar mortality after LT.
Critique of Methods
Feng et al. (2006) for the first time introduced the concept of donor risk index, a
parsimonious risk model that may predict the survival of the donated liver after
transplantation, a surrogate of donor quality. The DRI has been very useful in risk
stratification and to support matching between donors and recipients. However, it has
several limitations. The DRI was developed using data before the MELD era, and it does
not reflect current practice patterns. Moreover, after the incorporation of Share 35 in
2013, the impact of DRI may be affected by unmeasured geographic variations (Flores &
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Asrani, 2017). The DRI includes race, which is not a biologically plausible predictor of
graft failure, but it is likely to be a surrogate of center performance (Flores & Asrani,
2017).
The D-MELD combines the recipient’s MELD score with the donor’s age to
obtain a continuous variable that can identify donor-recipient matches predicted to result
in significantly poorer short- and long-term outcomes (Halldorson et al., 2009). The DMELD was designed to prevent donor-recipient matches with a high risk of unfavorable
outcomes. This allocation strategy can jeopardize very sick patients in the context of low
organ-donation rates.
Some studies have proposed scores to estimate graft survival, based on the
combination of multiple variables. The SOFT, and BAR scores can identify subgroups of
patients with poor prognoses after LT, but they use many variables, and not all of them
are available at the time allocation is made (Dutkowski et al., 2011; Rana et al., 2008).
The SOFT score is very complicated for clinical practice and emphasizes short term
survival. The BAR score ranges from 0 to 27, with a threshold of 18 distinguishing low
from high-risk LTs (Rana et al., 2008). The majority of LTs are classified as low risk
according to the BAR score. Both scores are not reliable metrics of donor quality.
While hepatitis C is projected to drop with advanced in direct-acting antiviral
therapy, NAFLD/NASH is projected to become the leading indication for LT due to
increasing obesity rates (Pais et al., 2016). Therefore, a donor risk model needs to be
tailored for recipients transplanted for NAFLD to remain relevant.
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Moreover, exploration of other relevant characteristics such as community risk factors
and distance from the transplant center is crucial to understand how external factors can
impact a donor risk model.
Summary and Conclusion
This chapter contains a review of the NAFLD disease spectrum, of NASH, and of
CC. Additionally, I conducted a literature review of the epidemiology and risk factors for
NAFLD, including epigenetic and environmental factors. A review of disease trends
revealed a rise in LT for NAFLD/CC, which is becoming the leading indication for LT.
Furthermore, I detailed a review of historical and logistical aspects of liver allocation.
Finally, I discussed a description of the UNOS regions, the DSAs, and changes in donor
allocation policies from the “Final Rule.” I reviewed the strengths and weaknesses of the
MELD score allocation system and its impact on the NAFLD/CC patients.
From literature review has emerged a gap projected to widen between liver donor
supply and LT candidates on the wait list, and the need to utilize high-risk donors. I
reviewed the concept of DRI and its usage in decision making to identify optimal and
suboptimal donors. Finally, I completed a thorough literature review of proposed risk
score models, including traditional statistical models and machine learning-based models,
along with their strengths and weaknesses. Through the extensive literature review, I
revealed that current prognostic scores for donor organ quality are not reliable and robust
prognostic tools that can predict short-term graft survival. Geographic variations,
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unmeasured recipient and donor characteristics, and community-level disparities can play
a role in predicting posttransplant graft survival.
The current study led to the creation and validation of a novel model for donor
quality score tailored for NAFLD/CC recipients and evaluated the impact of county-level
health indicators and geographic characteristics. The new donor risk model filled a
critical gap in the current knowledge base and is a step forward in the optimal utilization
of a scarce resource to achieve the ultimate goal of improving liver graft survival. In
Chapter 3, I presented research methodologies used in the study, including the study
design, the study population and sample, data acquisition, and statistical analyses.
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Chapter 3: Research Method
The number of advanced NAFLD candidates on the liver transplants wait list is
rapidly growing. Advanced NAFLD and CC candidates experience remarkably high
mortality on the wait list due to persistent organ shortage and low wait-list priority. For
NASH/CC patients in need of liver transplantation, the policies defining the priority of
donor liver allocation are of ultimate importance. Use of marginal donors may improve
donor allocation in these patients.
The purpose of this study was to develop parsimonious risk adjustment models to
quantify donor quality for advanced NAFLD and CC liver transplant recipients and to
explore the association between derived donor quality score and distance from the
transplant center, county health indicators, and communities where recipients of liver
transplant reside. The donor quality score can be used to explore appropriate
donor/recipient matching for risk stratification and to carefully select grafts from
nonoptimal donors that can lead to satisfactory outcomes, reducing the number of donors
turned down and reducing wait-list mortality. Moreover, geographic variations in liver
allocation are a recurrent topic in transplant debates, reflecting concerns about health
inequalities. A consideration of community-based health measures from the location
where liver transplant recipients reside in risk-adjusted models and distance from the
transplant center can be used to understand the interrelated causes of disparities to
support policies or interventions to mitigate them.
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In Chapter 2, I reviewed existing donor risk models along with their strengths and
weaknesses and found that none of the donor risk models from the literature was tailored
to NAFLD/CC recipients of liver transplant or adjusted for geographic or social
environmental factors. The impact of community health factors on transplant risk-adjust
models has been understudied. Chapter 3 includes a brief discussion of the targeted
population, sampling procedures, sample size and power analysis, data collection, data
cleaning, statistical analysis procedures, and techniques. Threats to internal and external
validity are also presented. The chapter concludes with a discussion of ethical
considerations, a summary of critical points, and a transition to the next chapter.
Research Design and Rationale
I used a quantitative correlational design (see Campbell & Stanley, 1963), more
specifically a retrospective and longitudinal cohort study design of consecutive
NAFLD/CC liver transplant recipients. This observational design allowed me to explore
the expected relationship among variables, but it could not be used to make causal
inferences. Because of the lack of randomization, there is always a possibility that the
association between dependent and independent variables may be explained by other
variables, the so-called unmeasured confounders that can be known or unknown.
A pivotal point in this study was that a combination of donor, recipient,
transplant, geographic, and social factors explained the hazard of liver graft failure in
NAFLD/CC recipients of a liver transplant. Therefore, to quantify the impact of donor
factors on graft survival, the donor quality was adjusted for recipient characteristic, and
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the impact of geographic and social factors was explored. The research questions
addressed whether graft failure or death occurred and whether donor factors played a
role. A retrospective population-based longitudinal cohort study design is appropriate
when the dependent variable of interest is a time-to-event outcome. This study was
quantitative and included transplant population-based registry data collected at transplant
milestones and publicly available county-level data. These data sources were consistent
with exploring donor risk factors of liver graft failure in the study population.
Sampling Population
The sampling population included all available adult NAFLD/CC patients on the
transplant registry who underwent cadaveric liver transplant between July 1, 2013, and
December 31, 2016. Multiorgan transplants were not included. Status 1 patients at risk of
imminent death at listing were excluded. All recipients in the study population were
transplanted after the implementation of the Share 35 allocation policy, on June 18, 2013,
to minimize the impact of changes in allocation policy.
Sampling Procedures
The SRTR database included all recipients of LT since 1987 in the United States.
An appropriate sampling strategy for this study was consecutive sampling, which is the
best nonprobability sampling strategy because it includes all subjects who meet the
inclusion criteria (Portney & Watkins, 2009). Consecutive sampling is very reliable and
likely to represent the target population (Portney & Watkins, 2009).
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Secondary Data Collection
Secondary data are data already available and collected for other purposes.
Secondary data available from the SRTR database and the County Health Ranking &
Roadmaps were used and adapted to answer the study research questions.
The SRTR Database
Every liver transplant performed in the United States since 1987 is included in the
SRTR database. SRTR receives data from the OPTN database, which is managed through
a federal contract by the United Network for Organ Sharing (UNOS). SRTR data comes
from multiple sources, including transplant centers, organ procurement organizations, and
histocompatibility laboratories.
SRTR data provide access to broad, comprehensive information on all donors,
wait-listed candidates, and transplant recipients in the United States, submitted by the
members of the OPTN (SRTR, 2018). Mandated reporting of every solid organ transplant
information performed in the United States allows inclusion in the study of each
transplant performed in the United States that meets the inclusion criteria. SRTR data
have been widely used to conduct a multitude of transplant studies (Saracino, 2017). In
addition to the UNOS data, other secondary sources including the Social Security Death
Master File, Centers for Medicare and Medicaid Services, National Death Index,
Surveillance Epidemiology and End Results, and National Center for Health Statistics
contribute to the SRTR database (Massie et al., 2014).
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Data collection. Data were collected at different points in time: before the
transplant, at the time of the transplant, and posttransplant. Recipients were followed
longitudinally, and a large amount of information was collected at each follow-up
transplant milestone until death (UNOS Transplant Pro, 2018). Donor information;
candidate organ matching data; and recipient, transplant, and follow-up data were
collected using standardized organ-specific data collection forms. Wait-list data were
collected using the Transplant Candidate Registration. When a candidate is transplanted,
the OPO recovering the organ and the transplant center complete the Transplant
Recipient Registration (TRR) form, which includes information about the recipient and
donor characteristics as well as information on matching donor to transplant candidates
(UNOS Transplant Pro, 2018). Transplant centers complete Transplant Recipient Followup (TRF) forms at 6 and 12 months posttransplant and yearly after that until the recipient
expires. TRR and TRF forms are submitted to the OPTN database using the UNet system
(UNOS Transplant Pro, 2018). UNet is a longitudinal database in which pretransplant
data are used to match waiting candidates with donated organs, and posttransplant data
are used to analyze transplant outcomes (Leppke et al., 2013).
SRTR data quality. Data submission to UNOS is federally mandated. Transplant
centers are required to maintain, and update transplant wait list by reporting candidate
outcomes such as changes in disease severity and other events, including death and
transplant (Leppke, 2013). Data used for organ allocation are generally reliable and
complete. However, missing data are a limitation of SRTR data and will require careful
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exploration and a strategy to address this limitation (Massie, Kucirka, & Segev, 2014;
Saracino, 2018).
In the United States, federal law requires transplant center outcomes to be
published. UNOS is required to publish center-specific risk-adjusted statistics to measure
the performance of transplant centers. Centers are flagged for poor performance when the
adjusted survival is below a threshold (SRTR, 2018). For this reason, transplant centers
are required to submit timely and accurate data to UNOS so that their survival statistics
can be adjusted appropriately. Therefore, transplant centers need to have processes in
place to prospectively collect and submit data to UNOS, contributing to a robust national
database (Leppke et al., 2013). The UNOS UNet electronic system has built-in data
validation processes to increase data accuracy. UNOS conducts site visits every three
years to ensure that transplant programs are following OPTN policies (UNOS, 2018).
During the UNOS site visit, data submitted to UNet are audited for completeness and
accuracy.
Usage of SRTR data. Data are routinely analyzed to answer research questions
about the events that follow transplant candidacy, organ donation, and organ transplant,
and used to publish annual trends in transplantation, outcomes, and statistics pertinent to
transplant center performance. Researchers can request data from the SRTR by
completing a data use agreement (DUA). Several investigators have used SRTR to
answer transplant-related questions (Israni et al., 2018). Researchers have analyzed
SRTR data and developed organ-specific donor risk models (Dutkowski et al., 2011;
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Feng et al., 2006; Halldorson et al., 2009; Rana et al., 2008,). However, to date, this study
is the only one that has used SRTR data to derive donor quality score tailored to
NAFLD/CC transplant candidates.
County Health Rankings & Roadmaps
The Robert Wood Johnson Foundation and the University of Wisconsin
Population Health Institute produce the County Health Rankings every year. The
rankings are derived with more than 30 measures of health indicators for nearly every
county in the United States, providing a snapshot of how healthy a community is. Data
are collated from different sources, including the Behavioral Risk Factor Surveillance
System; the National Center for Chronic Disease Prevention and Health Promotion; the
Dartmouth Institute; and the U.S. Census (County Health Rankings & Roadmaps, 2018).
The rankings are based on a population health model developed by the American’s
Health Ranking and used by the University of Wisconsin Population Health Institute to
rank counties. Remington, Catlin, and Gennuso (2015) describe the methodology used to
calculate the rankings. This study will utilize selected County Health Rankings.
Usage of county health rankings & roadmaps. Relationships between
community health indicators and transplant outcomes were explored for the first time by
Schold et al. (2012) in a kidney transplant study where the authors developed a composite
index called County Health Status (CHS), which is a proxy indicator of community
health disparities. They found that high-risk communities were associated with an
increased risk of kidney graft failure. Ross, Patzer, Goldberg, and Lynch (2017) found
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that the CHS score was a determinant of liver transplant wait-list survival. They found
that LT candidates in high health risk counties were associated with increased wait-list
mortality. Pointer et al. (2018) found that patients in high-risk communities had less
favorable post-pancreatic surgery outcomes.
Data Access and Data Linkage
The SRTR DUA requires that data will be used solely for bona fide analysis, and
not for any other purposes not indicated in the statistical analysis plan. I made no
attempts to identify patients or to use data unlawfully and unethically in violation of the
Health Insurance Portability and Accountability Act (HIPAA) or any federal or state laws
on confidentiality of patient medical records (SRTR, 2018; OPTN, 2018). SRTR released
data as SAS datasets that were linked as needed, as shown in Figure 5.
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Figure 5. SRTR data linkage.
Note: Adapted from https://www.srtr.org/assets/media/docs/SAFsLinkingDiagram.pdf

I used the following SAS datasets to identify the study population and to select original
or derived study variables.
1. DONOR_DECEASED: contains information on all deceased donor;
2. CAND_LIIN: includes all candidates for liver or intestine transplant and
contains candidate registration and wait list information;
3. TX_LI: contains recipient and liver transplant information collected through
the TRR forms; and
4. TXF_LI: post-transplant follow-up data table contains follow-up information
collected at six months, one year and then annually, until the patient receives a

78
subsequent transplant, dies or is lost to follow-up. Follow-up information in
this table is collected using the TRF forms.
I use the statistical software SAS version 9.4 (SAS Institute, Cary NC) to access
the SRTR database and to prepare and combine the data in one analytical SAS dataset.
The linkage diagram in Figure 5 indicates the foreign key variables needed to link the
SAS datasets (SRTR, 2018). I linked the candidate SAS dataset CAND_LIIN to the
donor table DONOR_DECEASED through donor_id and to the transplant table TX_LI
though px_id. I linked TX_LI to the follow-up table TXF_LI through tx_id.
I downloaded county health indicators from a publicly available website, County
Health Rankings & Roadmaps (2018). I used the County Federal Information Processing
Standard (FIPS) code, which is the geographic identifier used in the County Health
Rankings, for data linkage. I converted the county FIPS codes into zip codes and then
used them to link County Health Rankings to the recipient zip code in the SRTR
database.
Study Variables and Operational Definitions
I selected the research study variables based on expert opinion, literature review,
and the availability in the SRTR database. Below is a list of the variables that I
considered in model building; only some of these candidate predictors were included in
the final parsimonious model.
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Dependent Variables
I defined the outcome variable as liver allograft survival at 1-year posttransplant.
Graft survival was defined considering graft status: graft failure (date of graft failure), or
death (date of death), or if alive with graft functioning (date of the last follow-up). I
coded a censoring variable indicating graft survival at 1-year posttransplant as “one” if
liver allograft failed or if recipient expired within 1-year posttransplant, and “zero” if the
patient was alive with graft functioning at the date of the last contact. The outcome
variable was a time-to-event variable defined as the months from the date of LT to the
date of the last contact and paired with the appropriate censoring variable (Saracino,
2017). I provide in Table 4 the name and coding of the original variables available in the
SRTR database, and in Table 5, I describe the coding of the outcome variables that were
used in the survival analysis.
Table 4
SRTR Variables Used to Define Outcomes and Coding
SRTR variable name
TFL_PX_STAT

Label
Patient status

Coding
A: Living;
D: Death;
L: Lost to follow-up;
N: Not seen;
R: Retransplanted

TFL_PX_STAT_DT

Patient status/date

Date

REC_TX_DT

Transplant date

Date

TFL_FAIL_PRIME_GRAFT_FAIL Date of graft failure

Date
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Table 5
Derived Outcomes and Coding: Graft Survival post-Transplant
Outcome variables

Coding

Graft survival time

Months from transplant to last contact (death,
graft failure, last follow-up or date of
subsequent liver transplant).

Censoring

1 = liver graft failure or recipient expired;
0 = alive or lost to follow-up at last contact or
at subsequent liver transplant.

Independent Donor Variables
In the first step of the donor risk model development, I considered donor-only
variables as potential independent predictors of graft survival. These factors are known at
the time an offer for a liver organ is made. Some of the donor variables are related to
donor demographics, some to donor behaviors that can lead to disease transmission, and
some to the donor health and cause of death. Tables 6 and 7 describe donor variables as
they are stored in the SRTR database, and Table 8 their operationalization that I used to
develop the donor risk model.
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Table 6
SRTR Donor Variables and Original Coding
SRTR variable name

Label

Coding

DON_AGE_IN_MONTHS

Donor age (months)

Numeric

DON_GENDER

Donor gender

M = Male; F = Female

DON_HGT_CM

Donor height (cm)

Numeric

DON_WGT_KG

Donor weight (kg)

Numeric

DON_CAD_DON_COD

Donor cause of death 1: Anoxia;
2: Cerebrovascular/Stroke;
3: Head Trauma;
4: CNS Tumor; 998:
Unknown; 999: Other

DON_HIST_DIAB

History of diabetes

DON_HIST_INSULIN_DEPND Insulin dependent

1: No; 2: Yes, 0-5 Years; 3:
Yes, 6-10 Years;
4: Yes, > 10 Years;
5: Yes, Duration Unknown;
998: Unknown
1=Yes,0=No

DON_INSULIN

Donor insulin

N=No; Y=Yes;
U=Unknown

DON_HTN

History of
hypertension

1: No; 2: Yes, 0-5 Years; 3:
Yes, 6-10 Years;
4: Yes, > 10 Years;
5: Yes, Duration Unknown;
998: Unknown
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Table 7
SRTR Donor Labs and Infection Profile Variables and Coding
SRTR Variable Name

Label

Coding

DON_SODIUM

Last serum sodium
Prior to procurement

Numeric

DON_SERUM_CREAT

Final serum creatinine

Numeric

DON_HCV_STAT

HCV antibody status

1: Positive; 2: Negative;
3: Unknown; 4: Cannot
disclose; 5: Not done;
6: Indeterminate;
7: Pending.

DON_HBV_SURF
_ANTIBODY

HBsAb (Hepatitis B
surface antibody)

C: Cannot disclose;
I: Indeterminate;
N: Negative; ND: Not
Done; P: Positive; PD:
Pending;
U: Unknown.

DON_HBV_SURF
_ANTIGEN

HBsAg (Hepatitis B
surface antigen)

C: Cannot disclose;
I: Indeterminate; N:
Negative; ND: Not
done;
P: Positive; PD:
Pending;
U: Unknown
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Table 8
Derived Independent Donor Variables and Coding
Donor factors

Label

Coding

DONOR_AGE

Donor age (yrs.)

DON_HGT_CM

Donor height in (cm)

DON_WGT_CM

Donor weight (kg)

DONOR_BMI

Body mass index
(kg/m²)

Underweight = BMI<18.5;
Normal weight = 18.5≤ BMI≤ 24.9
Overweigh = 25≤ BMI≤ 29.9;
Obese = BMI ≥ 30

DONOR_COD

Donor cause of death

1: Anoxia;
2: Cerebrovascular/stroke;
3: Head trauma;
4: Other

DONOR_HTN

Donor hypertension

1=yes; 0=no

DONOR_DIAB

Donor diabetes

1=yes; 0=no

DON_DCD

1=Yes; 0=No

HCV_POS

Donor after circulatory
death
Donor hcv positive

HBSAB_POS

Donor HBsAb

1=positive; 0=negative

HBSAG_POS

Donor HBsAg

1=positive; 0=negative

DON_HYPERN

Donor hypernatremia

1=Yes (if DON_SODIUM ≥160 µmol/L);
0=No (if DON_SODIUM <160 µmol/L

DON_MDRD

Donor MDRD
(ml/min/1.73 m2)

1 = <15; 2 = 15-29; 3 = 30-44;
4 = 45-59; 5 = 60-89; 6 = >90

Continuous variable
Continuous variable
Continuous variable

1=positive; 0=negative

84
Below are descriptions of the donor variables that will be explored.
Donor age. The use of older donors has increased remarkably in the last two
decades. Although old donors have been associated with worse graft outcomes, especially
in patients with hepatitis C virus infections, there is evidence that some old donors can
still lead to excellent results. The independent variable donor age is available in months
and will be converted in years.
Donor height and body weight. Body height and body weights considered
associated with organ volume will be considered alone or in combined measurements,
such as body mass index and body surface area among the donor factor candidates for the
risk model.
Body surface area (BSA). BSA will be calculated using the Mosteller’s formula
using Equation 6:
√𝐻𝑒𝑖𝑔ℎ𝑡(𝑐𝑚)𝑥

𝑊𝑒𝑖𝑔ℎ𝑡(𝑘𝑔)
3,600

(6)

Donor BSA together with recipient BSA will be used in donor recipient matching to
estimate liver size.
Donor body mass index. The variable body mass index (BMI) of weight-forheight is an indicator of obesity. It is calculated using a person’s height and weight as in
Equation 7:
𝑊𝑒𝑖𝑔ℎ(𝑘𝑔)

𝐵𝑀𝐼 = 𝐻𝑒𝑖𝑔ℎ𝑡 (𝑚)2

(7)

Chang et al. (2017) showed that the relationship between BMI and posttransplant
overall survival is quadratic and U shaped. Therefore, I categorized BMI as suggested by
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the CDC. A BMI of less than 18.5 kg/m² indicates underweight; a BMI of 18.5-24.9
kg/m² normal weight; a BMI of 25-29.9 kg/m² the overweight category; and a BMI of
more than 30 is an indication of obesity (CDC, 2018).
Donation after cardiac death (DCD). Livers procured from DCD donors can
bridge the gap between the demand for liver organs and donor supply. If properly
managed, DCD donors can offer a valuable alternative to the donation after brain death
(DBD), considered the standard of care which supplies the majority of LTs. DCD donors
are associated with higher risk of graft failure, compared to DBD donations (Firl et al.,
2015).
Donor diabetes. Donor macrovesicular steatosis is a known predictor of graft
failure (Hamar & Selzner, 2017). However, macro-steatosis is only available in the SRTR
database on biopsied donors. I considered donor diabetes as a surrogate of donor steatosis
(Zheng et al., 2014). I combined three SRTR variables indicating the history of donor
diabetes or insulin dependence to indicate the presence or absence of donor diabetes.
Donor hypertension. Donor hypertension has been identified as a strong
predictor of low graft survival in kidney transplant, and I evaluated in this study as a
potential independent predictor of liver graft failure (Rao et al., 2009).
Donor cause of death. Donor cause of death has been found to be an independent
predictor of transplant outcomes. Stroke has been found to be associated with worse graft
survival in LT and used in donor risk-adjusted models (Feng et al., 2006).
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Donor hypernatremia. Donor hypernatremia before procurement, which could
be a surrogate of prolonged donor intensive care, is defined as donor plasma sodium level
≥160 µmol/L. Donor hypernatremia has been reported to reduce graft survival (Khosravi,
Firoozifar, Ghaffaripour, Sahmeddini, & Eghbal, 2013).
Disease transmission variables. Before being transplanted, donors are screened
for infectious disease and tested for positive hepatitis B surface antibody (HBsAb),
hepatitis B surface antigens (HBsAg) and HCV antibody status.
Modification of diet in renal disease (MDRD). Donor Glomerular Filtration
Rate estimated by the 4-variable equation from the MDRD was used to estimate the renal
function of potential donors using Equation 8:
MDRD = 175 x SerumCr-1.154 x age-0.203 x 1.212 (if black) x 0.742 (if female) (8)
Independent Transplant Variables
I considered a more extensive version of the donor risk model that included
transplant variables, such as cold ischemia time, donor ABO matching, and donor size
matching, to explore the impact of transplant factors and to assist in decision making
about donor/recipient matching. Tables 9 and 10 describe transplant variables and their
operationalization that I used in model building. I describe below the transplant variables
that were considered.
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Table 9
SRTR Transplant Matching Variables and Original Coding
SRTR Variable name

Label

Coding

REC_COLD_ISCH_TM

Total cold ischemic time

Numeric

REC_HGT_CM

Recipient height (cm)

Numeric

REC_WGT_KG

Recipient weight (kg)

DON_HGT_CM

Donor height (cm)

DON_WGT_KG

Donor weight (kg)

DON_ABO

Donor’s blood type

A; A1; A1B; A2B;
AB; B, 0

REC_ABO

Recipient’s blood type

A; A1; A1B; A2B;
AB; B, 0

Numeric
Numeric
Numeric

Table 10
Derived Transplant Matching Variables and Coding
Transplant Factors

Label

Coding

CIT

Cold ischemia time (hrs.)

Continuous variable

BSA_Ratio

Donor/recipient BSA ratio

Continuous variable

ABO_Match

ABO match

1: Incompatible;
2: Compatible;
3: Identical
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Cold ischemia time. Geographic disparities in access to liver transplantation can
lead to usage of liver organs with prolonged cold ischemia, a known risk factor for early
allograft dysfunction (Sibulesky et al., 2016). Cold ischemia time is defined as the
interval from the clamping of donors’ vessels, loss of blood supply and infusion of cold
organ preservation to the moment of removal from storage and insertion into the
recipient’s abdominal cavity. The in-vivo cold preservation solution maintains
hypothermic conditions and minimizes ischemic injuries. Cold ischemia time is
influenced by the distance between the donor and the recipient centers and increases
when long distances have to be traveled (Sibulesky et al., 2016).
BSA donor recipient ratio. Many factors affect liver size, such as weight, height,
BMI and BSA. Fukazawa et al., (2013) proposed using the ratio of donor to recipient
BSA index to predict size match. They found that both small-for-size and large-for-size
liver grafts had an adverse effect on liver graft survival.
Donor-to-recipient ABO match. Livers are usually matched by ABO.
Mismatched donors may either be ABO compatible or ABO incompatible. The usage of
ABO-mismatched organs has been controversial in liver transplantation in the past
because of the high risk of antibody-mediated rejection. However, due to improvements
in immune-suppressant regimen and improved graft survival, ABO incompatible organs
can be considered a viable option to increase donor availability and reach the goal of full
potential in organ utilization (Goss & Rana, 2017). Often, an ABO incompatible graft can
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represent the only option in case of urgency when an ABO compatible organ is not
readily available.
Recipient Covariates
Graft survival is affected not only by donor factors and transplant factors but also
by recipient factors. Moreover, the transplant center has an impact on graft outcomes.
Recipient factors will be used as covariates for risk adjustment. Table 11 presents known
recipient characteristics associated with graft survival after LT, and Table 12 indicates
grouped or calculated variables.
Table 11
SRTR Recipient Covariates and Original Coding.
SRTR variable name

Label

Coding

REC_AGE_IN_MONTHS_AT_TX Calculated recipient
age in months at TX

Numeric

CAN_GENDER

Candidate gender

M = male; F = female

REC_HGT_CM

Recipient height (cm)

Number

REC_WGT_KG

Recipient weight (kg)

Number

CAN_LAST_SERUM_SODIUM

Last SRTR MELD

Numeric
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Table 12
Derived Recipient Covariates and Coding.
SRTR variable name

Label

Coding

REC_AGE_AT_TX

Age at transplant

Continuous Variable

CAN_GENDER

Candidate gender

1 = Male; 2 = Female

REC_BMI

Body mass index (kg/m²)

underweight = BMI<18.5;
normal weight = 18.5≤ BMI≤ 24.9
overweigh = 25≤ BMI≤ 29.9;
obese = BMI ≥ 30

MELD

MELD score

1=<15; 2=15-20; 3=26-30; 4=>30

REC_DIAB

Recipient diabetes

1=Yes; 0=No

Recipient age and gender. I used recipient age and gender for demographic
adjustments.
Recipient BMI. BMI, an indicator of obesity in recipients of LT, was categorized
as suggested by CDC. Recipient BMI has been associated with graft and patient survival.
Model for end-stage liver disease score (MELD). The MELD score, a reliable
measure of disease severity, and known mortality risk after LT ranges from 6 to 40, with
low scores indicating healthier recipients. It is calculated using pre-transplant labs serum
creatinine, serum bilirubin, International Normalized Ratio for prothrombin time, as well
as ascites and hepatic encephalopathy, available in SRTR database (Kamath et al., 2001).
The MELD score is used to prioritize patients on the liver wait list. It represents the
recipient risk of wait-list mortality.
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Recipient diabetes. Recipientdiabetes, is a known risk factors of patient posttransplant survival (Northup et al., 2010). I recoded the SRTR variable that indicates the
type of diabetes to reflect the presence of non-insulin dependent, insulin dependent, or
absence of recipient diabetes.
Modifying External Variables
Modifying variables are associated with the outcome but not with the independent
predictors. The effect of the donor risk score can change among different subgroups. I
explored two external variables: distance from the transplant center and community
health status, as described in Table 13.
Table 13
Mediating External and Coding
Mediating variable

Label

Coding/measurement

DIST_FROM_CTR

Distance from center (miles)

Numeric

CHS_GRP

Community health status group

0–10; 11–20;
21–30; 31-40

Community health status (CHS). The CHS is a composite index that combines
ranks of 10 selected county health indicators likely to be related to transplant outcomes. I
provided detailed information on county health indicators in Appendix A. CHS ranges
from 0 (indicating that a county is in the first quintile or the lowest risk for each of the 10
health indicators) to 40 (indicating that a county is in fifth quintile or higher risk for each
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of the 10 health indicators). Table 14 illustrates the data sources and contributing
community health indicators that make up the CHS.
Other Variables
Expanded criteria donor. The SRTR database has a variable that indicates
whether or not a donor meets the expanded criteria. I did not include this variable in the
model because I explored the variables included in the ECD definition (donor age,
hypertension, and serum creatinine), individually in model building.
PHS increased-risk donors. Information about PHS increased-risk donors
(previously known as CDC high-risk donors) was available in SRTR. Increased-risk
donors are often discarded and not considered by LT candidates because at high risk of
blood-borne disease transmission. I explored the impact of increased-risk donors on liver
graft survival in the study population to determine if these donors increased the risk of
graft failure in NAFLD/CC recipients. The concept of increased risk donors was created
to identify a donor population potentially at risk of a recent acquisition of HIV or viral
hepatitis. These recently infected donors could inadvertently transmit the virus to
recipients yet would appear negative on serologic testing. Importantly, most increased
risk donors will be truly negative for each of these infections, and the chance that they
will transmit the infection is very low. So increased risk is not necessarily related to the
donor quality. Therefore, I did not consider the denomination PHS increased risk in the
model. Appendix B provides more details about CDC high-risk and PHS increased-risk
criteria.
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Table 14
Community Health Score and Contributing Health Indicators
Community Health
Indicator
Premature death (years)

Source

Value

National Center for
Health Statistics Mortality files

Quintiles:
1st = 0; 2nd = 1; 3rd = 2; 4th = 3; 5th = 4

Low birth weight (%)

National Center for
Health Statistics Natality files

Quintiles:
1st = 0; 2nd = 1; 3rd = 2; 4th = 3; 5th = 4

Poor physical health
(days)

Behavioral Risk Factor Quintiles:
Surveillance System
1st = 0; 2nd = 1; 3rd = 2; 4th = 3; 5th = 4

Poor mental health
(days)

Behavioral Risk Factor Quintiles:
Surveillance System
1st = 0; 2nd = 1; 3rd = 2; 4th = 3; 5th = 4

Fair or poor health (%)

Behavioral Risk Factor Quintiles:
Surveillance System
1st = 0; 2nd = 1; 3rd = 2; 4th = 3; 5th = 4

Income inequality

American Community
Survey

Quintiles:
1st = 0; 2nd = 1; 3rd = 2; 4th = 3; 5th = 4

Preventable hospital
stays (%)

Dartmouth Atlas of
Health Care

Quintiles:
1st = 0; 2nd = 1; 3rd = 2; 4th = 3; 5th = 4

Adult smoking (%)

Behavioral Risk Factor Quintiles:
Surveillance System
1st = 0; 2nd = 1; 3rd = 2; 4th = 3; 5th = 4

Adult obesity (%)

CDC Diabetes
Interactive Atlas

Quintiles:
1st = 0; 2nd = 1; 3rd = 2; 4th = 3; 5th = 4

Physical inactivity (%)

CDC
Interactive Atlas

Quintiles:
1st = 0; 2nd = 1; 3rd = 2; 4th = 3; 5th = 5
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Study Validity
Observational studies are not experimental as they involve the direct observation
of study subjects in their natural setting. Therefore, they are assessed for potential
selection or information biases that may influence the validity and reliability of study
findings. There are a few critical issues to consider in evaluating observational transplant
studies where the outcome is a time-to-event, such as patient and graft survival, including
a potential differential loss to follow-up and misclassification bias.
Information Biases
Transplant registry data are collected longitudinally. Therefore, it is possible to
analyze long-term outcomes, but at the same time, differential loss to follow-up can lead
to bias. In SRTR data, transplant recipients are followed until death occurs. However,
incomplete follow-up is often present for many reasons. Statistical methods used to
analyze cohort studies assume that censoring is non-informative, i.e., not related to the
study outcome, graft survival. Informative censoring occurs when subjects are lost to
follow-up for reasons related to this study, that may only lead to biased estimates in the
regression models and also reverse the effect of a risk factor that can appear as a
protective factor. Sensitivity analyses can be used to analyze data under the informative
censoring assumption using considering the best and worst-case scenarios and use of the
drop-out event as a study endpoint (Steyerberg, 2008, Saracino, 2017). Moreover, it is
likely that various recipient and donor factors were measured with error. Centers may use
different data collection approach or systematic errors in data collection.
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Selection Biases
Marginal or non-optimal donors are considered non-ideal for multiple reasons.
However, improvements in surgery strategies and medical management of these organs
have led to improved post-transplant graft and patient survival in the last decade.
Marginal donors are considered a plausible option to offset donor shortage, and, their
utilization has increased. Studies still provide conflicting results impeding the creation of
accepted guidelines, and transplant programs have center-specific decision-making rules
to determine which patients should receive marginal donors (Pezzati, Ghinolfi, De
Simone, Balzano, & Filipponi, 2015). Unobserved heterogeneity in center practice
variation can lead to selection bias. Heterogeneity between centers can be addressed by
incorporating the transplant center as a random effect. Survival models with random
effect, called frailty models, can be used to account for the center effect on graft survival.
I did not address center variation in this study.
Threats to Internal and External Validity
I did not include all possible donor factors associated with liver graft survival in
thefinal donor risk model. When relevant variables are omitted, the model functional
form is misspecified, or data are missing not at random. Therefore, in these cases, the
statistical model does not capture adequately the variation in the dependent variables for
the population being studied and can be a threat to internal validity. I used bootstrapping
to assess internal model validation (Harrell, 2015). I considered several steps to address
the threat of internal validity including the use of restricted cubic splines to fit nonlinear
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patterns and, appropriate coding of predictors, including combining variables (Harrell,
2015). Internal validation addressed the stability of the selection of predictors, and the
quality of predictions, and helped in selection among candidate models.
Inferences from SRTR studies are likely to generalize across the United States, but
unlikely to be extrapolated to other countries. External validation outside the United
States can be questionable due to differences in policies and procedures or because not all
variables available in SRTR are collected in foreign transplant registries (Massie,
Kucirka, & Segev, 2014). The donor risk models only apply to adult NAFLD/CC LT
recipients are invalid in a pediatric setting.
Data Analysis Plan
I described the data cleaning procedures in this section, and also the power analysis
and the statistical analysis approach used to answer the research questions.
Sample Size and Power Analysis
The study was not underpowered because SRTR data included all NAFLD/CC LT
performed in the United States that met the inclusion criteria. Therefore, the sample size
was sufficient for bootstrapping validation (Harrell, 2015). I used the Cox PH regression
to analyze the primary research question. The model tested whether or not the
independent variables predicted graft failure at 1-year post-transplant. Because I included
the total population of NASH/CC LT in the study, a priori power analysis was not
required but was useful to indicate the minimum sample size that was necessary to get the
desired power and effect size.
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I conducted Cox PH model-based power calculations using the R statistical
package powerSurvEpi (Qiu et al., 2015). Assumptions for sample size calculation
included: a power of .80, a type I error rate α=.005, and a postulated hazard ratio of 1.6
(i.e., the DCD donors having 1.6 times an expected risk of graft failure, compared to nonDCD donors). Previous studies assumed 15 percent of recipient transplanted with DCD
donors, and 16 percent of NAFD/CC recipients experiencing liver graft failure within 3year post-transplant. The required sample size was 1,742 (Qiu et al., 2015). Observational
studies need covariate adjustment, and the sample size calculation requires an additional
assumption regarding the correlation between the covariate of interest and the other
covariates. The sample size required increased to 2,178 under the assumption of covariate
correlation, ρ²= 0.20 and to 2,489 for ρ²= 0.30 (Qiu et al., 2015).
Data Cleaning and Screening Procedures
The SRTR database package provided Standard Analysis Files (SAF), datasets
and SAS formats along with information about data linkage and the data dictionary,
primary and foreign key variables that allowed linkage between candidate information;
donor information; transplant information; and post-transplant follow-up information
(SRTR, 2012). The first data management step I undertook was to identify the study
variables to include in the analysis either directly or as derived variables. In this
preliminary data preparation phase, I merged different datasets and processed to obtain a
final dataset that contains both original variables and composite variables, restricted to
NASH/CC recipients of LT that meet the inclusion criteria. I prepared the variables to

98
perform survival analyses. I merged the SRTR data with the Community Health
Indicators.
I used summary statistics to describe the study population. I summarized
quantitative variables using mean, standard deviations, minimum, maximum, median and
other quantiles. I summarized categorical variables using frequencies. I used descriptive
statistics to describe the distribution, central tendency, and dispersion to screen for
outliers, inconsistencies, and missing values. I set outliers to missing if there were
obvious mistakes. When necessary, I combined discrete variables in collapsed categories.
Different transplant centers collect SRTR data, and some variables are collected for
purposes other than research. Therefore, missing data and measurement errors were
possible. Exploratory data analysis of key variables helped identify quality issues
(Massie, Kucirka, & Segev, 2014).
Statistical Analysis
I summarized the characteristics of the study population through descriptive
statistics. I assessed group comparisons for continuous variables using independent t-tests
or when the assumption of normality is not met by Wilcoxon rank sum rank tests. I used
Fisher exact tests or the likelihood ratio chi-square tests to compare categorical variables.
I used the Cox PH regression model to assess the effect of independent donor, transplant,
recipient and external variables on the risk of the occurrence of graft failure for all
causes. I performed Wald tests to determine whether or not individual coefficients of the
Cox PH models were equal to zero.
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I selected the initial set of potential predictors and covariates to consider in the
model based on previous studies and expert knowledge. After restricting the list, I
reviewed variable distribution and missing data. I discarded variables with a large
number of missing data that were known to be powerful predictors of graft failure. I
removed variables with narrow distribution not expected to be important predictors of
graft failure. I used Kaplan-Meier curves to depict the univariate relationships of
categorical predictors at the initial stage of the analysis, as well as at the end of the study
to present the prediction characteristics of the model. I used the log-rank tests to compare
survival curves.
I performed preliminary univariate Cox PH regressions as a screening tool to
evaluate the association of each candidate predictor with graft survival, to assess the
functional form and to explore the non-linear effect of continuous predictors. I
categorized continuous variables when possible, based on clinically accepted thresholds.
When not possible, and when non-linear relationships exist, I transformed continuous
predictors using restricted cubic splines functions and modeled them as non-linear
predictors.
Restricted cubic splines are piecewise polynomial joined together at knots which
are constrained to be liner at the tails. Harrell (2015) suggests modeling continuous
predictors using restricted cubic splines with no more than five knots as they shape well
the non-linear predictors and provides a useful tool to investigate the relationships
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between dependent and independent variables. Restricted cubic splines are very flexible
and with a robust behavior at the tails of the predictor distributions (see Harrell, 2015).
I used augmented backward variable elimination using 1000 bootstrap samples for
model building and to select the final variables. I examined the proportional hazard
assumption, verifying the pattern of the scaled Schoenfeld residuals against time. To
evaluate the Cox PH model’s discriminative ability, I used Harrell’s C-statistics. Model
performance on the data used to fit it is optimistic, better than the performance with new
data from the same population. Overfitting causes optimism, a threat to model validity. I
used bootstrap resampling to correct overfitting or optimism in model performance (see
Harrell, 2015).
Most studies on identifying risk factors for graft failure risk have employed the
Cox PH model. Traditional models are unable to address the complexities of the donor,
transplant, recipient, and external factors. In this study, I explored the potential of random
survival forest (RSF), a statistical learning method adapted to right-censored survival
data. RSFs grow many trees using bootstrap samples from the original data and use
aggregate results of many trees for prediction and to rank variables by their predictive
importance. RSFs are non-parametric alternatives to the Cox PH model that can capture
complex and non-linear relationships and, high order interactions, and do not rely on
distributional assumptions. However, they are “black boxes,” and their inferential
procedures are not understood. In this study, I used machine learning approaches to
complement traditional models, not to replace them.
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I performed all statistical analyses using SAS version 9.4 (SAS Institute) and R
version R3.4.1 (R Foundation for Statistical Computing, Vienna, Austria).
Research Questions and Hypotheses
The purpose of this retrospective cohort study was to investigate donor,
transplant, recipient and community factor that impact graft survival in the study
population. I answered the following research questions and hypotheses:
Research Question 1
What are the relationships between post-transplant graft survival among
NAFLD/CC recipients and a number of donor characteristics (age, gender, height,
weight, BMI, the cause of death, hypertension, diabetes, donor after circulatory death,
HCV status, HBsAb status, HBsAg status, MDRD, hypernatremia)?
𝐻01 : There is no association between post-transplant graft survival among
NAFLD/CC recipients and a number of donor characteristics (age, gender, height,
weight, BMI, the cause of death, hypertension, diabetes, donor after circulatory death,
HCV status, HBsAb status, HBsAg status, MDRD, hypernatremia).
𝐻𝑎1 : There is an association between post-transplant graft survival among
NAFLD/CC recipients and a number of donor characteristics (age, gender, height,
weight, BMI, the cause of death, hypertension, diabetes, donor after circulatory death,
HCV status, HBsAb status, HBsAg status, MDRD, hypernatremia).
The analytic objective of this research question was to develop a donor risk model
that evaluated the intrinsic qualities of the liver allograft and predicted graft failure risk
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capturing donor only characteristics, and that summarizes into a single continuous graft
failure risk score the quality of the deceased liver donor, the DQ-NAFLD score.
Therefore, I included only variables known at the time of the donor offer and evaluation
in the development of a donor-only score. I fit a Cox PH model to estimate the relative
risk of graft failure independently associated with each donor variable. I generated
graphical displays of how each donor predictor is related to the log hazard of graft failure.
The Cox PH model expressed a relationship between the hazard rate and a set of
predictors or covariates. I derived the DQ-NASH score from the coefficient of the Cox
proportional hazard model.
Research Question 2
What are the relationships between post-transplant graft survival among
NAFLD/CC recipients and transplant factors (cold ischemia time, ABO matching, and
size matching)?
𝐻02 : There is no association between post-transplant graft survival among
NAFLD/CC recipients and a number of transplant factors (cold ischemia time, ABO
matching, and size matching).
𝐻𝑎2 : There is an association between post-transplant graft survival rate among
NAFLD/CC recipients and transplant factors (cold ischemia time, ABO matching, and
size matching).
This research question explored the impact of transplant factors on graft survival.
I fit a Cox PH model to estimate the relative risk of graft failure independently associated
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with transplant factor. I generated graphical displays of how each transplant predictor is
related to the log hazard of graft failure.
Research Question 3
What are the relationships between post-transplant graft survival among
NAFLD/CC recipients and a number of donor characteristics (age, gender, height,
weight, BMI, the cause of death, hypertension, diabetes, donor after circulatory death,
HCV status, HBsAb status, HBsAg status, MDRD, hypernatremia) and transplant factors
(cold ischemia time, ABO matching, size matching,) after adjusting for characteristics of
recipients of liver transplant (age, gender, BMI, biological MELD).
𝐻03 : There is no association between post-transplant graft survival among
NASH/CC recipients and a number of donor characteristics (age, gender, height, weight,
BMI, cause of death, hypertension, diabetes, donor after circulatory death, HCV status,
HBsAb status, HBsAg status, MDRD, donor hypernatremia) and transplant factors (cold
ischemia time, ABO matching, size matching) after adjusting for characteristics of
recipients of liver transplant (age, gender, BMI, biological MELD).
𝐻𝑎3 : There is an association between post-transplant graft survival rate among
NASH/CC recipients and a and a number of donor characteristics (age, gender, height,
weight, BMI, cause of death, hypertension, diabetes, donor after circulatory death, HCV
status, HBsAb status, HBsAg status, MDRD, hypernatremia) and transplant factors (cold
ischemia time, ABO matching, size matching) after adjusting for characteristics of
recipients of liver transplant (age, gender, BMI, biological MELD).
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Adding additional factors to the DQ-NAFLD donor-only model to account for
these other sources of variation resulted in a higher predictive ability of the model, or a
slightly higher C-statistic. However, the initial goal of the donor-only DQ-NAFLD was to
summarize the risk of graft failure based on deceased donor factors only, and not to
explain all sources of variation that contribute to liver graft outcomes. To address this
question, I adjusted the Cox PH model for recipient characteristics to evaluate how the
strength of the association between the donor risk score and graft failure changes after the
adjustment. I developed a more extended version of the DQ-NASH risk score that
included donor, transplant, and recipient factors useful in decision making for matching
individual candidates to donors.
Transplant clinicians are interested in exploring how donor age, brain versus
cardiac death, and cold ischemia time changed in subgroups of biochemical MELD
scores (S. Asrani, personal communication, September 3, 2018). To assess these factors, I
tested pre-specified interactions within strata of biochemical MELD score. I considered a
model containing a second-order interaction for the triplet of factors, as well as all firstorder interactions. All interaction effects were not significant.
Research Question 4
What are the relationships between post-transplant graft survival among
NAFLD/CC recipients and the health risk status of the county were recipients reside
measured by the community health score (CHS)?
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𝐻04 : There is no association between post-transplant graft survival among
NAFLD/CC recipients and the health risk status of the county were recipient resides,
measured by the CHS.
𝐻𝑎4 : There is an association between post-transplant graft survival among
NAFLD/CC recipients and the health risk status of the county were recipient resides,
measured by the CHS.
I used univariate Cox PH model to explore the effect of graft failure across
counties grouped by risk category to assess if high-risk counties were associated with
increased patient and graft survival.
Research Question 5
What are the relationships between post-transplant graft survival among
NAFLD/CC recipients and the distance from the transplant center?
𝐻05 : There is no association between post-transplant graft failure among
NAFLD/CC recipients and distance from the transplant center.
𝐻𝑎5 : There is an association between post-transplant graft failure among
NAFLD/CC recipients and distance from the transplant center.
This question explored the associations of distance from center and liver graft
failure, to study if living in a high community health risk is associated with worse posttransplant outcomes. To address this question, I developed a univariate Cox PH model to
explore the effect of increased distance from the transplant center on the risk of patient
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and graft survival. I used choropleths maps to visualize patterns in patient and graft
survival outcomes in relation to their geographic distance from the transplant center.
Research Question 6
What are the relationships between post-transplant graft survival among
NAFLD/CC recipients, DQ-NAFLD risk score and external community factors (CHS and
distance from the transplant center)?
𝐻06 : There is no association between post-transplant graft survival among
NASH/CC recipients, DQ-NAFLD risk score and external community factors (CHS and
distance from the transplant center).
𝐻𝑎6 : There is an association between post-transplant graft survival among
NAFLD/CC recipients, DQ-NAFLD risk score and external community factors (CHS and
distance from the transplant center).
I used Kaplan Meier curves to explore the graft survival curves by quintiles of
DQ- NAFLD risk score, by quintiles of community health risk score, and by quintiles of
distance from the transplant center. I tested differences in survival curves using the logrank test.
Moreover, I tested the interaction effect between DQ- NAFLD score and
Community Health Risk score as well as the interaction between DQ- NAFLD score and
distance from the transplant center. More specifically, I tested the hypothesis that
recipients who reside in high-risk communities, or who are very distant from the

107
transplant center, are more likely to fail their high-risk graft compared to recipients in
low-risk communities.
Ethical Considerations
In general, the usage of existing secondary data does not require IRB approval if
it does not involve human subjects. The Walden Institutional Review Board reviewed the
study to determine if the study met the ethics. Data requests to SRTR required
completing a DUA which included a research plan and a security plan, describing how
data would be stored and who would have access to data (Leppke et al., 2013). Data were
password protected, available only to authorized researchers.
Researchers required using the data solely for bona fide analysis, and not for any
other purposes. Researchers did not attempt to identify patients and use the information
unlawfully and unethically in violation of the Health Insurance Portability and
Accountability Act (HIPAA) or any federal or state laws regarding confidentiality of
patient medical records (Gliklich, Dreyer, & Leavy, 2014; OPTN, 2018). The final
analysis was reviewed by SRTR to ensure compliance with the terms of the DUA
regarding confidentiality (OPTN, 2018).
Summary
I proposed a population-based longitudinal cohort study that used SRTR data
between 2013 and 2016 and Community Health data to develop the DQ-NAFLD/CC a
donor quality index score. I achieved this by assessing multiple donor characteristics
estimates for the quality of a liver allograft. This study provides a useful metric for risk
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evaluation and stratification. Through additional analyses, I explored how donor quality
can predict liver graft survival independently or additively with recipient characteristics,
transplant, and external community factors. The analysis of how external factors impact
the transplant risk models shed important light on the understudied effect of
environmental factors on post-liver transplant outcomes. Chapter 4 presents the results of
the statistical analyses performed to answer the study hypotheses according to the
statistical analysis plan. Chapter 5 provides an interpretation of the results and the
potential implications and contributions of study findings, as well as suggestions for
future research.
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Chapter 4: Results
The purpose of this retrospective observational quantitative study was to analyze
data from the SRTR registry to develop a donor quality score tailored to NAFLD/CC
candidates on the wait list for a liver transplant (the DQ-NAFLD risk score) and to
explore the impact of external factors including community health indicators and
geographic factors related to the counties where recipients of LT reside. Both a donor
intrinsic factor DQ-NAFLD risk score, as well as an extended DQ-NAFLD risk score,
were developed. The study population included consecutive adult recipients of LT
between July 1, 2013, and December 31, 2016, whose indication for LT was NAFLD/CC.
During the study period, 24,497 patients received an LT, but only 3,165 met the inclusion
criteria. Moreover, the purpose of the study was to analyze the external impact on graft
survival within 1 year post LT, and of community health factors and distance from
recipient residence to transplant center on liver graft survival within 1 year post LT.
SRTR data were merged with data from the County Health Rankings & Roadmaps
database to link patients to their community health risk based on their county of
residence.
Cox PH models were used to predict liver graft failure at 1-year post LT. The
fourth chapter outlines the selection of the study cohort and contains the results of the
statistical analysis conducted to answer six research questions. This chapter contains a
summary of the baseline and demographic characteristics of the study cohort of
NAFLD/CC recipients of LT and a comparison of these characteristics to a control cohort
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of recipients transplanted for etiologies other than NAFLD/CC and HIV. The statistical
analysis methods used were checked to ensure the assumptions were met, and study
findings were summarized for each research question.
Data Collection
This study included retrospective secondary observational data from the SRTR
registry, a transplant population-based database that contains nationwide information on
recipients of solid organs transplant. SRTR combines data from different sources
including transplant centers. All recipients in the SRTR database remained anonymized,
and no attempt was made to identify patients. For this study, SRTR database tables were
merged with county health indicators downloaded from a publicly available website, the
County Health Rankings and Roadmaps (2018). The FIPS code was converted into zip
code and used to link county health indicators and rankings to the recipient zip code in
the SRTR database.
Data Access and Acquisition
Data were requested from SRTR. Walden University’s IRB approval number for
the study is 12-10-18-0296616. The SRTR database was queried to identify subjects that
met the inclusion criteria. Furthermore, all of the prespecified variables listed in Chapter
3 were reviewed. Donor steatosis, an important predictor of graft failure, was available
only when donor biopsy was performed. Not all donors were biopsied. Because a large
number of missing biopsies was expected, donor steatosis was not included on the
original list of the study variables. However, donor biopsy data were reviewed to assess
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the sample size availability and to evaluate the feasibility of a subset analysis that
included donor steatosis. The response variable, graft survival post LT, was censored at 1
year while graft failure or death for any causes were considered events as described in the
study protocol outlined in Chapter 3. Some variables were not used because insufficient
information was available or because they had poor distributions.
Inclusion Criteria and Cohort Selection
There were 24,997 liver-only transplants performed between July 1, 2013, and
December 31, 2016. Figure 6 depicts the selection process steps along with the patients
excluded at each step. By applying the exclusion criteria in sequence, I excluded
recipients younger than 18-year old (1,953), recipients with a previous transplant
(1,161), multiorgan transplant recipients (2,079), live donor transplant recipients (884),
Status 1 recipients (540), and recipients transplanted for indication other than NAFLD
and CC (15,220). As showed in Figure 6, the final study population consisted of 3,165
adult NASH/CC recipients of a primary, deceased donor, liver-only transplant during the
study period. Patient follow-up for graft failure started on the day of the transplant. The
outcome of interest in the current analysis was graft failure or death for any causes.
Patients were followed from the time of transplant until the earliest of graft failure, death,
loss to follow-up, or the conclusion of the observation period. In total, there were 419
graft failure events of which 294 died within 1-year post LT, whereas 2,746 patients had
a functioning graft at the end of follow-up. All consecutive patients who met the
inclusion criteria were considered.

112

Recipients of
LT
07/01/2013 12/31/2016

Age at
Transplant ≥
18 Years

Previous
Transplants
Excluded

Initial
Poulation

Age<18
Years
Excluded

N=21,883

N=24,997

N=23,044

Liver
Transplant
Alone

Figure 6. Flow chart of study population including exclusion criteria.
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Living
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Recipients
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NonNAFLD/CC
Excluded

N=19,809

N=18,925

N=18,385

N=3,165
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Exploratory Data Analysis
Data were initially explored to get a good first glimpse before formal modeling
using summary statistics and graphical representations to spot potential outliers, to
investigate patterns of missing variables, to assess correlations among variables, and to
explore the distributional shape of continuous variables and the frequency distribution of
categorical variables. Graphical analysis of study variables is provided in Appendix C.
Before modeling, I analyzed the mechanism of missingness to quantify the extent
of missing data and to examine combinations of predictors with missing data on the same
subjects. Most of the donor variables, including donor demographics, height and weight,
donor sodium, donor diabetes, and donor cause of death, had no or very few missing
values. Only 0.06% of patients in the study cohort had missing HIV data, while 0.09%
had missing cold ischemia time. Donor diabetes was missing in 1.14% of subjects, while
donor hypertension was missing in 0.76% of subjects, and they tended to be missing in
the same patients. Donor steatosis was missing in 38% of cases and was not included in
multivariate analyses. Data on HBsAb was missing in 79.3% of subjects; therefore, these
data were excluded from subsequent analyses.
Outliers are values outside a typical range. Boxplots were used to detect outliers,
or values at least 3 times the interquartile range, and those were checked for biological
plausibility. Exploratory data analysis did not indicate implausible values for most of the
study variables. Four extreme outliers for MDRD were found and removed.
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Descriptive Statistics
I compared the baseline characteristics of the study cohort to a control group of
recipients transplanted for other etiologies to identify differences. Since the advent of
DAAs, the number of LTs due to HCV has dramatically decreased. Therefore, patients
transplanted with HCV were excluded from the comparison because no longer relevant in
transplant practice. I compared and summarized baseline characteristics of LT recipients
for both NAFLD/CC and other indications for LT in Table 15, confirming literature
finding that NAFLD/CC patients are older and have more comorbidities (O’Leary et al.,
2011), and supporting the decision to develop risk models tailored to NAFLD/CC. I
assessed group differences using the non-parametric Wilcoxon rank sum test for
continuous variables and the chi-squared test or Fisher’s exact test to compare
proportions of categorical variables. I presented continuous data as median and
interquartile range (IQR), and categorical data as percentages as reported in Table 15.
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Table 15
Characteristics of Study and Control Cohorts

Recipient characteristics
Recipient age
Recipient sex:
Female
Male
Recipient BMI (kg/m2 )
Recipient BSA (m2 )
Biological MELD score

.

Non-NAFLD/CC
N=10534

NAFLD/CC
N=3165

58.0 (50.0, 64.0)

60.0 (54.0, 66.0)

31.8%
68.2%
28.0 (24.0, 32.0)
1.99 (1.81, 2.17)
19.0 (12.0, 30.0)

43.2%
56.8%
31.0 (27.0, 35.0)
<.001
2.08 (1.88, 2.27)
<.001
23.0 (17.0, 32.0)
<.001
(table continues)

p-value
<.001
<.001
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Donor characteristics
Donor age
Donor sex:
Female
Male
Donor height (cm)
Donor weight (kg)
Donor BMI (kg/M 2 )
Donor BSA (M 2 )
Donor diabetes
No diabetes
No insulin dependent
Insulin dependent
Donor HTN
Donor hypernatremia
Donor cause of death:
Trauma
Anoxia
Cva
Other
Donor DCD
Donor MDRD:
Whole/split:
Whole
Reduced/split
Increased risk

Non-NAFLD/CC
N=10534

NAFLD/CC
N=3165

pvalue

43.0 (28.0, 56.0)

45.0 (29.0;57.0)

.003
.850

41.1%
58.9%
170 (165, 178)
80.0 (68.0, 94.0)
27.0 (23.0, 31.0)
1.95 (1.77, 2.14)

41.3%
58.7%
172 (163, 180)
81.0 (68.9, 97.5)
28.0 (24.0, 32.0)
1.97 (1.79, 2.18)

87.5%
6.52%
6.00%
38.3%
7.15%

86.3%
7.03%
6.65%
40.1%
7.74%

29.6%
34.0%
33.9%
2.54%
6.89%
70.0 (40.0, 103)

28.8%
32.8%
35.8%
2.65%
6.96%
69.0 (39.0, 102)

98.6%
1.41%
21.5%

.264
<.001
<.001
<.001
.224

.083
.278
.243

.942
.405
.073

99.0%
0.98%
19.2%
.006
(table continues)

117

Transplant/matching
Cold ischemia time (hrs.)
ABO compatibility:
ABO identical/compatible
ABO incompatible
Donor/recipient size match:
Small for size
Normal for size
Large for size
Geography and community
Distance to transplant center
Distance to transplant center:
0-8
9-51
52-218
219+
Community health score
Community health score:
<=10
11-20
21-30
>30
1-year graft survival (%)

Non-NAFLD/CC
N=10534

NAFLD/CC
N=3165

pvalue

5.96 (4.65;7.42)

5.90 (4.60;7.33)

.360
1.000

98.9%
1.11%

98.2%
1.80%
<.001

7.82%
83.1%
9.12%

10.2%
81.7%
8.06%

36.0 (14.0, 104)

51.0 (18.0, 117)

15.2%
43.1%
31.1%
10.5%
15.0 (10.0, 21.0)

10.2%
40.5%
39.3%
10.0%
17.0 (12.0, 25.0)

<.001
<.001

<.001
<.001

28.6%
21.6%
45.2%
41.4%
20.8%
26.2%
5.32%
10.8%
86.1 (84.3,
87.4 (85.8, 89.1) .310
87.9)
Note. In the non-NAFLD/CC group, HCV patients (N=7,850) were excluded because
they were no longer relevant in transplant practice.

NAFLD/CC recipients were statistically significantly older (Mdn=60; IQR=54-66) than
the control group (Mdn=58, IQR=50-64) with a higher BMI (Mdn=31; IQR=27-35), as
compared the other etiologies (Mdn=28; IQR=24-32). There were statistically
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significantly more females (43%) than males (32%), with p<.001. NAFLD/CC recipients
were transplanted at significantly higher median MELD score at 23 (IQR=17-32), as
compared to the control group (Mdn=19; IQR=12-33) and received statistically
significantly more donor livers small for size, 10.2% versus 7.8%, p<.001). The overall
liver graft survival curves for the two groups were compared through the Kaplan-Meier
curves, as depicted in Figure 7. NAFLD/CC recipients were significantly less likely to
survive without losing the liver allograft within 1-year post LT, with an overall liver graft
survival at 1-year of 86.7% versus 89.0% (p<.001). The median CHS for the study cohort
was 15. Subjects were grouped by CHS, as shown in Table 16.

Figure 7. Kaplan-Meier survival curves by liver etiology.
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Table 16
Characteristics of Study Cohort by Community Health Score

Recipient characteristics
Recipient age
Recipient sex:
Female
Male
Recipient BMI (kg/M 2 )
Recipient BSA (M 2 )
Meld
Donor characteristics
Donor age
Donor sex:
Female
Male
Donor height (cm)
Donor weight (kg)
Donor BMI (kg/M 2 )
Donor BSA (M 2 )
Donor diabetes:
No diabetes
No insulin dependent
Insulin dependent
Donor HTN
Donor hypernatremia

Low CHS risk
N=1,463

High CHS risk
N=1,554

61.0 (54.0, 66.0)

60.0 (54.0, 65.0)

42.7%
57.3%
31.0 (26.0, 35.0)
2.05 (1.85, 2.26)
24.0 (18.0, 34.0)

44.0%
56.0%
32.0 (27.0, 36.0)
2.10 (1.91, 2.29)
22.0 (17.0, 29.0)

44.0 (29.0;57.0)

45.0 (30.0, 57.0)

39.9%
60.1%
173 (164,180)
81.0 (69.1;96.4)
27.0 (24.0;32.0)
1.97 (1.79;2.17)

41.8%
58.2%
172 (165,180)
81.6 (69.4,98.9)
28.0 (24.0, 2.0)
1.98 (1.80, 2.19)

86.7%
7.16%
6.12%
39.5%
6.70%

86.1%
6.87%
7.06%
40.1%
8.88%

p-value
.056
.496

.001
<.001
<.001
.791
.303

.876
.131
.155
.156
.565

.778
.031
(table continues)
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Donor cause of death:
Trauma
Anoxia
Cva
Other
Donor DCD:
DBD
DCD
Donor MDRD
Transplant/matching
CIT (hr)
Abo compatibility:
Identical/compatible
Incompatible
Donor/recipient size
match:
Normal for size
Small for size
Large for size
Distance to Tx Ctr
1-year graft survival (%)

Low CHS risk
N=1,463

High CHS risk
N=1,554

29.8%
33.6%
34.2%
2.46%

27.9%
32.3%
37.1%
2.77%

p-value
.337

.084
91.9%
8.07%
70.0 (41.0, 101)

93.6%
6.37%
68.0 (37.2, 103)

6.06 (4.95, 7.76)

5.70 (4.43, 7.10)

98.6%
1.37%

99.2%
0.84%

.389
<.001
.221

.001
80.0%
10.0%
9.98%
31.0 (14.0, 97.0)
86.1 (84.3, 87.9)

83.5%
10.2%
6.25%
70.0 (29.2;132.0)
87.4 (85.8, 89.1)

<.001
.310

Demographic characteristics of recipients in low and high-health risk
communities were comparable. Recipients resident in low health risk communities had a
statistically significantly lower BMI (Mdn=31.0; IQR=26.0-35.0) compared to residents
in high-risk communities (Mdn=32.0; IQR=27.0-36.0). NAFLD/CC recipients in low
health risk communities were transplanted at a statistically significantly higher median
MELD score at the time of transplant at 24 (IQR=18.0-34.0) compared to the high health
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risk counterpart at 22 (IQR=17.0-29.0). Recipients from low health risk counties were
more likely to receive donors who were large for size (9.98% versus 6.25%, p<.001).
Recipients resident in low health risk counties had a much longer median distance from
the transplant center (31 miles, IQR=14.0-97.0) than those who resided in high health risk
counties (70 miles, IQR=29.2-132.0). The Kaplan-Meier survival analysis in Figure 8
showed that 1-year graft survival did not differ significantly between recipients in low
and high health-risk communities.

Figure 8. Kaplan-Meier survival curves by community health score.
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Univariate Preliminary Analysis
I conducted univariate analyses to learn about candidate predictors and their
relation to 1-year graft survival post LT as a prelude to subsequent multivariate analyses.
The variables included in the univariate screening were donor’s gender, age, height, BMI,
BSA, donor cause of death, hypertension, diabetes, hypernatremia, microsteatosis,
macrosteatosis, MDRD, DCD, recipient’s age, gender, BMI, BSA, cold ischemia time,
ABO compatibility, donor and recipient size match.
Univariate Analysis of Continuous Predictors`
I conducted univariate analyses to explore the association between categorical and
continuous variables with 1-year graft survival post LT. Continuous predictors included
in a Cox PH model must meet the underlying assumption of linear relationship with the
log hazard of the time to event outcome. I transformed continuous variables using RCS
transformations, which are flexible functions with robust behavior at the tails of predictor
distributions. I used the linearity Wald tests via RCS transformations to test the
assumptions of linear relationships between continuous predictors and the risk of graft
failure for NAFLD/CC recipients of LT. I also used splines to model the effects of
nonlinear predictors in subsequent analyses, and I placed the knots on the spline curve
defining the end of one segment and the start of the next so that the overall curve was
smooth and continuous.
The fit depends more on the number of knots, and the exact location of knots is
not critical (see Harrell, 2015). So, I placed the knots at fixed percentiles of predictor’s
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marginal distribution as recommended by Harrell (2015), who also suggested that five
knots are sufficient to provide a good fit of nonlinear patterns that are likely to occur in
practice. Therefore, I selected the number of knots for each continuous predictor between
three and five to balance the best fit and overfitting, resulting in a parsimony model with
the lowest Akaike Information Criteria and maximum likelihood. In a univariate Cox PH
model, the relative hazard, which is the ratio of the hazard at time t to the hazard at
baseline is a function of the exponentiated continuous predictor x, as shown in Equation
9:
ℎ(𝑡)
ℎ(0)

= 𝑒𝑥

(9)

If the natural logarithm is taken in both size of the Cox PH model, the log relative hazed
is a linear function of the predictors:
𝑙𝑛(

ℎ(𝑡)
)=𝑥
ℎ(0)

Figures 9-11 depict univariate display plots of the estimated relationship between
continuous independent predictors modeled as RCSs and log hazard ratio for graft failure
from a sample of 3,165 NAFLD/CC recipients and 419 graft failures, including deaths.
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Figure 9. Functional relationships between donor height, donor weight, donor BMI and
donor BSA, and log relative hazard of graft failure at one-year post LT.
Note. Number of knots and location, respectively: donor height (3 knots at 157, 172 and
185 cm), donor weight (3 knots at 59, 81 and 113 kg), donor BMI (3 knots at 21, 28, and
23kg/m2 ), donor BSA (knots at 1.6, 2.0, and 2.4m2 ).
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Figure 10. Functional relationships between donor MDRD, donor age, recipient age and
recipient BMI, and log relative hazard of graft failure at 1-year post LT.
Note. Number of knots and location, respectively: donor MDRD (3 knots at 17, 69, and
137), donor age (4 knots at 18, 35, 52, and 71 years), recipient age (4 knots at 42, 57, 64,
and 70 years), and recipient BMI (3 knots at 24, 31 and 39 kg/m2 ).
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Figure 11. Functional relationships between recipient BSA, donor/recipient BSA, CIT,
and MELD score, and log relative hazard of graft failure at 1-year post LT.
Note. Number of knots and location, respectively: recipient BSA (3 knots at 1.7, 2.1 and
2.4m2 ), donor/recipient BSA (3 knots at 0.8, 1.0 and 1.2), CIT (4 knots at 3.1, 5.1, 6.6
and 10.0 hours) MELD score (3 knots at 13, 23 and 39).

Table 17 summarizes the results of the univariate association of each continuous
predictor modeled through RCS with the time-to-event outcome and formal tests of the
linearity using, respectively the Wald 𝜒 2 test for association and the Wald 𝜒 2 test for
linearity (Harrell, 2015). Donor height was significantly associated with the log hazard
for graft failure post LT (𝜒 2 (3) = 8.23, p = .035), and the association was not
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significantly different from linear 𝜒 2 (2) = 2.97, p=.226). The donor’s factors, weight,
BMI, BSA, MDRD, and age were not significantly associated with liver graft survival.
Recipient’s age (𝜒 2 (3) = 10.12, p=.016), BMI (𝜒 2 (2) = 6.12, p=.047), BSA
(𝜒 2 (2) = 7.32, p = .025) and MELD score (𝜒 2 (2) = 6.02, p=.044), were significantly
associated with graft failure, with significant nonlinearity, respectively, (𝜒 2 (1) = 6.10,
p=.013) for BMI, (𝜒 2 (1) = 5.13, p=.024) for BSA, and (𝜒 2 (1) = 4.37, p=.037) for
MELD score. Donor/Recipient BSA was significantly associated with the outcome
(𝜒 2 (2) = 8.27, p = .016), and with significant nonlinearity (𝜒 2 (1) = 5.12, p=.024),
while CIT was not significantly associated with the outcome.
Table 17
Univariate Association and Linearity Tests for Continuous Variables Predicting Liver
Graft Failure
Association
Wald 𝜒 2 (𝑑. 𝑓. )

Linearity
Wald. 𝜒 2 (𝑑. 𝑓. )

Variable
Donor height (cm)
8.23 (3)*
2.97 (2)
Donor weight (kg)
1.02 (2)
0.14 (1)
2
Donor BMI (kg/M )
4.18 (2)
0.37 (1)
2
Donor BSA (M )
0.81 (2)
0.74 (1)
Donor MDRD
4.18 (2)
1.42 (1)
Donor age (yrs.)
0.52 (3)
0.39 (2)
Recipient age (yrs.)
10.12 (3)*
1.73 (2)
2
Recipient BMI (kg/M )
6.12 (2)*
6.10 (1)*
2
Recipient BSA (M )
7.34 (2)*
5.13 (1)*
Donor/recipient BSA
8.27 (2)*
5.12 (1)*
CIT (hrs.)
1.62 (2)
0.07 (1)
MELD score
6.02(2)*
4.37 (1)*
Note. NAFLD/CC Recipients (n=3165).* p<.05. Each predictor modeled as RCS.

128

Univariate Analysis of Categorical Predictors
I conducted univariate Kaplan-Meier survival analyses to examine independent
predictors and their effect on graft survival by comparing the survival experiences across
each predictor categories. I performed log-rank tests to determine if there were
differences in the survival distribution for the different categories of each independent
variable. Pairwise log-rank comparisons were conducted to determine which categories
had different survival distributions. Compared to recipients of DBD donors, DCD donor
recipients experienced a significantly worse graft survival at 1-year post LT, 𝜒 2 (1) =
18, p = <.0001 (Figure 12).

Figure 12. Kaplan-Meier survival curves by donor type.
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The survival distributions for the three categories of donor diabetes were
statistically significantly different, 𝜒 2 (2) = 17.6, p < .0001 (Figure 13). The Bonferroni
corrected pairwise comparisons found that recipients who received a diabetes insulin
dependent donor had a statistically significant worse graft survival at one year, as
compared to recipients who received donors without diabetes (p=.004) or donors with
non-insulin dependent diabetes (p=.001) (Figure 13).

Figure 13. Kaplan-Meier survival curves by donor diabetes.
Donor/recipient liver size was associated with graft survival at 1-year post LT,
𝜒 2 (2) = 10.7, p = .005 (Figure 14). Bonferroni corrected post-hoc comparisons revealed
that compared to normal for size donors, large for size donors was associated with an
unfavorable graft survival experience (p = .003).
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Figure 14. Kaplan-Meier survival curves by donor/recipient size match.

Donor gender (𝜒 2 (1) = .4, p = .51), hypertension (𝜒 2 (1) = .3, p = .58), donor
cause of death (𝜒 2 (3) = 3.8, p = .28), micro steatosis (𝜒 2 (2) = 4.2, p = .12), macro
steatosis (𝜒 2 (3) = 5.1, p = .079), ABO compatibility (𝜒 2 (1) = 0.1, p = .74), and
hypernatremia (𝜒 2 (1) = 0.1, p = .72), were not associated with 1-year post LT graft
survival in Kaplan-Meier analyses (Figures 15, 16, 17, 18, 19, 20, 21).
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Figure 15. Kaplan-Meier survival curves by donor gender.

Figure 16. Kaplan-Meier survival curves by hypertension.
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Figure 17. Kaplan Meier survival curves by cause of death.

Figure 18. Kaplan-Meier survival curves by microsteatosis stage.
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Figure 19. Kaplan-Meier survival curves by macrosteatosis stage.

Figure 20. Kaplan-Meier survival curves by ABO compatibility.
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Figure 21. Kaplan-Meier survival curves by hypernatremia.
Figure 22 depicts Kaplan-Meier graft survival curves of NAFLD/CC recipients
who received Public Health Service increased risk and non-increased risk donors. The
log-rank test compared survival experience between the two donor risk categories and
found no statistically significant difference (p=.96). Table 18 contains information about
graft survival probability at 1-year post LT and the 95% CIs.
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Figure 22. Kaplan-Meier survival curves by public health increased donor risk.
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Table 18
One-year post LT Graft Survival Probability and 95% Confidence Intervals
Variable
Total
Gender

Level
Overall
Male
Female
Donor diabetes
No diabetes
No insulin dependent
Insulin dependent
Donor hypertension
No hypertension
Hypertension
Donor hypernatremia
Hypernatremia
No hypernatremia
Micro steatosis
Mo
M1
M2
Macro steatosis
Mo
M1
M2
Donor DCD
DBD
DCD
Donor cause of death
Trauma
Anoxia
CVA
Other
Size match
Normal for size
Small for size
Large for size
ABO compatibility
Identical/compatible
Incompatible
Note. * p<.05, **p<.01, ***p<.001.

1-year survival
.87
.86
.87
.90
.78*
.87
.86
.88
.87
.83
.87
.89
.86
.87
.80
.87
.77***
.88
.87
.86
.83
.87
.87
.81*
.87
.88

95% CI
(.84, .88)
(.84, .88)
(.86, .88)
(.87, .94)
(.72, .84)
(.85, .89)
(.84, .88)
(.84, .92)
(.85, .88)
(.80, .87)
(.84, .90)
(.84, .94)
(.83, .90)
(.84, .89)
(.73, .87)
(.86, .89)
(.72, .83)
(.86, .90)
(.85, .89)
(.84, .88)
(.75, .92)
(.86, .89)
(.83, .90)
(.77, .85)
(.85, .88)
(.79, .99)
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Research Question 1
The first research question was based on whether there is a relationship between
post-transplant graft survival among NAFLD/CC recipients and a number of donor
characteristics (age, gender, height, weight, BMI, the cause of death, hypertension,
diabetes, donor after circulatory death, HCV status, HBsAb status, HBsAg status,
MDRD, hypernatremia). To answer this question, I considered a semiparametric
approach or a multivariable Cox PH regression model using graft survival outcomes,
which included intrinsic donor factors and a nonparametric machine learning approach or
random survival forests (RSF).
The initial list of candidate predictors, based on literature review and combined
with knowledge matter, included 13 donor’s variables: age, sex, height, weight, BMI,
BSA, hypertension, the cause of death, hypernatremia, DCD, MDRD, HCV, and HBsAb.
I analyzed variable distributions and patterns of missing data in the preliminary phase.
The distributions of HCV and HBsAb status were too narrow to allow the inclusion in the
model. I excluded HBsAg because it was missing in a large number of subjects. I
removed four extremely high values for MDRD because they were considered as
potential errors.
Cox PH Approach
I analyzed donor height, donor BMI, and donor BSA separately in alternative
models because of collinearity, and I compared the models using the Akaike Information
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Criteria (AIC). At least one of the donor factors considered was missing in 47 cases (or
1.5% of cases). Because the sample size was large enough for adequate power, and the
sample was representative of the target population, I conducted complete cases analysis.
The effective sample size available was sufficiently large to allow fitting a
saturated pre-specified model with all predictors, including the non-significant in the
univariate analysis. I used smoothing transformations of continuous predictors to relax
the linearity assumption and prevent residual confounding. I tested model distributional
assumptions using smoothed scaled Schoenfeld residuals for each predictor and the
graphical visualization. I did not observe any trend against time and no major violations. I
tested the validity of the proportional hazard assumption for each covariate and globally.
The global test of proportional hazard was not statistically significant (p= .245) indicating
that the proportionality of hazards was met at significance level α=.05.
Dunkler, Plischke, Leffondré, & Heinze (2014) recently proposed a variable
selection strategy which combines significance and change in estimation criterion, the
augmented backward elimination, which enables assigning a specific role to independent
variables. This strategy allows the inclusion in the model of “passive variables,”
regardless of their significance, just based on subject-matter knowledge. I applied an
augmented backward elimination to reduce the number of predictors in the final model, in
1000 bootstrap samples drawn from the original data, with a level of significance set to
α=.2 and the threshold of the relative change-in-estimate criterion ‘τ’ set to .1. This
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strategy allowed to include into the model donor age and DCD regardless of their
statistical significance, as known predictors of graft failure.
The independent donor variables selected in the final model included: age, height,
diabetes, DCD, and MDRD. Harrell (2015) suggested that at least 10–20 events are
needed per degree of freedom, as a rule of thumb. The study sample included 412 events
and approximately 20 degrees of freedom to spend to fit the model, which used 12
degrees of freedom. I tested the overall significance of the Cox PH model or the model
goodness of fit using the likelihood ratio test (𝜒 2 (11) = 48.68, p <.0001) indicating that
the model was statistically significant and adequate in predicting the graft survival
experience of NAFLD/CC recipients of LT.
The results of the selected Cox regression model are presented in Table 19, which
shows the estimated coefficients, the adjusted hazard ratios (AHR) along with the 95%
confidence intervals (CI), of each categorical predictor, for each parameter used in the
splines. Recipients of DCD grafts were more than twice likely to lose their grafts within
1-year post LT (AHR=2.17, 95% CI=1.60, 2.95). Receiving donors with insulindependent diabetes was associated with an increased risk of graft failure within 1-year
post LT (AHR=1.71, 95% CI= 1.24, 2.38). The final RCS regression model results in
Table 19 include estimated coefficients for each parameter used in the splines, which do
not have an immediate interpretation but can be better described graphically. Tables 2022 provide useful interpretations of the RCSs variables.
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Table 19
Multivariate Cox PH Model for Donor Variables Predicting Liver Graft Function
Variable

Estimated β

Wald ᵪ2

AHR (95% CI)

4.96

2.17 (1.60, 2.95)**

SE(β)
Donor type
DBD

Reference

DCD

.776 (.156)

Donor diabetes
No Diabetes

Reference

Non-insulin dependent

-.344 (.230)

-1.49

0.71 (1.24, 2.38)

Insulin dependent

.539 (.167)

3.23

1.71 (1.24, 2.38)*

MDRD linear

-.004 (.003)

-1.34

1.00 (0.99, 1.01)

MDRD’

.001 (.003)

0.43

1.00 (0.99, 1.01)

Donor height linear

-.031 (.011)

-2.90

0.97 (0.95, 0.99)*

Donor height’

-.064 (.034)

1.87

1.07 (1.00,1.14)

Donor height’’

-.261 (.163)

-1.60

0.77 (0.56, 1.06)

Donor age linear

.009 (.014)

0.60

1.01 (0.98, 1.04)

Donor age’

-.038 (.045)

-0.83

0.96 (0.88, 1.05)

Donor age’’

.012 (.125)

0.95

1.13 (0.88, 1.44)

Note. NAFLD/CC recipients (n=3,165). β =estimated coefficient of Cox PH model,
SE=standard error, AHR=adjusted hazard ratio. CI=confidence intervals.
*p<.01, **p<.001
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Table 20
Selected Estimates for Donor Age from the Multivariate Cox PH Regression
Donor Age (yrs)
20

AHR
1.01

95% CI
(0.76, 1.33)

40

1.04

(0.95, 1.14)

45
Reference
50
0.97
(0.89, 1.05)
60
1.00
(0.85, 1.17)
Note: Donor age (yrs.) adjusted to donor height of 172 cm, no diabetes, DBD donor,
MDRD of 69. AHR=adjusted hazard ratio, CI=confidence intervals.
Table 21
Selected Estimates for Donor MDRD from the Multivariate Cox PH Regression
MDRD
30

ARH
1.14

95% CI
(0.97, 1.33)

50

1.06

(0.99, 1.14)

60

1.03

(1.00, 1.06)

69
80

Reference
0.96

(0.95, 0.99)

100

0.92

(0.87, 0.98)

120
0.88
(0.79, 0.98)
Note: MDRD adjusted to no diabetes, DBD, donor height of 172 cm, donor age of 45 yrs.
AHR=adjusted hazard ratio, CI=confidence intervals.
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Table 22
Selected Estimates for Donor Height from the Multivariate Cox PH Regression
Donor height (cm)
130

AHR
2.67

95% CI
(1.41, 5.07)

140

1.97

(1.26, 3.07)

160

1.08

(0.90, 1.29)

172
180

Reference
1.01

(0.89, 1.45)

180
0.84
(0.57, 1.23)
Note: Donor height (cm) adjusted to donor age of 45 yrs., no diabetes, DBD donor,
MDRD of 69. AHR=adjusted hazard ratio, CI=confidence intervals.

Table 21 summarizes the AHR and 95% CI for selected MDRD values.
Compared to a median reference donor with MDRD of 69, liver allografts from donors
with an MDRD of 100 provided a reduction of 8% in the risk of graft failure within 1year post LT (AHR=0.92, 95% CI=0.79, 0.98). Compared to a median donor of 172 cm
height, livers from donors of 140 cm height were associated with 97% higher risk of graft
failure (AHR=1.97, 95% CI 1.26, 3.07). This finding indicated that holding all other
variables constant to their reference values, liver allografts from donors with a height of
140 cm were almost twice more likely to fail within 1-year post LT, compared to grafts
from donors with a height of 172 cm (Table 22).
Figure 23 illustrates the adjusted hazard of graft failure as a function of donor age
(yrs.), as follows: (A) Donor MDRD (B) and donor height (cm) (C), holding all other
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variables constant at representative levels set at their reference category or mean values
(DBD donors, without diabetes, with MDRD of 69, of 45 years, with a height of 172 cm).

Figure 23. Restricted cubic splines of the association between donor age (A), donor
MDRD (B) and donor height (cm) (C) and adjusted relative hazard of graft failure at 1year post LT.
Note. The model is adjusted for the following variables set at reference category: donor
type (DBD), diabetes (No), or median category: MDRD (69), donor age (45 yrs.), donor
height (172 cm).
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When compared to an average reference donor, donor age was not associated with
the risk of graft failure, as shown in Figure 23 (A). The risk of graft failure decreased, as
MDRD increases as displayed in Figure 23 (B). Decreasing donor height was associated
with an increased risk of graft failure, as shown in Figure 23 (C).
After fitting a Cox PH model that included splines, I computed hazard ratios by
comparing specific values of a variable, with a single reference value. From Figure 23
(A), the 95% CI of the AHR includes one for each value of donor age, compared to an
average donor. From Table 20, the AHR for a 50-year donor compared to a 45-year
donor was 0.97 (95% CI=0.89, 1.05). From Figure 23 (B), donors with MDRD 80 or
greater were associated with improved survival.
The Donor Intrinsic DQ-NAFLD Score
The DQ-NAFLD risk score is an estimate of the relative risk of posttransplant
graft failure for an adult recipient from a cadaveric donor, compared to a reference donor:
a 45-year DBD donor of 172 cm height, with no diabetes and MDRD of 69. From the
Cox PH model, the risk for subject j is expressed as:
𝜆(𝑡|𝑥𝑗 ) = 𝜆0 (𝑡)𝑟𝑗 (𝑡)
I used the coefficients of the Cox PH model in conjunction with individual covariates to
estimate DQ-NAFLD risk score for an individual. The risk score for a subject ‘j’ is the
hazard ratio for that person relative to the baseline, as shown in Equation 10:
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𝐷𝑄 − 𝑁𝐴𝐹𝐿𝐷(𝑗)

(10)

′
= exp(𝛽1 x I(𝐷𝐶𝐷(𝑗) ) + 𝛽2 𝑥 𝑀𝐷𝑅𝐷(𝑗) + 𝛽3 𝑥 𝑀𝐷𝑅𝐷(𝑗)
+ 𝛽4 𝑥 ℎ𝑒𝑖𝑔ℎ𝑡(𝐽)
′
′′
′
+ 𝛽5 𝑥 ℎ𝑒𝑖𝑔ℎ𝑡(𝑗)
+ 𝛽6 𝑥 ℎ𝑒𝑖𝑔ℎ𝑡(𝑗)
+ 𝛽7 𝑥 𝑎𝑔𝑒(𝑗) + 𝛽8 𝑥 𝑎𝑔𝑒(𝑗)
′′
+ 𝛽9 𝑥 𝑎𝑔𝑒(𝑗)
+ 𝛽10 x I(𝑁𝑜𝑛 𝐼𝑛𝑠𝑢𝑙𝑖𝑛 𝐷𝑒𝑝𝑒𝑛𝑑𝑒𝑛𝑡(𝑗) )

+ 𝛽11 x I(𝐼𝑛𝑠𝑢𝑙𝑖𝑛 𝐷𝑒𝑝𝑒𝑛𝑑𝑒𝑛𝑡(𝑗) ))
𝑓𝑜𝑟 j=1….N
Where I(e)=1 if the event is true, I(e)=0 otherwise,
The predictors, donor’s age, height, and MDRD, are expressed as restricted cubic splines.
I modeled the predictor MDRD as RCR with 3 knots, 𝑡1 = 17, 𝑡2 = 69, 𝑡3 = 137. The
nonlinear term is:
𝑖
𝑀𝐷𝑅𝐷(𝑗)
= (𝑀𝐷𝑅𝐷(𝑗) − 𝑡1 )3+ −

+

(𝑡3 − 𝑡1 )
3
𝑥 (𝑀𝐷𝑅𝐷(𝑗) − 𝑡2 )+
(𝑡3 − 𝑡2 )

(𝑡2 − 𝑡1 )
3
𝑥 (𝑀𝐷𝑅𝐷(𝑗) − 𝑡3 )+
(𝑡3 − 𝑡2 )

I modeled the predictor donor height as RCS with 4 knots, 𝑡1 = 154, 𝑡2 = 167, 𝑡3 =
176, 𝑡4 = 188. The nonlinear terms are:
′
ℎ𝑒𝑖𝑔ℎ𝑡(𝑗)
= (ℎ𝑒𝑖𝑔ℎ𝑡(𝐽) − 𝑡1 )3+ −

+

(𝑡4 − 𝑡1 )
3
𝑥 (ℎ𝑒𝑖𝑔ℎ𝑡(𝐽) − 𝑡2 )+
(𝑡4 − 𝑡3 )

(𝑡3 − 𝑡1 )
3
𝑥 (ℎ𝑒𝑖𝑔ℎ𝑡(𝐽) − 𝑡4 )+
(𝑡4 − 𝑡3 )
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′′
ℎ𝑒𝑖𝑔ℎ𝑡(𝑗)
= (ℎ𝑒𝑖𝑔ℎ𝑡(𝐽) − 𝑡2 )3+ −

(𝑡4 − 𝑡2 )
3
𝑥 (ℎ𝑒𝑖𝑔ℎ𝑡(𝐽) − 𝑡3 )+
(𝑡4 − 𝑡3 )

(𝑡3 − 𝑡2 )
3
𝑥 (ℎ𝑒𝑖𝑔ℎ𝑡(𝐽) − 𝑡4 )+
(𝑡4 − 𝑡3 )

+

I modeled the predictor donor age as RCS with 4 knots, 𝑡1 = 18, 𝑡2 = 35, 𝑡3 = 52, 𝑡4 =
71. The nonlinear terms are:
(𝑡4 − 𝑡1 )
(𝑡3 − 𝑡1 )
3
3
𝑥 (𝑎𝑔𝑒(𝑗) − 𝑡2 )+ +
𝑥 (𝑎𝑔𝑒(𝑗) − 𝑡4 )+
(𝑡4 − 𝑡3 )
(𝑡4 − 𝑡3 )

′
𝑎𝑔𝑒(𝑗)
= (𝑎𝑔𝑒(𝑗) − 𝑡1 )3+ −

(𝑡4 − 𝑡2 )
(𝑡3 − 𝑡2 )
3
𝑥 (𝑎𝑔𝑒(𝑗) − 𝑡3 )+ +
𝑥 (𝑎𝑔𝑒 − 𝑡4 )3+
(𝑡4 − 𝑡3 )
(𝑡4 − 𝑡3 )

′′
𝑎𝑔𝑒(𝑗)
= (𝑎𝑔𝑒(𝑗) − 𝑡2 )3+ −

Where (𝑧)+ is equal to z if z > 0, and 0 otherwise.
Replacing the estimated model coefficients, the Equation 10 became:
𝐷𝑄 − 𝑁𝐴𝐹𝐿𝐷(𝑗) = exp[0.77 x I ( 𝐷𝐶𝐷(𝑗) ) −
3

3

(137−17)

0.04 𝑥 𝑀𝐷𝑅𝐷(𝑗) + 0.001 𝑥 (𝑀𝐷𝑅𝐷(𝑗) − 17)+ − (137−69) 𝑥(𝑀𝐷𝑅𝐷(𝑗) − 69)+ +
3

(69−17)
(137−69)

(188−154)
(188−176)

3

3

(176−167)
(188−176)

(71−52)

3

(176−154)

𝑥 (ℎ𝑒𝑖𝑔ℎ𝑡(𝐽) − 167)+ + (188−176) 𝑥(ℎ𝑒𝑖𝑔ℎ𝑡(𝐽) − 188)+ −

0.261 𝑥(ℎ𝑒𝑖𝑔ℎ𝑡(𝐽) − 67)+ −

(71−18)

3

𝑥 (𝑀𝐷𝑅𝐷(𝑗) − 137)+ − 0.031 𝑥 ℎ𝑒𝑖𝑔ℎ𝑡(𝐽) − 0.064 𝑥 (ℎ𝑒𝑖𝑔ℎ𝑡(𝐽) − 154)+ −

(188−167)
(188−176)

3

𝑥(ℎ𝑒𝑖𝑔ℎ𝑡(𝐽) − 176)+ +

3

𝑥 (ℎ𝑒𝑖𝑔ℎ𝑡(𝐽) − 188)+ + 0.009 𝑥 𝑎𝑔𝑒(𝑗) − 0.038 𝑥 (𝑎𝑔𝑒 − 18)3+ −
3

(52−18)

3

3

𝑥 (𝑎𝑔𝑒(𝑗) − 35)+ + (71−52) 𝑥(𝑎𝑔𝑒(𝑗) − 71)+ + 0.012 𝑥 (𝑎𝑔𝑒(𝑗) − 35)+ −
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(71−35)
(71−52)

3

(52−35)

3

𝑥 (𝑎𝑔𝑒(𝑗) − 52)+ + (71−52) 𝑥 (𝑎𝑔𝑒(𝑗) − 71)+ +

0.344 𝑥 I(𝑁𝑜𝑛 𝐼𝑛𝑠𝑢𝑙𝑖𝑛 𝐷𝑒𝑝𝑒𝑛𝑑𝑒𝑛𝑡(𝑗) ) + 0.539 𝑥 𝐼(𝐼𝑛𝑠𝑢𝑙𝑖𝑛 𝐷𝑒𝑝𝑒𝑛𝑑𝑒𝑛𝑡(𝑗) )]
Validation of the Donor Intrinsic DQ-NAFLD Model
I conducted an internal validation to assess the performance of the final chosen
model. The apparent performance of the model on the data used to fit the model will be
better than the performance of the model in another set of data. The bootstrap approach
described by Harrell et al. (1996) allows quantifying the overfitting or “optimism”
inherent in predictive accuracy. I estimated the optimism by taking 1000 bootstrap
samples with replacement from the full data and evaluating the difference between model
performance in each bootstrap sample and model performance on the whole sample. I
estimated the “optimism” as the average of these differences across 1000 bootstrap
samples. I then subtracted the estimate of optimism from the naïve estimate of predictive
ability to obtain the bias-corrected predictive ability.
Validation of model discrimination. Discrimination of the final model indicated
by the Harrell’s C-statistic represents the proportion of pairs of subjects that can be
ordered such that the subject with higher predicted survival is the one who survived
longer (not always possible, based on censoring). The C-statistic summarizes the
predictive power of the DQ-NAFLD. The C-statistic ranges from 0.5 to 1.0, with higher
values indicating greater discriminatory power, or the ability to separate more successful
from less unsuccessful graft outcomes along the DQ-NAFLD scale. The apparent or
naïve C-statistics was equal to 0.598, while the bootstrap optimism corrected C-statistics
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was 0.587. A C-statistic nearly 0.60 is only moderately predictive. This result is
consistent with other donor risk models since multiple factors are affecting graft survival
not included in the DQ-NAFLD model. A model that accounts for more sources of
variation would have a higher C-statistics. However, the goal of this intrinsic donor risk
model was to summarize graft failure risk based on donor characteristics alone and not to
describe all sources of variation (Rao et al., 2009).
Figure 24 displays the estimated relationship between DQ-NAFLD risk score
calculated from the intrinsic model and log hazard ratio for graft failure at 1-year post
LT.

Figure 24. Restricted cubic spline estimates of the relationship between
DQ-NAFLD risk score and log relative hazard of graft failure at 1-year post LT.
Note. Knots at 0.74, 0.93 and 1.67.
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I estimated the relationship using a RCS with 3 knots at 0.71; 0.95; and 1.66. I
further illustrated the discrimination of the final model by grouping patients in categories
of the DQ-NAFLD risk score. I used the cutoffs of 0.71 (first knot) and 1.65 (third knot)
obtained from the estimated spline transformation of the risk score to identify, low,
medium, and high-risk donors. The Kaplan-Meier curves in Figure 25 show that the 1year graft survival post LT was statistically significantly different across risk categories
of the DQ-NAFLD score (𝜒 2 (2) = 28.07, p < .0001). After adjusting for multiple testing,
recipients of high-risk donors based on the DQ-NAFLD score were more likely to
experience liver graft failure within 1-year post LT, compared to medium risk (p <.0001)
and low risk (p <.0001).

Figure 25. Kaplan-Meier graft survival by risk score.
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Validation of model calibration. I validated the model for calibration accuracy
in predicting the probability of graft surviving 1-year post LT. The model calibration plot
in Figure 26 illustrates the agreement between observed and predicted estimated graft
survival probability within 1-year post LT in the NAFLD/CC population. The blue curve
in Figure 26 represents the estimated overfitting-corrected calibration curve. Wellcalibrated models have a slope of 1, while models providing too extreme predictions have
a slope less than one. The calibration curve slope indicates some overfitting. The
bootstrap estimated calibration of slope shrinkage was 0.83, suggesting that about 17% of
the fitted model is noise.

Figure 26. Bootstrap estimate of calibration accuracy for 1-year from the final Cox PH
model.
Note. The blue curve corresponds to 1000 bootstrap corrected estimates.
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Nomogram of the Intrinsic DQ-NAFLD Cox Model
I used the multivariable Cox PH model to build a nomogram depicted in Figure
27 for predicting 1-year graft survival probability. The nomogram shows the impact of
each predictor on the outcome graphically. Points are assigned to each independent
variable, donor age, donor MDRD, donor diabetes, DCD status, and donor height,
according to the degree of their impact on graft survival. The nomogram allows
estimating the probability of 1-year graft survival for a NAFLD/C recipient of LT when
donor predictor variables are provided. The nomogram assigns to each independent donor
variable in the model a point, and the total points are projected to a probability of graft
survival scale that ranges for 0 to 1.
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Figure 27. Nomogram from the fitted Cox PH model of intrinsic donor factors for
predicting graft failure in NAFLD/CC.
The nomogram can be used to obtain manually predicted points for each subject
from a regression model. Once the reader manually totals the points, the predicted values
can be read at the bottom. For example, a recipient of LT from a donor who was 60-yearold (point 2), insulin dependent (points 62), DBD (points 0) with MDRD of 70 (points
15) and with a high of 170 (points 10), for a total of 86 points, had an estimated
probability of liver graft survival at 1 year equal to 0.82.
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Random Survival Forest (RSF)
RSF algorithm developed by Ishwaran et al. (2008) is a non-parametric tree-based
learning machine method that, unlike the Cox PH model, requires no distributional
assumption of the candidate predictors. RSF utilizes randomly selected bootstrap samples
from the data to grow survival trees and can be used to identify and rank important risk
factors for graft failure within 1-year posttransplant. I conducted an RSF based on trees
grown from a sample of 3,165 NAFLD/CC recipients of LT and nine independent donor
factors for the prediction of graft survival post LT. I created a random forest of 1000
survival trees with a pre-specified number of predictors randomly selected before each
node split set to three, with node size set to 10, or terminating nodes with no fewer than
ten observations. Table 23 summarizes details of the RSF parameters I used to grow the
forest and the generalization error estimate from the forest. The overall estimated
prediction error rate for the random survival forest was 35.26%.

Table 23
RFS Algorithm Result Using Random Log-Rank Splitting Criteria
Parameter

Value

Sample size
Number of events
Number of trees
Forest terminal node size
Average number of terminal nodes
Number of variables tried at each split
Total number of variables
Number of random split
Error rate

3115
412
1000
10
219
3
9
10
35.26%
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Out-of-bag prediction error. Each bootstrap sample selects approximately
63.2% of the data to train each tree. As the RSF is built, the remaining 36.8% of
observations (the Out-of-Bag (OOB) sample), can be used to test each tree and estimate
the OOB error, which is an unbiased estimate of the true error, a measure of the
predictive ability of the forest (Breiman, 1996). Hastie, Tibshirani, and Friedman (2009)
showed that the OOB prediction error estimates are almost identical to n–fold cross
validation estimates. This feature of the RSF allows obtaining internal model fit and
validation in the same algorithm. Figure 28 depicts the RSF generalization error as a
function of the number of trees and shows that the forest tends to stabilize after a few
hundred trees. The OOB error estimate was 35.26%, indicating that the forest was
reasonably good in predicting 1-year graft survival post LT. The OOB Harrell’s Cstatistics was .64, indicating a better predictive ability of the RSF, compared to the Cox
PH model.
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Figure 28. The OOB error for RSF for 1000 trees.

Variable importance in random survival forests. I used the RSF to assess the
relative importance of variables. I considered two different criteria of ranking variables:
variable importance (VIMP), and minimal depth. VIMP ranks the most important
variables according to their impact on the predictive ability of the forest, and minimal
depth assumes that variables with high predictive impact are those that most frequently
split at the root node. Figure 29 illustrates the VIMP and the minimum depth plots
showing the top variables contributing to the predictive accuracy of the forest, with
higher values indicating more importance for the VIMP measures and lower values more
importance for the minimal depth measure. Table 24 summarizes the ranking of
variables. Donor sex, hypertension, and hyponatremia were the least important factors
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based on both criteria. The top donor’s variables averaging the two measurements were
height, age, MDRD, diabetes, and DCD.
Table 24
Results for the Variable Importance Measures for Donor’s Characteristics
Variable
Height (cm)
Diabetes
DCD
Age (yrs.)
MDRD
Cause of death
Sex
Hypernatremia
Hypertension

Depth

Depth rank

VIMP

VIMP rank

1.75
1.75
1.87
1.92
1.96
2.43
3.92
4.09
4.26

1
2
3
4
5
6
7
8
9

0.038
0.020
0.017
0.039
0.042
0.026
0.017
0.005
0.014

3
5
6
2
1
4
7
9
8

Note. Variables considered in the RSF for NAFLD/CC recipients of LT.
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Figure 29. Variable importance, minimal variable depth of donor characteristics using
RSF to model liver graft failure for NAFLD/CC.
Variable dependence. Although the RSF is considered a “black box” approach,
graphical methods can help examine the dependency of the forest prediction on the
independent variables. Variable dependence plots show the predicted response relative to
a covariate of interest. The top donor’s variables identified using minimal depth, and
VIMP that contributed most to the predictive accuracy of the forest were further analyzed
to explore how the forest predicted graft failure or death depends on these variables.
Figures 30 illustrates the relationship among height, cadaveric donor type, age, and
MDRD on 1-year graft survival post LT for NAFLD/CC patients. Blue circles events and
red dots indicate censored cases, i.e., graft failure or death within 1-year. Boxplots
indicate the distribution of predicted survival for all cases within each cadaveric donor
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group (Figure 30) or diabetes group (Figure 31) and show that recipients of DCD donors
or recipients of insulin-dependent diabetes have lower predicted graft survival. Variable
dependence of predicted 1-year graft survival on continuous variables, donor’s height,
age, and MDRD are depicted in Figure 30. Censored cases are marked in red and events
in blue. Loess smooth curve indicates the survival trend with increasing values.
Recipients of donors taller than 160 cm, with high MDRD and younger than 60 years
have higher predicted graft survival within 1-year post LT. Variable dependence can be
interpreted only in general terms as a graft survival prediction for a patient, as a function
of the values of all covariates in that particular patient.

Figure 30. Variable dependence of 1-year graft survival post LT on height, cadaveric
donor type, age and MDRD.
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Figure 31. Variable dependence of 1-year graft survival post LT on diabetes.
Research Question 2
The second research question was based on whether there are relationships
between post-transplant graft survival among NAFLD/CC recipients and transplant
factors (cold ischemia time, ABO matching, and size matching). Univariate analyses
showed that ABO compatibility and CIT modeled as RCS with four knots were both not
statistically significantly associated with graft survival at 1-year post LT. The CIT, a
significant predictor of graft survival in other studies (Feng et al., 2006), although not
significant, was included in the model because of clinical relevance. The overall
significance of the Cox PH model or the model goodness of fit was tested using the
likelihood ratio test (𝜒 2 (6) = 49.21, p <.0001), indicating that the model was statistically
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significant and adequate in predicting the graft survival experience of a NAFLD/CC
recipients of LT.
ABO continued to be not statistically significant when adjusted for CIT and size
match. Compared to normal for size grafts, livers large for size (AHR=1.52, 95%
CI=1.15, 2.02) was associated with an increased risk of graft failure of 52% within 1-year
post LT (Table 25). Table 25 shows the estimated coefficients of transplant-related
predictors of graft survival at 1-year post LT, including each parameter used in the
splines, and the AHRs along with the 95% CIs. Figure 32 provides a useful interpretation
of association between CIT and the adjusted relative hazard and show that, after adjusting
for ABO and size match at their reference category, for each value of the CIT, the 95%
CI of the estimated AHR includes one, indicating that CIT is not statistically significantly
associated with the hazard of graft failure at 1-year post LT.
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Table 25
Multivariate Cox PH Model for Transplant Variables Predicting Liver Graft Failure.
Variable

Estimated β

Wald ᵪ2

AHR (95% CI)

-0.24

1.28 (0.78, 2.01)

SE (β)
ABO compatibility
ABO compatible
ABO incompatibility

Reference
-.121 (.501)

Donor/recipient size match
Normal for size

Reference

Small for size

.069 (.164)

0.42

1.07 (0.78, 1.48)

Large for size

.423 (.144)

2.92

1.52 (1.15, 2.02)***

CIT linear

.042 (.011)

0.39

0.97 (0.86, 1.01)

CIT’

-.114 (.421)

-0.27

1.45 (0.94, 2.23)

CIT’’

.389 (1.266)

0.31

0.31 (0.09, 1.05)

Note. NAFLD/CC recipients (n=3165). β =estimated coefficient of Cox PH model,
SE=standard error, AHR=adjusted hazard ratio, CI=confidence interval.
***p<.001
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Figure 32. Restricted cubic splines of the association between CIT and relative hazard of
graft failure at 1-year post LT.
Note. The model is adjusted for the following variables set at reference category: ABO
compatibility (compatible), donor/recipient size match (normal for size).

Research Question 3
Research question three explores the relationships between post-transplant graft
survival among NAFLD/CC recipients and a number of donor characteristics (age,
gender, height, weight, BMI, the cause of death, hypertension, diabetes, donor after
circulatory death, HCV status, HBsAb status, HBsAg status, MDRD, hypernatremia) and
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transplant factors (CIT, ABO matching, size matching) after adjusting for characteristics
of recipients of liver transplant (age, gender, biological MELD).To answer the third
research question, I developed an extended version of the intrinsic donor model that
included in addition to donor factors, recipient and transplant factors. At the first step, I
used a priori information based on subject-specific knowledge and literature review to
derive a working set of candidate independent variables known as relevant predictors or
covariates for the study question to consider during statistical modeling. Next, I excluded
variables whose distributions were too narrow or with a substantial amount of missing
data, and this led to a final list of candidate predictors. I used Cox PH regression to
examine the association between selected donor, recipient and transplant variables, and
with the outcomes.
Model Building
The pre-specified list of candidate predictors included donors’ age, gender,
diabetes, MDRD, hypertension, hypernatremia, the cause of death, and donor DCD,
recipient’s age, gender, and biological MELD, organ size match, ABO compatibility, and
cold ischemia time. To reduce the number of predictors in the final model, I applied an
augmented backward elimination in 1000 bootstrap samples drawn from the original data,
with the level of significance ‘α’ set to 0.2 and the threshold of the relative change-inestimate criterion ‘τ’ set to 0.1 (Dunkler, Plischke, Leffondré, & Heinze, 2014). This
strategy allowed to include into the model regardless of their statistical significance donor
age, DCD and CIT, as known predictors of graft failure.
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The total number of complete cases included 3,118 recipients of LT, while 47 or
1.5% of cases were missing. I conducted a complete case analysis, and there were no
significant interactions. The final selected parsimonious model included eight predictors
from the initial set: recipient’s age and MELD score, donor’s age, DCD, MDRD,
diabetes, donor/recipient size match, and CIT. The overall likelihood ratio test was
𝜒 2 (19) =70.91 (p< .0001). This test evaluates the omnibus null hypothesis that all model
coefficients were 0, which was rejected against the alternative hypothesis that the
selected Cox PH regression model was statistically significant, and adequate in
explaining the graft survival experience of NAFLD/CC recipients of LT patients.
I used smoothing transformations of continuous predictors to relax the linearity
assumption and prevent residual confounding. I tested the model distributional
assumption using smoothed scaled Schoenfeld residuals for each predictor and graphical
visualization. I did not observe any trends against the log of time. The global test of
proportional hazard (p=.08) supported the validity of the proportional hazard assumption
at the α=.05 level of significance.
Model Selected
The independent variables selected in the final model included: recipient’s age
and MELD score, donor’s age, DCD, MDRD, diabetes, donor/recipient size match, and
CIT. Harrell (2015) suggested as a rule of thumb that at least 10–20 events are needed per
degree of freedom. The study sample included 412 events and approximately 20 degrees
of freedom to spend-to-fit the model, which used 19 degrees of freedom. The available
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effective sample size was sufficiently large to allow the fit of an initial saturated prespecified model, where I considered all predictors, including the non-significant in the
univariate analysis. I tested the overall significance of the Cox PH model or the model
goodness of fit using the likelihood ratio test with 𝜒 2 (19) = 70.91, p <.0001), indicating
that the model was statistically significant and adequate in predicting the graft survival
experience of a NAFLD/CC recipients of LT.
The results of the Cox regression model selected presented in Table 26 include
the estimated coefficients, the standard errors as well as the AHRs along with the 95%
CIs of each categorical predictor, for each parameter used in the splines. Recipients of
livers from donors with insulin-dependent diabetes were almost twice more likely to lose
their liver allograft within 1-year post LT (AHR=1.77, 95% CI=1.27, 2.46), compared to
recipients of donors with no diabetes. Receiving a DCD liver allograft was associated
with a 2.5-fold increased risk of graft failure (AHR=2.51, 95% CI=1.83, 3.46).
NAFLD/CC recipients of large for size livers were 1.4 times more likely to lose their
liver allograft or die within 1-year post LT than recipients of normal for size donors
(AHR=1.45, 95% CI=1.08, 1.92). The final RCS Cox regression model results presented
in Table 26, include estimated coefficients for each parameter used in the splines that do
not have an immediate interpretation.

166
Table 26
Multivariate Cox PH Model for Donor, Recipient and Transplant Variables Predicting
Liver Graft Failure
Wald ᵪ2

Donor age linear

Estimated β
SE(β)
-0.004 (0.014)

-0.29

1.00 (0.91, 1.02)

Donor age’

0.007 (0.044)

0.16

1.01 (0.92, 1.02)

Donor age’’

0.002 (0.123)

0.01

1.00 (0.79, 1.27)

MDRD linear

-0.004 (0.003)

-1.74

1.00 (0.99, 1.00)

Mdrd’

0.002 (0.003)

0.99

1.00 (1.00, 1.00)

Exposure

AHR (95% CI)

Donor diabetes
Non-diabetic

Reference

Non-insulin dependent

-0.313 (0.231)

-1.36

0.73 (0.46, 1.15)

Insulin dependent

0.572 (0.168)

3.41

1.77 (1.27, 2.46)***

Cadaveric donor type
DBD

Reference

DCD

0.922 (0.162)

5.69

2.51 (1.83, 3.46)**

CIT

-0.007 (0.109)

-0.07

0.99 (0.80, 1.23)

CIT’

0.083 (0.423)

0.20

1.09 (0.47, 2.49)

CIT ‘‘

-0.118 (0.285)

-0.09

0.89 (0.07, 11.03)
(table continue)
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Exposure

Estimated β
SE(β)

Wald ᵪ2

AHR (95% CI)

Donor/recipient size
Normal for size

Reference

Small for size

0.149 (0.168)

0.89

1.16 (0.84, 1.61)

Large for size

0.369 (0.147)

2.52

1.45 (1.08, 1.92)

MELD
MELD <15

Reference

MELD score 15-24

-0.169 (0.151)

-1.12

0.84 (0.63, 1.13)

MELD score 25-34

0.199 (0.160)

1.24

1.22 (0.89, 1.67)

MELD score ≥35

0.285 (0.171)

1.66

1.33 (0.95, 1.86)

Recipient age linear

-0.002 (0.015)

-0.12

0.99 (.97, 1.10)

Recipient age’

0.037 (0.029)

1.25

1.04 (.98, 1.01)

Recipient age ‘‘

-0.248 (0.226)

-1.10

0.78 (.50, 1.21)

Note. NAFLD/CC recipients (n=3,115), β =estimated coefficient of Cox PH model,
SE=standard error, AHR=adjusted hazard ratio, CI=confidence interval.
* p<.05, **p<.01, ***p<.001

Tables 27-29 provide a useful interpretation of RCS. After fitting a Cox PH model
that includes splines, I computed hazard ratios by comparing specific values of a
continuous variable, with a single reference value. I calculated AHRs, and 95% CIs
constructed from splines for donor age (Table 27), for CIT (Table 2), and donor MDRD
(Table 28), at selected predictor values. From Table 28, compared to a reference donor

168
with MDRD of 69, liver allografts from donors with an MDRD of 30 provided an
increase in the risk of graft failure within 1-year post LT of 17% (ARH=1.17, 95% CI=
1.01, 1.37).

Table 27
Estimated AHRs and 95% CI for Selected Values of Donor Age from the Multivariate
Cox PH Regression
Selected donor age (yrs.)

ARH

95% CI

20

1.05

(0.80, 1.39)

30

1.01

(0.85, 1.21)

45

Reference

60

1.09

(0.92, 1.28)

Note. AHR=adjusted hazard ratio, CI=confidence interval.
Table 28
Estimated AHRs and 95% CI for Selected Values CIT from the Multivariate Cox PH
Regression
Selected CIT (hrs.)

AHR

95% CI

3

0.98

(0.72, 1.35)

5

0.98

(0.89, 1.08)

5.9

Reference

10

1.24

Note. AHR=adjusted hazard ratio, CI=confidence interval.

(0.98, 1.58)
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Table 29
Estimated AHRs and 95% CI for Selected Values of MDRD from the Multivariate Cox
PH Regression
Selected MDRD

ARH

95% CI

30

1.17

(1.00, 1.37)

45

1.08

(0.84, 1.39)

60

1.03

(1.00, 1.06)

69

Reference

80

0.96

(0.94, 0.99)

90

0.94

(0.91, 0.98)

Note. AHR=adjusted hazard ratio, CI=confidence interval.

Figures 33-35 show the predicted relative risk of graft failure as a function of
donor age, CIT, and donor MDRD, holding all other variables constant at representative
levels (DBD, no diabetes, 45-year old, donor MDRD of 69, CIT of 5.9) by MELD score.
The solid blue line represents the estimated adjusted hazard ratio or relative risk for the
Cox regression model with restricted cubic splines and dashed lines represent the 95%
confidence interval of the estimate. If the 95% confidence interval includes 1, the hazard
ratio is not significant. I did not observe any association between donor age and 1-year
graft survival in each MELD score category (Figure 33). Decreased CIT is associated
with improved 1-year graft survival for recipients for MELD score 15-24 (Figure 34).
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Figure 35 (A and B) shows that the relative risk of graft failure increases as MDRD
decreases, respectively, for MELD score <15 and MELD score 15-24. No association
between MDRD and the risk of 1-year graft failure for other MELD score categories.

Figure 33. RCS relationships between donor age (yrs.) adjusted to reference values by
MELD score: <15 (A), 15-24 (B), 25-34 (C), > 35 (D).
Note. The model is adjusted for the following variables set at reference category: donor
type (DBD), diabetes (No), or median category: MDRD (69), normal for size donors, and
CIT of 5.9 hours.
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Figure 34. RCS relationships between CIT (hrs.) adjusted to reference values by MELD
score: <15 (A), 15-24 (B), 25-34 (C), > 35 (D).
Note. The model is adjusted for the following variables set at reference category: donor
type (DBD), diabetes (No), or median category: MDRD (69), donor age (45 yrs.), and
normal for size donors.
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Figure 35. RCS relationships between donor MDRD adjusted to reference values by
MELD score: <15 (A), 15-24 (B), 25-34 (C), > 35 (D).
Note. The model is adjusted for the following variables set at reference category: donor
type (DBD), diabetes (No), or median category: donor age (45 yrs.), normal for size
donors, and CIT of 5.9 hours.

The extended DQ-NAFLD risk score is an estimate of the relative risk of
posttransplant graft failure for an adult recipient from a particular cadaveric donor,
compared to a reference 45-year old donor, DBD, with a height of 172 cm, with no
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diabetes and MDRD of 69, with an estimated graft normal for size, a 60-year old
recipient with MELD score between 15 and 24, and with CIT of 5.9 hours. The Cox PH
model assumes that the risk for subject j is:
𝜆(𝑡|𝑥𝑗 ) = 𝜆0 (𝑡)𝑟𝑗 (𝑡)
I used the coefficients of the Cox PH model in conjunction with individual covariates to
estimate extended DQ-NAFLD risk score for an individual. The risk score for a subject
‘j’ is the hazard ratio for that person relative to the baseline, as shown in Equation 11:
𝐸𝑥𝑡𝑒𝑛𝑑𝑒𝑑 𝐷𝑄 − 𝑁𝐴𝐹𝐿𝐷(𝑗)

(11)

′
′′
= exp(𝛽1 𝑥 𝐷𝑜𝑛𝑜𝑟 𝐴𝑔𝑒(𝑗) + 𝛽2 𝑥 𝐷𝑜𝑛𝑜𝑟 𝐴𝑔𝑒(𝑗)
+ 𝛽3 𝑥 𝐷𝑜𝑛𝑜𝑟 𝐴𝑔𝑒(𝑗)
𝑖
+ 𝛽4 𝑥 𝑀𝐷𝑅𝐷(𝑗) + 𝛽5 𝑥 𝑀𝐷𝑅𝐷(𝑗)
+ 𝛽6 𝑥 𝐼(𝑁𝑜𝑛 𝐼𝑛𝑠𝑢𝑙𝑖𝑛 𝐷𝑒𝑝𝑒𝑛𝑑𝑒𝑛𝑡(𝑗) )

+ 𝛽7 𝑥 𝐼(𝐼𝑛𝑠𝑢𝑙𝑖𝑛 𝐷𝑒𝑝𝑒𝑛𝑑𝑒𝑛𝑡(𝑗) ) + 𝛽8 𝑥 𝐼(𝐷𝐶𝐷(𝐽) ) + 𝛽9 𝑥 𝐶𝐼𝑇(𝐽)
′
′′
+ 𝛽10 𝑥 𝐶𝐼𝑇(𝑗)
+ 𝛽11 𝑥 𝐶𝐼𝑇(𝑗)

+ 𝛽12 𝑥 𝐼(𝑆𝑚𝑎𝑙𝑙 𝑓𝑜𝑟 𝑆𝑖𝑧𝑒(𝑗) ) + 𝛽13 𝑥 𝐼(𝐿𝑎𝑟𝑔𝑒 𝑓𝑜𝑟 𝑆𝑖𝑧𝑒)
+ 𝛽14 𝑥 𝐼(𝑀𝐸𝐿𝐷 (15 − 24)(𝑗) ) + 𝛽15 𝑥 𝐼(𝑀𝐸𝐿𝐷 (25 − 34)(𝑗) )
+ 𝛽16 𝑥 𝐼(𝑀𝐸𝐿𝐷 (≥ 35)(𝑗) ) + 𝛽17 𝑥 𝑅𝑒𝑐𝑖𝑝𝑖𝑒𝑛𝑡 𝐴𝑔𝑒(𝑗)
′
′′
+ 𝛽18 𝑥 𝑅𝑒𝑐𝑖𝑝𝑖𝑒𝑛𝑡 𝐴𝑔𝑒(𝑗)
+ 𝛽19 𝑥 𝑅𝑒𝑐𝑖𝑝𝑖𝑒𝑛𝑡 𝐴𝑔𝑒(𝑗)
)

Where I(e)=1 if the event is true, I(e)=0 otherwise
𝑓𝑜𝑟 j=1….n
I expressed the predictors: donor age, MDRD, CIT and recipient age as RCSs.
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I modeled the predictor donor age as RCS with four knots, 𝑡1 = 18, 𝑡2 = 35, 𝑡3 = 52,
𝑡4 = 71. The nonlinear terms are:
′
𝐷𝑜𝑛𝑜𝑟 𝐴𝑔𝑒(𝑗)
= (𝐷𝑜𝑛𝑜𝑟 𝐴𝑔𝑒(𝑗) − 𝑡1 )3+ −

+

(𝑡3 − 𝑡1 )
3
𝑥 (𝐷𝑜𝑛𝑜𝑟 𝐴𝑔𝑒(𝑗) − 𝑡4 )+
(𝑡4 − 𝑡3 )

′′
𝐷𝑜𝑛𝑜𝑟 𝐴𝑔𝑒(𝑗)
= (𝐷𝑜𝑛𝑜𝑟 𝐴𝑔𝑒(𝑗) − 𝑡2 )3+ −

+

(𝑡4 − 𝑡1 )
3
𝑥 (𝐷𝑜𝑛𝑜𝑟 𝐴𝑔𝑒(𝑗) − 𝑡2 )+
(𝑡4 − 𝑡3 )

(𝑡4 − 𝑡2 )
3
𝑥 (𝐷𝑜𝑛𝑜𝑟 𝐴𝑔𝑒(𝑗) − 𝑡3 )+
(𝑡4 − 𝑡3 )

(𝑡3 − 𝑡2 )
3
𝑥 (𝐷𝑜𝑛𝑜𝑟 𝐴𝑔𝑒(𝑗) − 𝑡4 )+
(𝑡4 − 𝑡3 )

I modeled the predictor MDRD as RCS with three knots, 𝑡1 = 17, 𝑡2 = 69, 𝑡3 = 137.
The nonlinear term is:
𝑖
𝑀𝐷𝑅𝐷(𝑗)
= (𝑀𝐷𝑅𝐷(𝑗) − 𝑡1 )3+ −

+

(𝑡3 − 𝑡1 )
3
𝑥 (𝑀𝐷𝑅𝐷(𝑗) − 𝑡2 )+
(𝑡3 − 𝑡2 )

(𝑡2 − 𝑡1 )
3
𝑥 (𝑀𝐷𝑅𝐷(𝑗) − 𝑡3 )+
(𝑡3 − 𝑡2 )

I modeled the predictor CIT as RCS with four knots, 𝑡1 = 3.1, 𝑡2 = 5.1, 𝑡3 = 6.6, 𝑡4 =
10. The nonlinear terms are:
′
𝐶𝐼𝑇(𝑗)
= (𝐶𝐼𝑇(𝐽) − 𝑡1 )3+ −

(𝑡4 − 𝑡1 )
(𝑡3 − 𝑡1 )
3
3
𝑥 (𝐶𝐼𝑇(𝐽) − 𝑡2 )+ +
𝑥 (𝐶𝐼𝑇(𝐽) − 𝑡4 )+
(𝑡4 − 𝑡3 )
(𝑡4 − 𝑡3 )

′′
𝐶𝐼𝑇(𝑗)
= (𝐶𝐼𝑇(𝐽) − 𝑡2 )3+ −

(𝑡4 − 𝑡2 )
(𝑡3 − 𝑡2 )
3
3
𝑥 (𝐶𝐼𝑇(𝐽) − 𝑡3 )+ +
𝑥 (𝐶𝐼𝑇(𝐽) − 𝑡4 )+
(𝑡4 − 𝑡3 )
(𝑡4 − 𝑡3 )
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I modeled the predictor recipient age as RCS with four knots, 𝑡1 = 42, 𝑡2 = 57, 𝑡3 = 64,
𝑡4 = 70. The nonlinear terms are:
′
𝑅𝑒𝑐𝑖𝑝𝑖𝑒𝑛𝑡 𝐴𝑔𝑒(𝑗)

= (𝑅𝑒𝑐𝑖𝑝𝑖𝑒𝑛𝑡 𝐴𝑔𝑒(𝑗) − 𝑡1 )3+ −
+

(𝑡4 − 𝑡1 )
3
𝑥 (𝑅𝑒𝑐𝑖𝑝𝑖𝑒𝑛𝑡 𝐴𝑔𝑒(𝑗) − 𝑡2 )+
(𝑡4 − 𝑡3 )

(𝑡3 − 𝑡1 )
3
𝑥 (𝑅𝑒𝑐𝑖𝑝𝑖𝑒𝑛𝑡 𝐴𝑔𝑒(𝑗) − 𝑡4 )+
(𝑡4 − 𝑡3 )

′′
𝑅𝑒𝑐𝑖𝑝𝑖𝑒𝑛𝑡 𝐴𝑔𝑒(𝑗)

= (𝑅𝑒𝑐𝑖𝑝𝑖𝑒𝑛𝑡 𝐴𝑔𝑒(𝑗) − 𝑡2 )3+ −
+

(𝑡4 − 𝑡2 )
3
𝑥 (𝑅𝑒𝑐𝑖𝑝𝑖𝑒𝑛𝑡 𝐴𝑔𝑒(𝑗) − 𝑡3 )+
(𝑡4 − 𝑡3 )

(𝑡3 − 𝑡2 )
3
𝑥 (𝑅𝑒𝑐𝑖𝑝𝑖𝑒𝑛𝑡 𝐴𝑔𝑒(𝑗) − 𝑡4 )+
(𝑡4 − 𝑡3 )

Where (𝑧)+ is equal to z if z > 0, and 0 otherwise.
Replacing the estimated model coefficients, Equation 11 is obtained:
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𝐸𝑥𝑡𝑒𝑛𝑑𝑒𝑑 𝐷𝑄 − 𝑁𝐴𝐹𝐿𝐷(𝑗)
= exp (−0.004 𝑥 𝐷𝑜𝑛𝑜𝑟 𝐴𝑔𝑒(𝑗)
3

+ 0.007 𝑥 ((𝐷𝑜𝑛𝑜𝑟 𝐴𝑔𝑒(𝑗) − 𝑡1 )+ −
+

(𝑡3 − 𝑡1 )
3
𝑥 (𝐷𝑜𝑛𝑜𝑟 𝐴𝑔𝑒(𝑗) − 𝑡4 )+ )
(𝑡4 − 𝑡3 )
3

+ 0.002 𝑥 ((𝐷𝑜𝑛𝑜𝑟 𝐴𝑔𝑒(𝑗) − 𝑡2 )+ −
+

(𝑡4 − 𝑡2 )
3
𝑥 (𝐷𝑜𝑛𝑜𝑟 𝐴𝑔𝑒(𝑗) − 𝑡3 )+
(𝑡4 − 𝑡3 )

(𝑡3 − 𝑡2 )
3
𝑥 (𝐷𝑜𝑛𝑜𝑟 𝐴𝑔𝑒(𝑗) − 𝑡4 )+ ) − 0.004 𝑥 𝑀𝐷𝑅𝐷(𝑗)
(𝑡4 − 𝑡3 )
3

+ 0.002 𝑥 ((𝑀𝐷𝑅𝐷(𝑗) − 𝑡1 )+ −
+

(𝑡4 − 𝑡1 )
3
𝑥 (𝐷𝑜𝑛𝑜𝑟 𝐴𝑔𝑒(𝑗) − 𝑡2 )+
(𝑡4 − 𝑡3 )

(𝑡3 − 𝑡1 )
3
𝑥 (𝑀𝐷𝑅𝐷(𝑗) − 𝑡2 )+
(𝑡3 − 𝑡2 )

(𝑡2 − 𝑡1 )
3
𝑥 (𝑀𝐷𝑅𝐷(𝑗) − 𝑡3 ) )
+
(𝑡3 − 𝑡2 )

− 0.313 𝑥 𝐼(𝑁𝑜𝑛 𝐼𝑛𝑠𝑢𝑙𝑖𝑛 𝐷𝑒𝑝𝑒𝑛𝑑𝑒𝑛𝑡(𝑗) )
+ 0.572 𝑥 𝐼(𝐼𝑛𝑠𝑢𝑙𝑖𝑛 𝐷𝑒𝑝𝑒𝑛𝑑𝑒𝑛𝑡(𝑗) ) + 0.922 𝑥 𝐼(𝐷𝐶𝐷(𝐽) )
3

− 0.07 𝑥 𝐶𝐼𝑇(𝐽) + 0.083 𝑥 ((𝐶𝐼𝑇(𝐽) − 𝑡1 )+ −

(𝑡4 − 𝑡1 )
3
𝑥 (𝐶𝐼𝑇(𝐽) − 𝑡2 )+
(𝑡4 − 𝑡3 )

+

(𝑡3 − 𝑡1 )
3
3
𝑥 (𝐶𝐼𝑇(𝐽) − 𝑡4 )+ ) − 0.118 𝑥((𝐶𝐼𝑇(𝐽) − 𝑡2 )+
(𝑡4 − 𝑡3 )

−

(𝑡4 − 𝑡2 )
(𝑡3 − 𝑡2 )
3
3
𝑥 (𝐶𝐼𝑇(𝐽) − 𝑡3 )+ +
𝑥 (𝐶𝐼𝑇(𝐽) − 𝑡4 )+ )
(𝑡4 − 𝑡3 )
(𝑡4 − 𝑡3 )

+ 0.149 𝑥 𝐼(𝑆𝑚𝑎𝑙𝑙 𝑓𝑜𝑟 𝑆𝑖𝑧𝑒(𝑗) ) + 0.369𝑥 𝐼(𝐿𝑎𝑟𝑔𝑒 𝑓𝑜𝑟 𝑆𝑖𝑧𝑒)

177
− 0.169 𝑥 𝐼(𝑀𝐸𝐿𝐷 (15 − 24)(𝑗) ) + 0.199 𝑥 𝐼(𝑀𝐸𝐿𝐷 (25 − 34)(𝑗) )
+ 0.285 𝑥 𝐼(𝑀𝐸𝐿𝐷 (≥ 35)(𝑗) ) − 0.002 𝑥 𝑅𝑒𝑐𝑖𝑝𝑖𝑒𝑛𝑡 𝐴𝑔𝑒(𝑗)
′
′′
+ 0.037 𝑥 𝑅𝑒𝑐𝑖𝑝𝑖𝑒𝑛𝑡 𝐴𝑔𝑒(𝑗)
− 0.248 𝑥 𝑅𝑒𝑐𝑖𝑝𝑖𝑒𝑛𝑡 𝐴𝑔𝑒(𝑗)
)

Model Validation
I performed the internal validation to assess the performance of the final chosen
model. The bootstrap approach described by Harrell et al. (1996) allows quantifying the
overfitting or “optimism” inherent in predictive accuracy. I estimated the optimism by
taking 1000 bootstrap samples with replacement from the full data and evaluating the
difference between model performance in each bootstrap sample and on the whole
sample. I estimated the optimism as the average of these differences across 1000
bootstrap samples. I then subtracted this estimate of optimism from the naïve estimate of
predictive ability to obtain the bias-corrected predictive ability.
Validation of model discrimination. Discrimination of the final model indicated
by the Harrell’s C-statistic represents the proportion of pairs of ordered subjects such that
the subject with higher predicted survival is the one who survived longer. The C-statistic
summarizes the predictive power of the DQ-NAFLD and ranges from 0.5 to 1.0. High
values indicate greater discriminatory power, or the ability to separate “more successful”
from “less unsuccessful” graft outcomes along the DQ-NAFLD scale. According to 1000
bootstrap samples, the apparent or naïve C- statistics was equal to .613, and the bootstrap
optimism corrected C-statistics was .601. The extender DQ-NAFLD model provides only
a slight improvement in accuracy, compared to the donor intrinsic DQ-NAFLD model. A
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C-statistic nearly 0.60 is only moderately predictive. This ted result is consistent with
other donor risk models since multiple factors not included in the DQ-NAFLD model
affects graft survival.
Figure 36 displays the estimated relationship between DQ-NAFLD risk scores
calculated from the extended model and log-hazard ratio for graft failure at 1-year post
LT. The relationship was estimated using an RCS with three knots at 0.62, 0.69 and 1.73.
I used the cutoffs of 0.62 (first knot), and 1.73 (third knot) obtained from the estimated
spline transformation of the risk score to identify low, medium, and high-risk donors.

Figure 36. Restricted cubic spline estimates of the relationship between the extended
DQ-NAFLD risk score and log relative hazard of graft failure at 1-year post LT.
Note. Knots at 0.62, 0.96 and 1.73.
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The Kaplan-Meier curves and log-rank test in Figure 37 show that the 1-year graft
survival post LT was statistically significantly different across risk categories of the DQNAFLD score (𝜒 2 (2) = 45.4, p <.0001). After adjusting for multiple testing, recipients of
high-risk donors based on the DQ-NAFLD score were more likely to experience liver
graft failure within 1-year post LT, compared to medium risk (p<.0001) and low risk (p
<.0001).

Figure 37. Kaplan-Meier graft survival by risk score.

Validation of model calibration. I validated the model for calibration accuracy
in predicting the probability of graft survival 1-year post LT. The model calibration plot
in Figure 38 determines the agreement between observed and predicted estimated graft
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survival probability within a 1-year post LT in the NAFLD/CC population. The blue
curve in Figure 38 represents the estimated overfitting-corrected calibration curve. The
calibration curve slope indicates some overfitting. The bootstrap estimated calibration of
slope shrinkage was 0.80, suggesting that about 20% of the fitted model is noise.

Figure 38. Bootstrap estimate of calibration accuracy for 1-year from the final Cox PH
model.
Note. The blue curve corresponds to 1000 bootstrap corrected estimates.
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Nomogram of the Extended DQ-NAFLD Cox Model
I used the multivariable Cox PH model to build a nomogram, as depicted in
Figure 39, for predicting 1-year graft survival probability. The nomogram shows the
impact of each predictor on the outcome graphically. Points are assigned to each
independent donor, recipient, and transplant variables in the model according to the
degree of their impact on graft survival. The nomogram allows estimating the probability
of 1-year graft survival for a NAFLD/CC recipient of LT when the selected donor,
recipient, and transplant predictor variables are provided. The nomogram assigns a point
to each independent donor variable in the model, and the total points are projected to a
probability of graft survival scale that ranges from 0 to 1. The nomogram can be used to
obtain manually predicted points for each subject from a regression model. Once the user
manually totals the points, the predicted values can be read at the bottom.
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Figure 39. Nomogram from the fitted Cox PH model of extended donor factors for
predicting graft failure in NAFLD/CC.

For example, a NAFLD/CC recipient of LT of 60 years (26 points) and MELD Score 18
(0 points) is considered herein matched with a DCD donor (100 points), 35-year-old (2
points), without diabetes (0 points), with MDRD of 80 (4 points), with an estimated CIT
of 5 hours (0 points) and with an estimated graft large for size (40 points). The resulting
total points are 172, which has an estimated probability of .78 for liver graft survival at
one year.
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Predicted DQ-NAFLD Scores
Figure 40 provides an insight into the distributions of the calculated DQ-NAFLD
scores using the two models. In this figure, the variation of the donor predicted hazard
ratios of graft failure within 1-year posttransplant using the two DQ-NAFLD models is
presented. The observed DQ-NAFLD scores in the donor-only model ranged from 0.1 to
6.6 with a median value of 0.93 (IQR, 0.83, 1.11) while the observed scores in the
extended DQ-NAFLD ranged from 0.26 to 4.2, with a median value of 0.96 (IQR, 0.76,
1.25). The DQ-NAFLD score can be interpreted as a measure of relative graft failure
hazard rate compared with the median donor, which has a relative hazard failure rate of 1.
Figure 41 displays the side by side of the DQ-NAFLD scores classified by risk group
category using the two DQ-NAFLD models.

Figure 40. Kernel density distributions of DQ-NAFLD scores.
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Figure 41. Side by side boxplots by DQ-NAFLD model and risk group.
Research Question 4
The fourth research question explores the relationships between post-transplant
graft survival among NAFLD/CC recipients and the health risk status of the county were
recipients reside, measured by the community health score (CHS). A total of 3017
NAFLD/CC recipients of LT had CHS data, and there were 397 events, i.e., graft failures
or deaths within 1-year post LT. CHS data were not available for 148 study subjects. To
answer the research question, I modeled CHS as RCS with four knots at 6, 12, 18, and 30
in a Cox PH model of graft survival. The corresponding global likelihood ratio test
(𝜒 2 (3) = 4.70, p=.185) indicated that CHS was not statistically significantly associated
with graft survival at 1-year post LT. Therefore, the null hypothesis of no association
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between CHS and post-transplant graft failure is not rejected. Alternatively, I ued the
knot positions as cutoffs to categorize CHS in five groups: CHS ≤ 6, 7 ≤ CHS ≤ 12, 13 ≤
CHS ≤ 18, 19 ≤ CHS ≤ 30, and HCS>30. I estimated survival curves using the KaplanMeier method for each of the five categories of CHS, as portrayed in Figure 42.

Figure 42. Kaplan-Meier graft survival by CHS with cut-off points obtained from the
estimated spline transformation of the risk score.
I compared the survival curves using the log-rank test. The overall log-rank test
(𝜒 2 (4) = 10.6, p=.0.032) indicated a statistically significant difference in graft survival
experience among the CHS groups. I performed post hoc Benjamín and Hochberg
adjusted multiple comparisons that control the false discovery rate to identify where the
differences across groups lied. The pairwise corrections revealed that, compared to
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recipients of LT who resided in low health risk counties (CHS<6), recipients who resided
in counties with high community health risk (CHS >30) had a worse graft survival
experience post LT (p = .041). All other pairwise comparisons were not statistically
significant.
Similarly, when, I modeled CHS as a categorical predictor in a Cox PH model,
the global likelihood ratio test (𝜒 2 (4) = 10.34, p =.04) revealed that CHS was
statistically significantly associated with graft survival at 1-year post LT indicating that
the null hypothesis of no association between CHS and graft survival is rejected. The
association between CHS and 1-year graft survival tends to be conflicting depending on
how CHS is modeled: significant when CHS is categorized, not significant when CHS is
modeled as RCS.
Table 30 summarizes the results of the Cox PH model. Compared to the reference
category of CHS <6, recipients of LT who reside in counties with CHS>30 were more
likely to lose their liver allograft within 1-year post LT (HR=1.81, 95% CI 1.08, 3.05).
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Table 30
Univariate Cox Regression Model for CHS Predicting Liver Graft Failure
Variable (CHS)

Estimated β

Wald ᵪ2

AHR (95% CI)

SE(β)
<6

Reference

7-12

0.216 (0.265)

1.12

1.35 (0.78, 2.26)

13-18

0.255 (0.271)

0.94

1.29 (0.76, 2.20)

19-30

0.328 (0.297)

1.10

1.40 (0.78, 2.48)

>30

0.594 (0.265)

2.24

1.81 (1.08-3.05)*

Note. NAFLD/CC recipients (n=3017). β =estimated coefficient of Cox PH model,
SE=standard error, AHR=adjusted hazard ratio. CI=confidence interval.* p<.05.

Choropleth graph (Figure 43) shows the donor graft survival aggregated by
county by three groups of graft failures. The graph illustrates the county estimated graft
survival at 1-years colored according to group value from light to dark blue, with darker
colors indicating more favorable graft survival. Counties with unavailable information
are indicated in black. The choropleth graph provides a visual illustration of the variation
in graft survival across countries. There were 1145 counties represented in the analysis,
and there were counties with few patients.
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Figure 43. Choropleth graph of 1-year graft survival by county.
Research Question 5
The fifth research question was based on whether or not there was a relationship
between post-transplant graft survival among NAFLD/CC recipients and the distance
from recipient residence to the transplant center. I analyzed a total of 3,137 NAFLD/CC
recipients of LT. There were 414 events; r graft failures or deaths within 1-year post LT.
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I excluded from the analysis twenty-eight subjects with missing zip code data as I could
not calculate the distance from their residence to the transplant center.
To answer the research question, I modeled distance from recipient residence to
transplant center as RCS with four knots at 5, 27, 85, and 422 miles. The corresponding
global likelihood ratio test (𝜒 2 (2) = 4.10, p=.25) indicated that distance from recipient
residence to the transplant was not significantly associated with graft survival at 1-year
post LT. Therefore, the null hypothesis of no association is not rejected. Alternatively, I
used the knot positions as cutoffs to categorize distance to the transplant center in 5
groups: ≤5 (miles), 6-27 (miles), 28-85 (miles), 46-422 (miles), and >422 (miles). Figure
44 illustrates the Kaplan-Meier survival curve for the five distance groups. The log-rank
test (𝜒 2 (4) = 4.0, p =.40) showed no differences in survival experience across the five
distance from transplant center groups.
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Figure 44. Kaplan-Meier graft survival by distance from transplant center with cut points
obtained from the estimated spline transformation of the risk score.
Similarly, when I modeled the distance from transplant center as a categorical
predictor in a Cox PH model, the global likelihood ratio test ( 𝜒 2 (4) = 4.02, p = .40)
indicated that geographic distance was not associated with graft survival at 1-year posttransplant. Compared to the reference category of LT recipients’ distance from the
transplant center of ≤ 5 miles, all other recipients in other distance categories were as
likely to lose their liver graft within 1-year post LT, as summarized in Table 31. These

191
results confirm that the null hypothesis of no association between distance and graft
survival is not rejected.
Table 31
Univariate Cox Regression Model for Distance from Transplant Center Predicting Liver
Graft Failure
Wald ᵪ2

≤5

Estimated β
SE (β)
Reference

6-27

-0.105 (0.222)

-0.474

.90 (0.58, 1.39)

28-85

-0.052 (0.221)

-0.234

.94 (0.62, 1.47)

86-422

-0.283 (0.226)

-1.256

.75 (0.48, 1.17)

> 422

-0.203 (0.307)

-0.660

.82 (0.45, 1.40)

Variable (Distance, miles)

AHR (95% CI)

Note. NAFLD/CC recipients (n=3017). β =estimated coefficient of Cox PH model,
SE=standard error, AHR=adjusted hazard ratio, CI=confidence interval.

Research Question 6
Research question six was based on exploring relationships between DQ-NAFLD
risk score and external community factors (CHS and distance from recipient residence to
transplant center) among NAFLD/CC recipients of LT.
To answer the question, I developed a Cox PH model to measure the combined
effect of DQ-NAFLD risk score category, distance from recipient residence to transplant
center, and CHS on the risk of graft failure within 1-year post LT. There were 2971
observations, and 390 events, and no significant interactions. The model goodness-of-fit
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tested using the likelihood ratio test (𝜒 2 (10) = 39.05, p <.0001) indicated model adequacy
in explaining the graft survival experience of NAFLD/CC recipients of LT patients. The
results of the Cox PH model are summarized in Table 32. Compared to recipients with
low-risk donors based on the DQ-NAFLD score, recipients of medium risk livers
(HR=1.57, 95% CI 1.12, 2.19) and high-risk livers (HR=2.57, 95% CI 1.84, 4.13) based
on the DQ-NAFLD score were more likely to lose their grafts within the first-year post
LT. Compared to the reference category of CHS <6, recipients of LT who resided in
counties with CHS>30 were more likely to lose their liver allografts within 1-year post
LT (HR=1.85, 95% CI 1.08, 3.17). The scatterplots in Figure 45 depict the direction and
strength of the relationship between the donor risk score and community health score,
respectively, Figure 45(A) and distance from transplant center Figure 45 (B).
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Table 32
Multivariate Cox Regression Model for NAFLD/CC Risk Score and External Factors
Predicting Liver Graft Failure.
Variables

Estimated β
SE (β)

Wald ᵪ2

AHR (95% CI)

Risk Score
Low
Reference
Medium
0.452 (0.171)
2.95
1.57 (1.12, 2.20)*
High
1.014 (0.206)
4.91
2.76 (1.84, 4.13)***
CHS
<6
Reference
7-12
0.331 (0.276)
1.20
1.39 (0.81, 2.39)
13-18
0.280 (0.280)
1.00
1.32 (0.76, 2.29)
19-30
0.387 (0.312)
1.25
1.47 (0.80, 2.71)
>30
0.616 (0.274)
2.25
1.85 (1.08, 3.17)*
Distance
<6
Reference
7-27
-0.181 (0.225)
-.81
0.83 (0.54, 1.30)
28-85
-0.086 (0.224)
-.38
0.92 (0.59, 1.4)
86-422
-0.299 (0.229)
-1.29
0.74 (0.47, 1.17)]
≥ 422
-0.245 (0.324)
-.75
0.78 (0.41, 1.48)
Note. NAFLD/CC recipients (n=2971), β =estimated coefficient of Cox PH model,
SE=standard error, AHR=adjusted hazard ratio, CI=confidence intervals.
* p<.05, **p<.001, ***p<.0001.
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Figure 45. Scatterplot of NAFLD/CC donor risk score; (A) CHS, (B) distance from
recipient residence to transplant center.
Summary of Results
In summary, the current study revealed that NAFLD/CC recipients of a liver
transplant had different characteristics from recipients transplanted for other etiologies:
they were sicker, as transplanted at a higher MELD score, older, and more obese, as
having a higher BMI. The novel donor risk model tailored to this patient population is
driven by four donor factors: insulin-dependent diabetes, DCD, height, and MDRD.
Donor age did not have a strong impact on liver graft survival in the Cox PH model.
However, in addition to the variables identified as strong predictors in the semiparametric
model, the RSF selected donor age as a predictor of graft failure. An extended version of
the intrinsic donor model, which included selected transplant and recipient factors, found
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no association between donor age and 1-year graft survival in each MELD score
category. Decreased CIT was associated with improved 1-year graft survival recipients
with MELD score 15-24 but not for low MELD score (<15) or high MELD score (≥25).
In addition to donor insulin-dependent diabetes, DCD, donor MDRD, donor/recipient
size match, and recipient age had an impact on graft survival within 1-year post LT.
NAFLD/CC recipients of LT had a higher probability of losing their graft within the firstyear post LT. The study also revealed that receiving a Public Health extended high-risk
donor did not increase the risk of graft survival.
In the context of community health scores, a difference in graft failure was
observed at the extremes; between recipients of LT who resided in low health risk
counties (CHS<6) versus recipients who resided in high health risk communities
(CHS>30). The impact of community health scores on graft failure within 1-year post LT
was observed in both univariate and multivariable Cox PH models. Findings suggested
that in addition to donor quality, the environment in which the patient resides had an
impact on the risk of graft failure. Residing far from the transplant centers was not
associated with an increased risk of graft failure.
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Chapter 5: Discussion, Conclusions, and Recommendations
The epidemic increase in the incidence of NAFLD has led to an increase in the
prevalence of liver disease from NAFLD progression compared to other liver etiologies
(O’Leary et al., 2011; Pais et al., 2016). Consequently, NAFLD has become one of the
leading indications for liver transplant. The incidence of NAFLD has been intimately tied
to the components of metabolic syndrome. NAFLD patients who progress to cirrhosis or
HCC, leading to the need of a liver transplant, have to face two major obstacles: (a) the
presence of comorbidities and (b) a low MELD score due to better liver functioning,
placing them on the bottom of the wait list. Therefore, many of them may die while being
on the liver transplant wait list due to organ shortage and low priority (O’Leary et al.,
2011). Transplant centers are trying to increase the utilization of marginal donors to
increase the donor pool. Donor risk models provide useful tools to help match marginal
donors to the appropriate recipients.
Interpretation of the Findings
This study confirmed that NAFLD/CC patients have baseline characteristics
different from other etiologies, which justifies the decision to develop donor risk models
tailored for NAFLD/CC. Moreover, NAFLD/NASH recipients of LT had lower 1-year
graft survival compared to other etiologies, reflecting their longer permanence on the
wait list and comorbidities. The purpose of this retrospective study was to develop an
intrinsic donor and an extended DQ-NAFLD score aimed at identifying the donor
characteristics that can lead to poor posttransplant outcomes in this patient population.
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The theoretical framework that guided this study was grounded in the socio-ecological
model, which allowed me to explore the complex interplay among external
environmental factors, expressed in terms of the county CHS and distance from the
transplant center. Two sources of data, the SRTR database and the community health
indicators, were adapted from the Robert Wood Johnson Foundation’s community health
rankings, making it possible to explore different levels of the socio-ecological model in
the development of donor risk models.
The developed extended donor model improved only slightly the predictive
accuracy but allowed the assessment of the additional impact of MELD score and CIT on
posttransplant graft failure. Findings indicated that although the distance from the
transplant center does not have an impact on post LT graft survival, the county where a
patient resides has an impact. However, it is not clear whether the CHS is the appropriate
metric to explain county discrepancies in health and socioeconomic risk.
Public Health Service Increased Risk
Increasing the donor pool by increasing the utilization of marginal donors can
improve access to a scarce resource for NAFLD/CC candidate for LT. Potential organ
donations at an increased risk for transmitting hepatitis B, hepatitis C, and human
immunodeficiency virus are often discarded because the label associated to PHS
increased risk organ carries a stigma that dramatically reduces the utilization of this organ
source (Fleetwood, Lusciks, Poirier, Hertl, & Chan, 2016). However, the risk of
transmitting disease in the era of nucleic acid testing is very low; still, patients are
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reluctant to accepting PHS increased risk donors (Volk et al., 2017). This study
demonstrated that the use of PHS increased risk donor livers did not alter significantly the
risk of liver graft failure within 1-year post LT.
Kaplan-Meier graft survival curves between recipients of non-PHS increased risk
versus PHS increased risk overlapped, suggesting that some of the underutilized PHS
increased risk donors could be used for NAFLD/CC patients and not discarded due to
stigmatization. This result is aligned with the findings from a study conducted by Pruett,
Clark, and Taranto (2017) that showed that posttransplant outcomes, including 1-year
patient and graft survival as well as the risk of unexpected transmission of HIV, HBV, or
HCV after deceased donor kidney transplantation, did not change with the status of PHS
extended risk donors. The finding that donor livers with PHS extended risk denomination
did not alter the probability of graft survival in NAFLD/CC patients may be used to
support patients’ and physicians’ decision-making regarding the use of PHS increased
risk livers. This finding can also be used to help patients gauge the potential risk of
undetected HIV, HBV, or HCV infection transmission versus refusing an organ for
transplant and prolonging the stay on the wait list.
Intrinsic Donor DQ-NAFLD Model
Donor risk models have been previously proposed to evaluate donor quality of
deceased donor livers to assist in decision-making. Feng et al. (2006) developed the first
donor risk index using data in the pre-MELD era. This was followed by other developed
risk models to predict posttransplant graft survival using donor, recipient, and transplant
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factors (Blok et al., 2015; Braat et al, 2012; Dutkowski et al., 2011; Halldorson et al.,
2009; Winter et al., 2018). These models have been used for risk stratification and
validated in subsequent studies. However, none of these models is tailored for
NAFLD/CC recipients of LT.
The intrinsic DQ-NAFLD donor model was developed using post-MELD and
post-Share 35 data, and only included donor factors available at the time of donor offer
that summarized the likelihood of graft failure after LT. The model reflects current
practice and is tailored for NAFLD/CC recipients of LT. The model is driven by DCD,
donor diabetes, MDRD, and donor height. Donor age, not a significant predictor in the
Cox PH model, was included in the model to adjust the results because of clinical
relevance, and also because it was used in other donor risk models. Donor diabetes, as a
surrogate of liver steatosis, was not taken into account in previous donor risk models,
while kidney function (expressed by the MDRD) was recently included to develop a
donor quality index using the French liver transplant registry (Winter et al., 2018).
Macrosteatosis on donor biopsy, a known predictor of graft failure (de Graaf et
al., 2012), was only available for 38% of donors who had biopsy data in SRTR. For this
reason, macrosteatosis was not included in the multivariable donor risk models. The
Kaplan-Meier curve shows a tendency of macrosteatosis donors with Stage M2 to have a
worse but not statistically significant 1-year graft survival experience, compared to M0
and M1 stages of macrosteatosis when transplanted to NAFLD/CC recipients.
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The DQ-NAFLD score represents the relative risk of posttransplant liver graft
failure from the use of a particular deceased donor, compared to the average donor set at
reference values for categorical predictors and average values of continuous covariates.
For example, a donor with an estimated DQ-NAFLD of 1.45 will have an estimated risk
of liver graft failure of 45% higher than the average reference donor. Lower DQ-NAFLD
values are associated with increased donor quality and longer graft survival. Intrinsic
donor DQ-NAFLD classifies liver organs as high, medium, or low risk. The observation
of transplant practices and outcomes with these organs in NAFLD/CC recipients based on
these estimated risk classifications can help identify subsets of NAFLD/CC recipients
across these risk categories who can still achieve excellent outcomes. This is a definite
step forward for an optimal allocation of donor livers to NAFLD recipients.
Impact of Transplant Factors
Fukazawa et al. (2013) proposed using the ratio of donor to recipient BSA index
to estimate size match, and found that both small-for-size and large-for-size liver graft
extremes can increase the risk of graft failure post LT. In a single-center study on adult
and pediatric patients, Akdur et al. (2015) found that large-for-size liver grafts can cause
abdominal compartment syndrome leading to graft failure. The current study revealed
that, in the context of NAFLD/CC recipients of LT, receiving a large-for-size donor had a
higher likelihood of graft failure compared to a normal-for-size done in both univariate
and multivariate analyses.
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Extended DQ-NAFLD Model
Among the candidate donor predictors considered, insulin-dependent diabetes,
DCD, height, and MDRD were selected as stronger predictors of graft failure in the Cox
PH model for the NAFLD/CC population. Additionally, donor age resulted as an
important predictor of graft failure in the RSF model. With the addition of recipient and
transplant factors, the extended version of the DQ-NAFLD improved only slightly the
predictive ability of the model but allowed the prediction of the relative risk of a
specified donor liver across different MELD score or different values of CIT.
The extended donor model revealed that donor/recipient size match affected graft
survival. In particular, recipient age and reception of a large-for-size donor led to
worsening graft survival. In both donor risk models, NAFLD/CC recipients using elderly
donors did not experience a worse 1-year graft survival, suggesting that matching elderly
donors to recipients with NAFLD/CC may be safe. Long term effects of old donors
transplanted in NAFLD/CC recipients on graft and patient survival and other
posttransplant outcomes should be further investigated.
Impact of Community Health Scores
Factors such as socioeconomic status, individual behavior, education,
environmental risks, social support, access to healthy food, and health care vary widely
by region and counties. Under the lens of the socio-ecological system, there are complex
social and environmental determinants that increase or decrease the risk of poor
posttransplant outcomes. Ross et al. (2017) included the CHS adapted from the Robert
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Wood Johnson Foundation’s community health rankings and found that disparities in
health and economic conditions, and travel distance, had an impact on wait-list mortality.
To address the impact of external factors in the social-ecological model, I used in
this analysis the CHS, a county-level measure of community health resources and risk.
CHS is a score derived from multiple aspects of community health factors, such as access
to care, and social and environmental risk factors, such as: (a) years of potential life lost,
(b) proportion of children with low birth weight, (c) proportion of adults with poor or fair
reported health, (d) adults’ poor reported physical health days, (e) poor reported mental
health days, (f) proportion of individuals reporting tobacco use, (g) adult obesity
prevalence, (h) physical inactivity prevalence, (i) rate of preventable hospital stays, and
(j) median annual household income. A cumulative score with a range from 0-40 was
computed for each county (the county CHS), obtained by adding up scores from each of
the 10 community health indices. Each county received a score of 0-4 based on quintile
ranking (zero points if the county belonged to the 1st quintile for a particular index and
one point for each subsequent quintile). NAFLD/CC recipients of LT who resided in high
health risk counties with a CHS > 60 were more likely to lose their grafts within 1-year
post LT compared to low health risk counties (p = .041) suggesting that the environment
can play a role in post-transplant outcomes.
Impact of Geographic Distance from Transplant Center
Studies revealed that among patients eligible for a liver transplant, greater
geographic distance from the transplant center was associated with a lower likelihood of
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being listed or receiving a liver transplant (Goldberg et al., 2017). Although geographic
distance has proven important on wait-list outcomes, this study has shown that greater
geographic distance from the transplant centers was not associated with worsening 1-year
graft survival post-transplant, suggesting that long-distance management of NAFLD/CC
liver transplant recipients is not associated with worsening outcomes. However, the
analysis was biased towards recipients that got transplanted.
Limitations of the Study
This study has several limitations that merit discussion. Retrospective nature of
this quantitative study can only prove associations but not causation and can lead to
confounding attributable to unobserved variables. The SRTR database I used in this study
had a significant amount of missing data that were not analyzed. Donor biopsy was only
present in 38% of cases; therefore, I did not include macrosteatosis in the multivariable
models. This study revealed that donor insulin-dependent diabetes increased the
likelihood of graft failure within 1-year post LT. Information about donor diabetes
obtained from the donor next of kin might be inaccurate if the person interviewed had
limited or erroneous information. The study was powered to develop multivariate donor
risk models.
Consecutive sampling selection of all patients that met the inclusion criteria
reduced selection bias. Therefore, inferences from SRTR studies are likely to generalize
across United States. However, the model is expected to present some threats to external
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validity and unlikely to generalize with data from non-US transplant centers with
different policies and procedures (Massie, Kucirka, & Segev, 2014).
I calculated the distance from recipient residence to transplant center through zip
code distances using the Haversine formula, which is the shortest distance between two
points on the surface of a sphere, an approximation of the actual distance.
The aggregate nature of the community health factors can lead to model estimates
that may be subject to ecologic bias. Moreover, at the county-level, the choropleth graph
showed a county-based variation in liver graft survival. However, some counties had only
a few study subjects, which can decrease the accuracy of the estimated graft survival by
county. The small number of LT performed for NAFLD/CC recipients complicate the
task of demonstrating that patients from disadvantaged counties all share the same
elevated risk of poor outcomes making county rankings of transplant outcomes highly
unstable.
Many factors can impact post-transplant outcomes, and both DQ-NAFLD models
developed herein do not capture all aspects. Therefore, even if the models have shown
that some donor factors have a large or small impact, they can only be used to support
decision making at the time of donor acceptance, as several many other factors will play a
role as well. For example, even though the analyses showed that, in both Cox PH models
used to develop the DQ-NAFLD scores, donor age did not impact graft survival, it does
not imply that it is safe to transplant each elderly donor to NAFLD/CC recipients. The
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analysis was biased towards elderly donors that got transplanted, as transplant centers can
reject older donors for several reasons.
Recommendations
This current study found that donor age is not a strong predictor of 1-year graft
survival and may be extended in the future to explore whether older donors can be safely
used to transplant NAFLD/CC recipients. The rate of steatosis among the general
population is increasing, leading to an increasing number of cadaveric donors with
hepatic steatosis. The progression from steatosis to fibrosis, and ultimately, cirrhosis is
quite slow. However, in the current donor pool with an increasing prevalence of
metabolic syndrome, the impact of donor steatosis on NAFLD/CC recipients and the
likelihood to result in long term recurrence of NAFLD or NASH, compared to other
etiologies, should be explored further.
The DQ-NAFLD, as well as other donor risk metrics, have been developed
considering 1-year organ survival post-transplant. However, liver transplant recipients
tend to gain weight within the first-year post LT. Therefore, some NAFLD/CC recipients
of LT can develop recurrent NAFLD and NASH, and a smaller percentage can incur
cirrhosis and require a re-transplant. Defining donor quality for NAFD/CC recipients of
LT beyond 1-year graft survival but based on the recurrence of NAFLD in its progressive
forms of NASH cirrhosis, can enhance the definition of donor quality and measure
peculiar aspects of NAFLD/CC recipients. The SRTR database does not include post-LT
complications needed to explore this aspect. However, data collected at the transplant
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centers could be used to explore disease recurrence and the need for re-transplant in the
short and long term
County differences in post-transplant graft survival do exist as the choropleth map
revealed. These disparities are driven only in part by county socioeconomic status or
CHS. The county aspect could be analized as a shared frailty term in a Cox PH model
with a random effect to represent any unexplained variation in graft survival across
counties, excluding low volume counties from the analysis. Moreover, CHS resulted as
an independent predictor of graft failure when categorized, but not when modeled as
RCS. This instability and conflicting result show the need for further validation of CHS
in other populations. Further exploration of alternative county metrics and patient-level
socioeconomic factors could contribute to explain county variation if used in risk
adjustment donor models.
This study revealed that the use of PHS increased risk donors did not alter the
probability of graft survival in NAFLD/CC patients. Different reasons can lead to the
denomination of PHS extended risk donor, not all of them equally likely to increase the
probability of undetected HIV, HBV, or HCV infection transmission. Therefore, further
studies are needed to identify a subset of PHS increased risk donors that increase the risk
of unintended transmission and graft failure.
Implications
The changing patterns in indication for LT herein pointed to the development of a
post-MELD era post Share 35 donor quality score tailored to NAFLD/CC recipients. DQ-

207
NAFLD quantifies the quality of the liver graft by scoring the characteristics of the graft
before LT. Therefore, it is a crucial factor for a better match between a liver graft and its
recipient and can lead to a positive social change if used as a tool to assist both
physicians and patients in the decision of graft usage.
The nomogram developed in this study using the DQ-NAFLD donor models, or a
calculator created using the model estimates, can provide some information to patients
and physicians of an expected outcome, which can be expressed in terms of expected 1year survival or as expected AHR for a specific donor matched to a particular recipient.
Understanding and quantifying the impact of donor factors that do affect
posttransplant graft survival, and donor factors that have minimal or no impact for this
patient population, can contribute to freeing more donors to allocate to NAFLD/CC, who
are at high risk of death while waiting for a liver. Moreover, understanding the impact of
recipient factors, such as MELD, and transplant factors, such as CIT and donor/recipient
size match, can help in achieving the ultimate goal of optimal donor/recipient matching.
Conclusion
Organ shortage leads to the utilization of non-optimal donors, and donor risk
models provide a metric to quantify donor quality and help allocate non-optimal donors
to appropriate recipients. However, many organs are discarded, some of which could be
utilized with excellent results if adequately selected and matched to the appropriate LT
candidates. Donor risk models provide the first step to match marginal donors to the
appropriate recipients optimally. The creation and validation herein of DQ- NAFLD
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donor risk models, tailored to NAFLD/CC recipients of LT, is a major step forward in the
optimal utilization of a scarce resource for this patient population. NAFLD/CC is
becoming one of the top indications for LT, but often NAFLD/CC candidates have low
priority and high mortality on the wait list. The DQ-NAFLD score can contribute to
NAFLD/CC LT candidates matched appropriately, who may die while on the wait list or
may be removed because they are too sick to be transplanted. Moreover, understanding
the impact of external geographic and community factors can help develop more accurate
donor risk models adjusted for sociodemographic risk factors. Concerns remain that after
adjusting for donor characteristics, posttransplant graft failure in NAFLD/CC recipients
continues to be subjected to community disparities.
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Appendix A: County Health Indicators
County Health Indicators (CHI) are compiled annually using county-level
measures from a variety of national and state data sources by the University of Wisconsin
Population Health Institute and the Robert Wood Johnson Foundation. Since 2010, CHIs
are available for almost all counties (over 30000 counties) and are used to compare
county health status. The estimated CHI and their 95% CI are available for each county.
Tables A1-A5 describe the CHSs by category: health outcomes, health behaviors, clinical
care, social and economic factors, and physical environments. They indicate how each
CHI is measured and the source of data and identify the selected group of indicators that
will be used to develop the transplant community health score.
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Table A1
Community Health Indicators: Health Outcomes
Focus
Area

CHI
Measure

Description

Length of
life

Premature death

Years of potential life lost before
age 75 per 100,000 population (ageadjusted)

National Center for
Health Statistics Mortality files

Quality
of life

Poor or fair
health

Percentage of adults reporting fair
or poor health (age-adjusted)

Behavioral Risk Factor
Surveillance System

Yes

Poor physical
health days

Average number of physically
unhealthy days reported in past 30
days (age-adjusted)

Behavioral Risk Factor
Surveillance System

Yes

Poor mental
health days

Average number of mentally
unhealthy days reported in past 30
days (age-adjusted)

Behavioral Risk Factor
Surveillance System

Yes

Low birthweight

Percentage of live births with low
birthweight (< 2500 grams)

National Center for
Health Statistics Natality files

Yes

Notes: CHI: County health index; CHS: community health score.
Source: http://www.countyhealthrankings.org/

Source

Used in
Transplant
CHS
Yes
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Table A2
Community Health Indicators: Health Behaviors
Focus Area

CHI
Measure

Description

Source

Used in
Transplant
CHS
Yes

Tobacco
use

Adult smoking

Percentage of adults who are
current smokers

Behavioral Risk Factor
Surveillance System

Diet and
exercise

Adult obesity

Percentage of adults that report a
BMI of 30 or more

CDC Diabetes Interactive
Atlas

Yes

Food environment
index

Index of factors that contribute to
a healthy food environment, 0
(worst) to 10 (best)

USDA Food
Environment Atlas, Map
the Meal Gap

No

Physical inactivity

Percentage of adults aged 20 and
over reporting no leisure-time
physical activity

CDC Diabetes Interactive
Atlas

Yes

Access to exercise
opportunities

Percentage of population with
adequate access to locations for
physical activity

Business Analyst, Delorme
map data, ESRI, & US
Census Tigerline Files

No

Excessive
drinking

Percentage of adults reporting
binge or heavy drinking

Behavioral Risk Factor
Surveillance System

No

Alcohol-impaired
driving deaths

Percentage of driving deaths with
alcohol involvement

Fatality Analysis
Reporting System

No

Sexually
transmitted
infections

Number of newly diagnosed
chlamydia cases per 100,000
population

National Center for
HIV/AIDS, Viral
Hepatitis, STD, and TB
Prevention

No

Teen births

Teen birth rate per 1,000 female
population, ages 15-19

National Center for Health
Statistics - Natality files

No

Alcohol
and drug
use

Sexual
activity

Notes: CHI: County health index; CHS: community health score.
Source: http://www.countyhealthrankings.org/
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Table A3
Community Health Indicators: Clinical Care
Focus
area
Access to
care

CHI
measure

Description

Source

Used in
transplant
CHS
No

Uninsured

Percentage of population under age 65
without health insurance

Small area health
insurance estimates

Primary care
physicians

Ratio of population to primary care
physicians

Area health resource
file/American Medical
Association

No

Dentists

Ratio of population to dentists

Area Health Resource
file/national provider
identification file

No

Mental health
providers

Ratio of population to mental health
providers

CMS, national provider
Identification file

No

Preventable
hospital stays

Number of hospital stays for
ambulatory-care sensitive conditions
per 1,000 Medicare enrollees

Dartmouth Atlas of
Health Care

Yes

Diabetes
monitoring

Percentage of diabetic Medicare
enrollees ages 65-75 that receive
HbA1c monitoring

Dartmouth Atlas of
Health Care

No

Percentage of female Medicare
enrollees ages 67-69 that receive
mammography screening
Notes: CHI: County health index; CHS: community health score.
Source: http://www.countyhealthrankings.org/

Dartmouth Atlas of
Health Care

No

Quality of
care

Mammography
screening
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Table A4
Community Health Indicators: Social and Economic Factors
Focus Area

Education

CHI
Measure

Description

Source

Used in
transplant
CHS
No

High school
graduation

Percentage of ninth-grade cohort
that graduates in four years

EDFacts

Some college

Percentage of adults ages 25-44
years with some post-secondary
education

American
Community Survey

No

Employment

Unemployment

Percentage of population ages 16
and older unemployed but seeking
work

Bureau of Labor
Statistics

No

Income

Children in
poverty

Percentage of children under age 18
in poverty

Small Area Income
and Poverty
Estimates

No

Income
inequality

Ratio of household income at the
80th percentile to income at the 20th
percentile

American
Community Survey

Yes

Children in
single-parent
households

Percentage of children that live in a
household headed by single parent

American
Community Survey

No

Social
associations

Number of membership associations
per 10,000 population

County Business
Patterns

No

Violent crime

Number of reported violent crime
offenses per 100,000 population

Uniform Crime
Reporting - FBI

No

Injury deaths

Number of deaths due to injury per
100,000 population

CDC WONDER
mortality data

No

Family and
social
support

Community
safety

Notes: CHI: County health index; CHS: community health score.
Source: http://www.countyhealthrankings.org/
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Appendix B: Donor Screening for Disease Transmission
Donor Screening
OPTN policy requires donor screening to determine if the potential donor has an
infection that could be transmitted to recipients through the transplanted organ. All
donors are screened for human immunodeficiency (HIV), hepatitis B (HBV), hepatitis C
(HCV), syphilis, cytomegalovirus (CMV) and Epstein Barr viruses (EBV). Serological
tests can screen donors who developed HIV, HBV, or HCV several months before organ
donation. Federal law only prohibits the transplantation of HIV infected donors. Donor
shortage and medical advances in treating viral infections lead to the utilization of organ
with HCV and HBV infections. HBV and HCV-infected donors are typically offered to
patients known to have the same infections, or to uninfected patients in urgent need for a
transplant.
CDC High Risk and PHS Increased Risk Donors
OPTN policy also requires a medical and social history interview conducted with
the deceased donor’s close family members to assess potential donor social behaviors and
past medical history. This information is used to identify at-risk of transmitting HIV,
HBV, or HCV to transplant recipients. High or increased risk refers to a set of donor
behaviors that can increase the risk of transmission, as described in Table B1.
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Table B1
CDC High-Risk and PHS Increased-Risk Donors
CDC High Risk (1994)
MSM in the preceding 5 years

PHS Increased Risk (2013)
MSM in the preceding 12 months

Non-medical injection drug use in preceding 5
years

Non-medical injection drug use in preceding 12 months

Sex in exchange for money/drugs in preceding 5
years

People who have had sex in exchange for money or drugs
in the preceding 12 months

Known or suspected to have HIV infection in the
preceding 12 months

People who have had sex with a person known or
suspected to have HIV, HBV, or HCV infection in the
preceding 12 months
Women who have had sex with a man with a history of
MSM behavior in the preceding 12 months

Women who have had sex with a man with a
history of MSM behavior in the preceding 12
months
People who have had sex with a person who had
sex in exchange for money or drugs in the
preceding 12 months

People who have had sex with a person who had sex in
exchange for money or drugs in the preceding 12 months

People who have had sex with a person who
injected drugs by intravenous, intramuscular, or
subcutaneous route for nonmedical reasons in the
preceding 12 months

People who have had sex with a person who injected drugs
by intravenous, intramuscular, or subcutaneous route for
nonmedical reasons in the preceding 12 months

A child who is ≤18 months of age and born to a
mother known to be infected with, or at increased
risk for HIV infection (should not be used)

A child who is ≤18 months of age and born to a mother
known to be infected with, or at increased risk for HIV,
HBV, or HCV infection

A child who has been breastfed in the past 12
months by a mother known to have or at risk for
HIV infection

A child who has been breastfed within the preceding 12
months and the mother is known to be infected with, or at
increased risk for, HIV infection

Inmates of correctional systems

People who have been in lockup, jail, prison, or a juvenile
correctional facility for more than 72 consecutive hours in
the preceding 12 months

Persons who cannot be tested for HIV infection
because of refusal, inadequate blood samples
(e.g. hemodilution that could result in falsenegative tests), or any other reasons

When a deceased potential organ donor’s blood specimen
is hemodiluted, the donor should be considered at
increased risk for HIV, HBV, and HCV infection because
the donor’s risk for infection is unknown
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In 1994, the Centers for Disease Control (CDC) developed guidelines for highrisk behaviors to designate donors with an increased risk of transmitting HIV. In 2013 the
CDC high-risk criteria were extended to include the screening of HBV and HCV in
addition to HIV, and the U.S. PHS increased risk criteria was developed. PHS increased
risk guidelines replaced the CDC high-risk guidelines.
The Nucleic Acid Testing (NAT), which has a much shorter window that
serological tests, is required to screen these high-risk donors. The aim of the CDC highrisk and later of PHP increased risk designation was to inform candidates on the potential
risk of HIV, HBV and HCV transmission from high-risk donors, recently infected, who
tested negative on serologic testing or NAT but still potentially capable of transmitting
these viral infections due to the window period between infection and seroconversion.
PHP increased risk does not translate into donor quality. However, because of the
designation, many of these organs are rejected with the perception that they can lead to
poor survival. Acceptance practices vary by transplant program. Moreover, not all
increase-risk donors have the same likelihood to transmit disease, but there is a wide
variation: incarceration or sexual behaviors carry a much lower risk than intravenous
drug use. However, because the risk of donor-derived HIV, HBV, or HCV transmission
from a NAT negative donor is lower than 1%, often the risk of rejecting risk donors may
be greater than the risk of accepting them.
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Appendix C: Graphical Exploratory Analysis
Variable Distributions of Categorical Variables
Bar graphs visualize the frequency distribution of categorical variables and
quantify the values within the categories of each variable to identify categories more
frequents. (Describe). A review of the variable distributions revealed that only eight
donors (or 0.2%) were HCV positive, and only two donors (or .06 %) were HBV Ag
positive. Therefore, HCV and HBV were not considered in modeling and subsequent
analyses because of the lack of predictive ability.

Figure C1. Bar chars of donor gender, diabetes, hypertension, hypernatremia.
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Figure C2. Bar chars of donor HCV, HBsAG, cause of death and DCD.

Figure C3. Bar chars of donor macrovascular steatosis, microvascular steatosis, recipient
gender and ABO compatibility.
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Distribution of Continuous Variables and Outlier Detection
The distribution of continuous variables was depicted using histograms with
density and boxplots, to examine the shape of the distribution and detect the presence of
outliers.

Figure C4. Histograms with density and boxplots o donor height and weight
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Figure C5. Histograms with density and boxplots o donor BMI and BSA

Figure C6. Histograms with density and boxplots of donor age and MDRD.
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Figure C7. Histograms with density and boxplots of recipient BMI and age

Figure C8. Histograms with density and boxplots of MELD score and cold ischemia
time.
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Figure C9. Histograms with density and boxplots of distance to transplant center and
community health indicators.

